New approaches to heterocyclic scaffolds using Diels-Alder chemistry by Ma, Zhiyuan
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2013
New approaches to heterocyclic
scaffolds using Diels-Alder
chemistry
https://hdl.handle.net/2144/14148
Boston University
 
 
BOSTON UNIVERSITY 
GRADUATE SCHOOL OF ARTS AND SCIENCE  
 
Dissertation 
 
NEW APPROACHES TO HETEROCYCLIC SCAFFOLDS USING 
DIELS-ALDER CHEMISTRY 
 
by 
 
ZHIYUAN MA 
B. S., University of Science and Technology of China, 2004 
 
 
Submitted in partial fulfillment of the  
requirement for the degree of  
Doctor of Philosophy  
2013 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©    Copyright by 
            ZHIYUAN MA 
            2013 
 
  
 
 
Approved by 
 
 
First Reader  ____________________________________________________ 
   John K. Snyder, Ph.D. 
   Professor of Chemistry 
 
 
 
Second Reader ___________________________________________________ 
   Aaron Beeler, Ph.D. 
   Professor of Chemistry 
   
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
 
for my parents and my beloved grandparents 
in consideration of Love and Affection 
 
For dreams. For love. For life. 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Acknowledgments 
 
 I cannot celebrate this wonderful moment of completing my dissertation without 
saying my sincere gratitude to people whom I love and who supported me during all these 
years.  
 I am appreciative that fate has led me to this path pursuing my education in 
chemistry. It has allowed me to encounter so many kinds of different experiences, good or 
bad, it never made me give up but only made me stronger and made me who I am now. I 
cannot appreciate this wonderful life enough.  
 I am extremely grateful to my advisor, Professor John Snyder for giving me the 
opportunity to work in his group. He seeded much knowledge in me and directed me in 
becoming a fine chemist. I will never forget his support, patience and encouragement, 
especially in the darkest phase during the program which made this thesis possible. Also, 
I will always remember him as a passionate and incredible teacher! I would like to extend 
my special thanks to Professor Aaron Beeler for careful revision on my thesis and his 
helpful suggestions. I would like to thank the rest of my defense committee members, 
Professors Grinstaff, Jasti, and Panek for their valuable advices and encouragements.  
 I would like to thank all members of the Snyder Group. First, I give my sincerest 
appreciation to my friend Sam Lo, who shares many unforgettable moments with me. She 
taught me most of the chemistry techniques when I first joined the group knowing nothing 
about organic chemistry. Her affection, generosity, support and understanding made the 
first couple of rocky years meaningful and more delightful. I extend my special gratitude 
vi 
 
to my senior colleagues Dr. Xiang Liu, and Dr. Grace Woo. Their ample knowledge and 
dedication to chemistry overwhelmed me with admirations and inspirations. I would like 
to express my sincere indebtedness to Dr. Ya Zhou, Dr. Feng Ni, Dr. Alex Hours and Dr. 
Seann Mulcahy, Dr. Amanda Jones, Cuifang Cai and Kyle Strom, for important advices, 
support as well as their genuine friendships. I also like to extend my thanks to my 
undergraduate students Grant Rice, James Johnson and many other talented young 
chemists in the Snyder group. Finally, I would like to thank the rest of the Snyder group 
members, friends from other groups, the colleagues and staff here at Boston University 
both past and present, I really appreciate their friendships, help and support during the 
years, which made these rough years less painful and somehow enjoyable.  
 I also extend my appreciation to my dearest friends Kunyang Fang, Dr. Ying Zhou, 
Dr. David Horst, Dr. Jing Zhang, Xing Zhao, Jinzhao Shen, they are my surrogate family 
in Boston during these years away from home. Not only did they share great moments in 
life with me, but also helped, supported and encouraged me through the seemingly hopeless 
dark phase at the end of my program, even when I almost lost faith in myself. But they 
never did. Their constant love, care, and support for me will always be cherished. I truly 
love you guys. I could not have completed this work without you after all.  
 Most importantly, I owe my greatest gratitude and guilt to my parents, Ji Ma and 
Lan Li. They have been always standing by me supporting me, emotionally and financially. 
They taught me the meaning of love, hope and life, and provided me with the best 
environment for me to grow in. They sacrificed so much just so that I could pursue a better 
vii 
 
life I thought I needed and deserved. I will never forget their endless love and support. I 
am most proud to be their son.  
 And to my grandparents, my uncle and my cousin, who left us too early to witness 
my accomplishment. I miss you guys. I hope I made you proud.  
  
viii 
 
NEW APPROACHES TO HETEROCYCLIC SCAFFOLDS USING 
DIELS-ALDER CHEMISTRY 
(Order No.  ) 
ZHIYUAN MA 
Boston University Graduate School of Arts and Science, 2013 
Major Professor: John K. Snyder, Professor of Chemistry  
 
Abstract  
 
 
 Isatin-derived 1,2,4-triazines were employed as electron deficient azadienes in 
inverse electron demand Diels-Alder (IEDDA) chemistry with tethered alkynyl 
dienophiles, leading to biologically interesting heterocyclic lactam- and lactone-annulated 
-carbolines in excellent yields under microwave promotion. The chemistry scope was 
probed using various alkynyl amines and alcohols, and the impact of the tether length 
between the triazines and the dienophiles was also investigated. This IEDDA methodology 
was subsequently applied to the synthesis of an -carboline library, producing eighty-eight 
members starting with various isatin-derived triazines, indole-derivatives, and 
propargylamine derivatives.  
ix 
 
 In a related project, a regioselective Lewis acid catalyzed amidation of dimethyl 
5H-pyridazino[4,5-b]indole-1,4-dicarboxylate was established to selectively direct the 
amidation to occur at either the C1 or C4 ester positions. This chemistry was then applied 
to tether dienophiles to the pyridazinoindole ring via an amide linkage. Subsequent IEDDA 
cycloadditions of these pyridazinoindole/dienophile pairs afforded carbazoles in excellent 
yields under thermal conditions. The scope of this chemistry scope was also thoroughly 
probed, leading to a library of one hundred and eighty-eight members.  
 
 The synthesis of a third heterocyclic scaffold using Diels-Alder chemistry was also 
accomplished. Asymmetric cycloadditions of anthrone with various maleimides were 
successfully achieved using different chiral organocatalysts. The identity of the optimal 
catalytic system depended upon the dienophile, with good enantioselectivities achieved 
(78-83% ee). This chemistry was successfully applied as the stereocontrol element in a 
Diels-Alder/Functional Group Transformation/retro-Diels-Alder sequence to prepare 
alkaloidal scaffolds in an optically enriched form. 
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Chapter I 
 
 
 
 
Introduction 
 
 
1.1 Inverse Electron Demand Diels-Alder Reaction 
 
Ever since the Diels-Alder reaction was first reported by Otto Diels and Kurt Alder 
in 1928 (Scheme 1.1) [1], [4+2] cycloaddition chemistry has become one of the most 
powerful and widely used synthetic strategies in organic chemistry for its ability to 
construct two -bonds (carbon-carbon or carbon-heteroatom) simultaneously for 
preparation of six-membered carbocyclic and heterocyclic systems [2-6]. Furthermore, 
asymmetric Diels-Alder reactions have the potential to generate multiple stereogenic 
centers in single step from achiral precursors with highly controlled stereoselectivity and 
regioselectivity, making it even more appealing to organic chemists [2]. Though nearly a 
century has passed since the discovery of this reaction, the [4+2] cycloaddition will be 
continuously developed and utilized in modern organic chemistry in the foreseeable future. 
 
2 
 
Scheme 1.1 First Reported Diels-Alder Reaction 
 
 
 
According to Frontier Molecular Orbital (FMO) theory, the Diels-Alder reactions 
can be classified into three sub-categories according to the most favorable orbital overlap 
match (the smallest energy gap) between the highest occupied molecular orbital (HOMO) 
and the lowest unoccupied molecular orbital (LUMO) [7-12]. In all three cases, the 4 
electron system of a conjugated diene reacts with a 2 electron system of a dienophile to 
construct a six-membered ring either in a synchronous or concerted nonsynchronous 
mechanism [13, 14]. These sub categories are:  
 
The first class of Diels-Alder (DA) reaction is the normal/standard Diels-Alder 
reaction, which is controlled by the orbital overlap of HOMOdiene and LUMOdienophile, 
shown in Scheme 1.2. In the normal Diels-Alder reaction, the relatively electron rich diene 
has molecular orbitals that are higher in energy than the orbitals of the electron poor 
dienophile. The difference in relative orbital energies means that, the HOMO of the diene 
and the LUMO of the dienophile are closer in energy than the HOMO of dienophile and 
LUMO of the diene, making the former interaction the strongest. Electron-donating groups 
on the diene, and/or electron-withdrawing groups on the dienophile accelerate the reaction 
3 
 
by narrowing the energy difference between the HOMOdiene and LUMOdienophile. The first 
Diels-Alder reaction reported by Diels and Alder in the reaction of cyclopentadiene with 
acrolein, producing bicyclic aldehyde I_3 (Scheme 1.1) belongs to this subgroup [1]. 
 
Scheme 1.2 Frontier Molecular Orbital Overlap of Normal Diels-Alder Reactions 
 
 
 
The second class of Diels-Alder reactions, the neutral Diels-Alder reaction, is 
controlled by a near equal orbital overlap of HOMOdiene/LUMOdienophile pair and 
HOMOdienophile/LUMOdiene pair, illustrated in Scheme 1.3. As such, many of the reactions 
are dimerizations, the orbital energies are identical or nearly so, and there is no dominance 
of the interaction of the HOMO or the LUMO of either the diene or the dienophile. The 
HOMO and the LUMO of each species are farther apart in energy than in either normal 
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Diels-Alder or inverse electron demand Diels-Alder reactions, the third class, and therefore 
neutral Diels-Alder reactions are the least efficient and usually low yielding because of this 
relatively large energy difference. The dimerization of isoprene affording limonene, 
discovered by Wallach in 1885, belongs to this subgroup, which is really the first true 
example of [4+2] cycloaddition chemistry [15]. 
 
Scheme 1.3 Frontier Molecular Orbital Overlap of Neutral Diels-Alder Reactions 
 
 
 
The third class of [4+2] cycloadditions, the inverse electron demand Diels-Alder 
reaction (IEDDA), is controlled by the orbital overlap between the HOMOdienophile and 
LUMOdiene, shown in Scheme 1.4. The inverse electron demand Diels-Alder reaction 
involves an electron deficient diene and an electron rich dienophile. The frontier molecular 
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orbital energy levels of the diene and the dienophile are reversed from those of the normal 
Diels-Alder reaction. Thus, the LUMOdiene and the HOMOdienophile are the frontier orbitals 
that interact most strongly, and result in the most energetically favorable bond formation 
[14, 16-22]. Therefore, electron-withdrawing groups on the diene, and/or electron-donating 
groups on the dienophile, accelerate the reaction by narrowing the energy gap between 
these FMO’s.  
 
Scheme 1.4 Frontier Molecular Orbital Overlap of Inverse Electron Demand 
Diels-Alder Reactions 
 
 
 
 The dienes in inverse electron demand Diels-Alder reaction are electron deficient 
species and have lower molecular orbital energies compared to their normal Diels-Alder 
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counterparts. This lowered energy is typically the result of either electron-withdrawing 
substituents or electronegative heteroatoms within the 4 system. Inverse electron demand 
Diels-Alder reactions often involve heterodienes, and thus can be utilized to construct 
heterocyclic systems. Common dienes in the inverse electron demand Diels-Alder reaction 
include oxo- and aza-butadienes [17, 23]. Heteroaromatic compounds such as 1,2,4-
triazines, 1,2,4,5-tetrazines and 1,3,5-triazines are also important, common classes of 
dienes that can often be found in inverse electron demand Diels-Alder reactions. These 
heteroaromatic systems possess electron deficient azadienes that are locked in s-cis 
conformations and can usually release gaseous dinitrogen following the cycloaddition. 
 
Inverse electron demand Diels-Alder reactions do not have an unambiguous date 
of inception due to the difficulties in differentiating the three sub categories of the Diels-
Alder reactions before the advent of modern computational methods [24]. However, it is 
commonly accepted that the first inverse electron demand Diels-Alder reactions were the 
cycloadditions of 1-vinylnaphthalene with 1,3-butadiene-1-carboxylic acids generating 
regioisomeric -unsaturated carboxylic acids, reported by Bachmann and Deno in 1949 
(Scheme 1.5) [25].  
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Scheme 1.5 IEDDA Reactions by Bachmann and Deno 
 
 
 
Later in 1959, Carboni reported the inverse electron demand Diels-Alder reaction 
of electron deficient 1,2,4,5-tetrazines with various unsaturated compounds as dienophiles, 
introducing heteroatoms into the LUMOdiene system for the first time [26]. In their report, 
they demonstrated the [4+2] cycloaddition of electron deficient disubstituted 1,2,4,5-
tetrazines I_8 with various unsaturated compounds to generate 3,6-disubstituted 
pyridazines I_9, I_16 and dihydropyridazines I_12, I_14 (Scheme 1.6). Because of the 
presence of the more electronegative nitrogen atoms in the tetrazine ring system, lowering 
the LUMOdiene, the cycloadditions proceeded smoothly with various dienophiles at room 
temperature. The electron-withdrawing groups, CHFCF3, in tetrazine I_8a further 
accelerated the cycloaddition compared to the less electron deficient tetrazine I_8b bearing 
the phenyl groups, which required both longer reaction time and higher temperature. It was 
also noted that the reaction was thermodynamically favorable and irreversible due to the 
elimination of dinitrogen following the cycloaddition. This cycloaddition chemistry of 
1,2,4,5-tetrazines, as well as that of 1,2,4-triazines, was explored in depth by Neunhoeffer 
and Sauer in the 1960’s and 1970’s [80, 81, 84, 87, 116, 121, 125].  
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Scheme 1.6 Reactions of Tetrazines with Unsaturated Compounds by Carboni 
 
 
 
Over the past few decades, many chemists have continued to explore this powerful 
inverse electron demand Diels-Alder reaction expanding the chemical scope and practical 
applications.  Much of the synthetic work in this area can be attributed to Boger and Taylor, 
though Seitz, Gribble, Snyder and many others have also published numerous papers about 
this inverse electron demand Diels-Alder reaction demonstrating the ability of various 
acyclic and cyclic hetero aza-dienes to react with diverse electron rich dienophiles [27].  
 
Common acyclic heterodienes include: 1-aza-1,3-butadienes I_17 [28-39], 2-aza-
1,3-butadienes I_18 [40-47], 1-oxo or 1-thio-1,3-butadienes I_19 [20], 1-oxo or 1-thio-3-
aza-1,3-butadienes I_20 [20, 48-57], 1-oxo or 1-thio-2,3-diaza-1,3-butadienes I_21 [20, 
48-57], 1,2-diaza-1,3-butadienes I_22 [58, 59], 1,3-diaza-1,3-butadienes I_23 [60], 1,4-
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diaza-1,3-butadienes I_24 [61-63], 2,3-diaza-1,3-butadienes I_25 [64], 1,2,4-triaza-1,3-
butadienes I_26 [18-22], and cationic azadienes I_27 [65-70], summarized in Figure 1.1.  
 
Figure 1.1 Common Acyclic Heterodienes Used in Inverse Electron Demand 
Diels-Alder Reactions 
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 Common cyclic heterodienes include: oxazoles I_28 [71-75], imidazoles I_29 [76-
79], pyridazines I_30 [80-83], pyrimidines I_31 [84-86], pyrazines I_32 [87], 1,2,3-
triazines I_33 [88-93], 1,3,5-triazines I_34 [94-100], 1,2,4-triazines I_35 [18-22, 101, 
102], 1,2,4,5-tetrazines I_36 [103-105], and cationic heteroaromatic azadienes I_37 [65-
70], mesoionic munchnones I_38 [106-113], and isomunchnones I_39 [114, 115], 
summarized in Figure 1.2. 
 
Figure 1.2 Common Cyclic Heterodienes Used in Inverse Electron Demand 
Diels-Alder Reactions 
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 Both acyclic and cyclic heterodienes react with various electron rich dienophiles, 
such as enol ethers, alkynyl ethers, ketene acetals, enamines, ynamines, ketene aminals, 
indoles, pyrroles and imidazoles to produce other heterocyclic compounds. Among these 
azadienes, 1,2,4-triazines and 1,2,4,5-tetrazines are the most thoroughly investigated and 
widely utilized in heterocyclic synthesis. In this thesis, the applications of 1,2,4-triazines 
and 1,2,4,5-tetrazines in the synthesis of novel heterocyclic molecules and library 
preparations will be discussed and presented.  
 
1.2 1,2,4-Triazines as Electron Deficient Dienes in Intramolecular Inverse 
Electron Demand Diels-Alder Reactions 
 
Due to the asymmetric structures of the 1,2,4-triazines, intermolecular inverse 
electron demand Diels-Alder cycloadditions of these triazines with non-symmetric 
dienophiles can produce regioisomers. Though the regioselectivity of these cycloadditions 
might be sufficiently controlled by the electric or steric properties of the substituents on 
the parent triazines, the reactivity of the electron rich dienophiles, the reaction conditions, 
the polarity of the solvents, and a combination of all these factors can make these 
cycloadditions somewhat unpredictable [116-125]. In contrast, an intramolecular approach 
restricts the regiochemistry to a single pathway, which was preferred in many cases of 
target oriented and chemical library synthesis. Furthermore, the unimolecular nature of an 
intramolecular cycloaddition offers an entropic advantage over intermolecular 
counterparts, which often enables otherwise resistant reactions to proceed successfully. 
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There is a very large number of intramolecular inverse electron demand Diels-Alder 
reactions reported in the literature, effectively constructing specific ring systems that 
appear in natural products and their analogues, while enabling the less reactive dienes and 
dienophiles to achieve cyclization [126, 127]. 
 
For intramolecular cycloadditions, the tether plays a very important role in linking 
the diene/dienophile pairs. Important factors include the length of the tether. For the 1,2,4-
triazine and dienophile pairs separated by three-atom tethers generate 5,6-fused ring 
systems with significantly higher reactivity than those of four-atom tethers to generate 6,6-
fused ring systems [132, 133]. Furthermore, the structural properties of the tether, 
incorporating conformationally restricted functionality into the tether, such as a cis double 
bond or an aromatic ring, can enhance the intramolecular cycloaddition, by increasing the 
entropic assistance [128]. The electronic properties of the tether, can also affect the electron 
deficiency level of the 1,2,4-triazines or the electron richness of the dienophile, both of 
which are critical for the intramolecular cycloaddition to be successful. Geminal 
substitution on the tether also exploits the Thorpe-Ingold effect in promoting the 
intramolecular inverse electron demand Diels-Alder reactions [129-131]. The following 
examples illustrate the factors mentioned above: 
 
 In 1987, Taylor and coworkers reported the synthesis of a series of bicyclic 
structures with annulated pyridine rings via thermally promoted inverse electron demand 
Diels-Alder cycloadditions using 1,2,4-triazines tethered with various alkyne and nitrile 
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dienophiles as precursors (Scheme 1.7) [132, 133]. The triazines were tethered to alkynes 
and nitriles via nucleophilic aromatic displacement reactions (SNAr). The nucleophilic 
alcohols or amines I_41 bearing alkyne or nitrile functionalities displaced the leaving 
groups, SMe or SO2Me, from the parent triazines I_40, affording precursors I_42 and I_46 
with various tethers of different lengths in good yields. The thermally promoted inverse 
electron demand Diels-Alder cycloadditions afforded pyridine fused bicyclic structures 
I_44 and tricyclic structures I_47 following the release of dinitrogen from the 
intermediates I_43. Notably, the cycloaddition employing three atom tether (n=1) leading 
to 5,6-fused ring systems worked considerably better than the four atom tether (n=2) 
leading to a 6,6-fused ring systems, while no cycloaddition occurred for the tether bearing 
five or more atoms (n≥3). The oxygen atom tethers also worked better than nitrogen 
because of the stronger electronegativity of oxygen atom, which resulted in a lower the 
LUMO of the triazines. Furthermore, the tether with a planar aromatic ring incorporated in 
the precursors I_46 caused conformational restrains, which also contributed to the 
intramolecular advantages.  
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Scheme 1.7 Intramolecular Cycloaddition of 1,2,4-Triazine/Alkyne Pairs – Taylor 
 
 
 
In 1990, Sagi and coworkers also reported an intensive study on the intramolecular 
inverse electron demand Diels-Alder cycloaddition of 1,2,4-triazine derivatives [134]. In 
addition to repeating Taylor’s tethers to connect the triazines and electron rich dienophiles, 
they introduced ester linkage onto the tether in the triazine/dienophile pairs, to lower the 
triazine LUMO and favor the cycloadditions. Triazine acid I_48 was treated with ethyl 
chloroformate to produce the mixed anhydride, followed by treatment with alkynyl 
alcohols to generate the corresponding carboxylic ester cycloaddition precursors I_49 and 
I_51. The thermally promoted inverse electron demand Diels-Alder cycloadditions of I_49 
and I_51 afforded lactones I_50 and I_52, respectively. Starting with triazine acid I_53 
and following the same protocol, isomers I_55 and I_57 were prepared in good yields 
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(Scheme 1.8). In this work, tethers incorporating aromatic rings were also used in 
precursors I_51 and I_56. 
 
Scheme 1.8 Intramolecular Cycloaddition of 1,2,4-Triazine/Alkyne Pairs – Sagi 
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 An in depth investigation of the inverse electron demand Diels-Alder reactions of 
1,2,4-triazine derivatives and their applications was also conducted by our group in the 
synthesis of alkaloidal core structures and natural products via both inter- and 
intramolecular approaches. While the intermolecular inverse electron demand Diels-Alder 
cycloadditions of 1,2,4-triazines with indoles provided several regioisomeric carboline 
products I_61, I_63, and I_65, depending on the triazine substituents (Scheme 1.9) [135, 
136], the intramolecular approach was exploited to produce a single cycloadduct, -
carbolines [137]. In this latter synthesis, the 1,2,4-triazines I_66 were tethered to the C3 
position with the indolyl nitrogen via a thiourea linkage to prepare the triazine/dienophile 
pairs as the cycloaddition precursors I_68.  The inverse electron demand Diels-Alder 
reactions led to -carbolines I_69 in good yield. Subsequent reduction of the thiourea gave 
I_70 and I_71, which contain the tetracyclic core structure of eudistomidines E and F 
(Scheme 1.10). A different strategy exploiting a removable tether was also developed to 
prepare the tricyclic -carboline scaffolds I_75 (Scheme 1.11) by our group [138]. 
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Scheme 1.9 Intermolecular IEDDA Approach to Carbolines 
 
 
 
Scheme 1.10 Synthesis of -Carbolines via Intramolecular IEDDA of 1,2,4-
Triazines and Indoles – the Snyder Group 
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Scheme 1.11 Removal Tether Strategy to -Carbolines – the Snyder Group 
 
 
 
An intramolecular inverse electron demand Diels-Alder approach was also applied 
to the synthesis of the biologically interesting canthines by our group (Scheme 1.12) [139-
140]. The 1,2,4-triazine derivatives were tethered from the C3 position to the indolyl 
nitrogen using a dimethylene or a trimethylene chain to prepare the triazine/indole pairs as 
the cycloaddition precursors I_77. The cycloadditions of precursors I_77 with three-atom 
separation between the diene and dienophile gave the desired cycloadducts in good yield, 
but the precursors with two-atom separation failed to yield any desired products, 
presumably due to the severe ring strain. The longer, four carbon tether did allow for the 
cycloaddition to proceed, producing -carbolines annulated to a seven-membered D-ring 
(I_78, n = 2), but these cycloadducts proved to be unstable to storage. 
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Scheme 1.12 Synthesis of Canthines via Intramolecular IEDDA of 1,2,4-Triazines 
and Indoles 
 
 
 
Oxidation of the canthines I_78 (n=1), with benzyltriethylammonium 
permanganate (BTAP) afforded the canthinone alkaloids I_79 in excellent yield. Later in 
2003, Lindsley reported the same IEDDA approach to the canthine cycloadducts applying 
microwave irradiations instead of traditional thermal conditions. They achieved a “one pot” 
procedure: an acyl hydrazine-tethered indole I_80 underwent a 3-component condensation 
to form a triazine/indole pair precursor I_77, followed by an inverse electron demand 
Diels-Alder reaction with subsequent expulsion of dinitrogen to deliver canthines I_78. In 
Lindsley’s report, although the overall isolated yields were not any higher than the yields 
we obtained from conventional thermal methods, the microwave-protocol was able to 
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reduce the reaction time by 10 to 700 fold, which would be highly appreciated in 
preparations of chemical libraries with large number of molecule members. 
 
More recently in 2004, our group reported another application of the intramolecular 
inverse electron demand Diels-Alder reaction using the 1,2,4-triazine/imidazole pairs to 
produce 1,2,3,4-tetrohydro-1,5-naphthyridines (Scheme 1.13) [101]. The 
imidazole/triazine pairs I_82 were prepared from imidazoles I_81, featuring a trimethylene 
tether from the imidazole N1 position to the triazine C3 position. Inverse electron demand 
Diels-Alder cycloadditions of I_82 led to intermediates I_83 after the expulsion of 
dinitrogen. Subsequent elimination of a nitrile eventually delivered the 1,2,3,4-
tetrahydron-1,5-naphthyridines I_84 as the final products. Intramolecular cycloadditions 
employing tetramethylene tethers also proceeded to give 2,3,4,5-tetrahydro-1-H-
pyrido[3,2-b]azepines in acceptable, but reduced yields (11-72%). The microwave protocol 
was also applied, which accomplished comparable yields with significantly shortened 
reaction times.  
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Scheme 1.13 Synthesis of 1,2,3,4-Tetrahydro-1,5-naphthyridines via 
Intramolecular IEDDA of 1,2,4-Triazines and Imidazoles – the Snyder Group 
 
 
 
 In 2009, a library of small molecule inhibitors of hepatitis C virus was prepared and 
reported by our group, again applying the intramolecular inverse electron demand Diels-
Alder cycloaddition methodology between indoles and triazine (Scheme 1.14) [102]. In 
this work, 1,2,4-triaizines were tethered to tryptamine and tryptophan amino groups to 
prepare the cycloaddition precursors, utilizing chemistry our group investigated ten years 
earlier [141]. The cycloaddition precursors I_87 were prepared by nucleophilic aromatic 
displacement reactions of L-tryptophan derivatives I_85 on triazine I_86. Heating I_87 in 
1,2-dichlorobenzene in the presence of TFAA and DIPEA gave the cycloadducts I_89 in 
good yields. It was shown that in situ trifluoroacetylation of the nitrogen linker likely 
precedes the cycloaddition, lowering the LUMO of the heteroaromatic azadiene and 
thereby enabling the cycloaddition to proceed immediately affording I_89 without 
isolating the intermediate I_88. Deacylation of I_89 upon chromatography on silica gel 
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delivered final cycloadducts I_90, which resembled truncated Aspidosperma-type 
alkaloids, in good to excellent yields. Further chemical diversification of the cycloadduct 
N14 position led to a sub-library I_91.  
 
Scheme 1.14 Synthesis Inhibitors of Hepatitis C Virus via Intramolecular IEDDA 
of 1,2,4-Triazines and Indoles 
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An amide linkage was also applied in the synthesis of a similar -lactam sub-library 
(Scheme 1.15) [102]. The cycloaddition precursors I_92 were prepared from N-substituted 
indolylpropionic acids and 3-amino triazines with an amide tether. The intramolecular 
inverse electron demand Diels-Alder cycloadditions of I_92 gave cycloadducts I_93 in 
quantitative yields under conventional thermal conditions. 
 
Scheme 1.15 Preparation of -Lactam Sub-Library 
 
 
 
1.3  Pyridazines (1,2-Diazines) as Electron Deficient Diene in Inverse Electron 
Demand Diels-Alder Reactions 
 
The synthetic utility of 1,2,4-triazines and 1,2,4,5-tetrazines as azadienes in [4 + 2] 
cycloadditions with a variety of dienophiles has been extensively studied over the past 
decades, however, the pyridazine system as the 4- subunit is rather limited. The higher 
LUMO of this azadiene, in comparison to the more reactive 1,2,4-triazines and 1,2,4,5-
tetrazines, typically renders this azadiene less reactive. However, electron-deficient 
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pyridazine derivatives with electron withdrawing substituents, such as dicyanopyridazines, 
pyridazine carboxylates, have been shown to react with electron-rich dienophiles to afford 
products of [4 + 2] cycloadditions.  
 
In 1972, Neunhoeffer and coworkers reported the intermolecular inverse electron 
demand Diels-Alder reaction of pyridazine carboxylates I_94 and 1-methoxy-1-
(dimethylamino)ethylene (I_95) (Table 1.1) [142]. 1-Methoxy-1-
(dimethylamino)ethylene (I_95) added selectively across the C3/C6 positions of the 
pyridazines I_94, the regioselectivity of the cycloaddition guided by the strong directing 
effects of the dienophile matching those of the ester substituents. Loss of dinitrogen from 
the initial bicycloadduct followed by the elimination of methanol or dimethylamine from 
the intermediate I_96 yielded the corresponding benzenecarboxylates I_97. The rate and 
the yield of the reaction increased as the level of carboxylate substitution was increased. 
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Table 1.1 Cycloadditions of Pyridazine Carboxylates with 1-Methoxy-1-
(dimethylamino)ethylene (Scheme 1.16) 
 
Pyridazine 
Carboxylate I_94 
Conditions 
Product I_96 
R= NMe2:OMe 
Yield 
 
dioxane, 101 °C, 
24-48 h  
15:1 
60% 
 
dioxane, 101 °C, 
24 h  
12:1 
57% 
 
dioxane, 101 °C, 
24 h 
 
8:1 
90% 
 
dioxane, 101 °C, 
24 h  
3:1 
80% 
 
dioxane, 101 °C, 
1 h 
 
2:1 
93% 
 
dioxane, 101 °C, 
30 min 
 
10:1 
88% 
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Neunhoeffer and coworkers later reported another intermolecular inverse electron 
demand Diels-Alder reaction of pyridazine carboxylates I_94 using 1-
(diethylamino)propyne (I_98) as the dienophile (Table 1.2) [143]. Two cycloaddition 
products were observed from this Diels-Alder reaction. Thus, 1-(diethylamino)propyne 
(I_98) added either across the C3/C6 positions of the pyridazines, which produced 1-
diethylamino-2-methylbenzene carboxylates I_99 as the cycloadducts, or added across the 
N2/C5 positions of the pyridazines, which produced 2-ethylamino-3-methylpyridine 
carboxylates I_100 as the cycloadducts. The mode of the observed regioselectivity was 
controlled by the pyridazine substitution pattern. In each case only one of the two modes 
of cycloaddition was observed for each pyridazine carboxylate, and in no case there was a 
mixture of two products I_99/I_100 reported. And as anticipated, the rate and the yield of 
the reaction also increased as the level of carboxylate substitution was increased. 
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Table 1.2 Cycloadditions of Pyridazine Carboxylates with 1-
(Diethylamino)propyne (Scheme 1.17) 
 
 
Pyridazine 
Carboxylate I_94 
Conditions 
Product 
I_99/I_100 
Yield 
 
xylene, reflux, 
40 h 
 
23% 
 
dioxane, 101 °C, 
24-48 h 
 
30% 
 
dioxane, 101 °C, 
50 h 
 
75% 
 
CH3CN, reflux 
 
74% 
 
dioxane, 101 °C, 
24 h 
 
85% 
 
xylene, 25 °C, 
3 h 
 
73% 
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4,5-Dicyanopyridazine (I_101) is another pyridazine derivative which has also 
been extensively studied as an electron deficient heterocyclic azadiene in inverse electron 
demand Diels-Alder reactions with various dienophiles. In 1990s, the Turchi group 
published a series of reports on inverse electron demand Diels-Alder reactions of 4,5-
dicyanopyridazine with dienes, alkenes, alkynes and enamines [144-150]. The inverse 
electron demand Diels-Alder reactions of 4,5-dicyanopyridazine (I_101) with dienes 
functioning as bisdienophiles provided a general strategy for the one-pot synthesis of 
polycyclic carbo- and hetero-cage systems through pericyclic three-step domino processes. 
For example, by heating I_101 with an excess of 2,3-dimethylbuta-1,3-diene (I_102) in 
CHCl3 at 110 °C in a sealed tube, the tricyclic carbo-cage compound I_103 was afforded 
as the main reaction product in 64% yield, while only minor amounts of compounds I_104 
and I_105 were detected (Scheme 1.18, Eq 1) [144]. Another example employed 
diallyether (I_106): tricyclic hetero-cage compound I_107 was prepared applying the same 
methodology (Scheme 1.18, Eq 2) [145]. A total of 19 diene examples were investigated 
as dienophiles in this report, providing 21 – 99% yields of products of sequential Diels-
Alder cycloaddition.  
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Scheme 1.18 Cycloadditions of 4,5-Dicyanopyridazine with Dienes 
 
 
 
The inverse electron demand Diels-Alder reactions of 4,5-dicyanopyridazine 
(I_101) with simple alkenes, afforded dicyanocyclohexa-1,3-dienes, which could be 
further oxidized to the corresponding aromatic compounds. For example, treating 4,5-
dicyanopyridazine (I_101) with an excess of styrene at 110 °C in the presence of 10% Pd/C 
to favor the aromatization of the cyclohexadiene intermediate I_108, afforded I_109 in 
38% isolated yield (Scheme 1.19, Eq 1). Cycloalkenes could also be used as dienophiles, 
producing bicyclic dicyanocyclohexadienes I_110 (Scheme 1.19, Eq 2). The yields of 
compounds I_110a and I_110b were lower due to the competing formation of bis-adducts 
and aromatization products [148].  
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Scheme 1.19 Cycloadditions of 4,5-Dicyanopyridazine with Alkenes 
 
 
 
The inverse electron demand Diels-Alder reactions of 4,5-dicyanopyridazine 
(I_101) with alkynes and enamines provided a direct approach to variously substituted 
phthalonitriles. The aromatic products I_112 and I_115, isolated in good to excellent 
yields, came from the initial cycloadducts I_111 and I_114 by losing dinitrogen or 
sequential elimination of dinitrogen and amine, respectively (Scheme 1.20). 4,5-
Dicyanopyridazine (I_101) reacted with disilylacetylene at 110 °C allowing the isolation 
of cycloadduct I_112 in near quantitative yield (Eq 1). When enamine I_113 was applied, 
the corresponding substituted phthalonitrile I_115 was prepared in 72% yield (Eq 2). A 
total of 15 alkynes and enamines were investigated as dienophiles in this report, with the 
reactions proceeding in 29 – 98% yields [149].  
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Scheme 1.20 Cycloadditions of 4,5-Dicyanopyridazine with Alkynes and 
Enamines 
 
 
 
Similar to the case of 1,2,4-triazines previously discussed, inverse electron demand 
Diels-Alder reactions of pyridazines and dienophiles has been adapted to intramolecular 
pathways. An intramolecular inverse electron demand Diels-Alder cycloaddition of 3-
chloro-6-(2-allyphenoxy)-pyridazine (I_116) was reported by Takeshiba in 1972 [151, 
152]. Heating cycloaddition precursor pyridazine/dienophile pair I_116 with or without 
solvent afforded xanthene I_118 in excellent yield (Scheme 1.21).  
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Scheme 1.21 Intramolecular Cycloaddition of 3-chloro-6-(2-allyphenoxy)-
pyridazine 
 
 
 
 Intramolecular inverse electron demand Diels-Alder cycloadditions of pyridazines 
were applied by Boger in the total synthesis of PDE-II methyl ester. In 1986, Boger 
reported the total synthesis of PDE_II methyl ester featuring the utilization of two 
heterocyclic azadiene Diels-Alder reactions: an intermolecular inverse electron demand 
Diels-Alder reaction of dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate (I_119), and a 
subsequent intramolecular inverse electron demand Diels-Alder reaction of an alkyne-
tethered 1,2-diazine I_123 resulting from the initial cycloaddition (Scheme 1.22). Starting 
with 4,4-dimethoxybut-3-en-2-one (I_120) as dienophile and dimethyl 1,2,4,5-tetrazine-
3,6-dicarboxylate (I_119) as azadiene, the intermolecular inverse electron demand Diels-
Alder cycloaddition in refluxing dioxane afforded the dimethyl 1,2-diazine-3,6-
dicarboxylate (I_121) as cycloadduct in 71% yield. After a series of functional group 
transformations and a Mitsunobu alkylation, compound I_122 was prepared completing 
the assemblage of the necessary components for the subsequent intramolecular 1,2-diazine 
Diels-Alder construction of the indoline ring system of the PDE-II core structure. 
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Hydrolysis of I_122 followed by oxidation and N-acetylation afforded amide I_123 as the 
inverse electron Diels-Alder cycloaddition precursor. Intramolecular Diels-Alder 
cycloaddition of I_123 in 1,3,5-triisopropylbenzene (230 °C, 18 h) in a sealed tube under 
argon provided an 82% isolated yield of indoline I_124 and completed the construction of 
the indoline ring system of the PDE-II core structure. Further treatments of indoline 
cycloadduct I_124 eventually led to PDE-II methyl ester I_125 [153].  
 
Scheme 1.22 Total Synthesis of PDE-II Methyl Ester by Boger 
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1.4 Objective 
 
The work described in this thesis continues the investigations of our group into new 
inverse electron demand Diels-Alder reactions and their applications to heterocyclic 
synthesis. In these projects, we have utilized 1,2,4-triazines, 1,2,4,5-tetrazines and 
pyridazines as electron deficient azadienes in inverse electron demand Diels-Alder 
cycloadditions with various electron rich dienophiles to construct tetracyclic carboline and 
carbazole core structures. Both inter- and intramolecular [4+2] cycloadditions were 
investigated. We have established robust methodologies featuring the inverse electron 
Diels-Alder cycloaddition for the synthesis of libraries of drug-like compounds, for 
biological screening. 
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Chapter II 
 
 
 
 
An Intramolecular Inverse Electron Demand Diels-Alder Approach to 
Annulated α-Carbolines, Library Synthesis and Studies toward the 
Synthesis of the Grossularines  
 
 
2.1 Introduction  
 
In comparison with the well-known -carbolines, -carboline alkaloids are quite 
rare, and only a few natural products isolated to-date contain this pyrido[2,3-b]indole (-
carboline, II_1, Figure 2.1) core. The most prominent examples are grossularine-1 (II_3) 
and grossularine-2 (II_5), marine cytotoxic agents which were isolated from the tunicate 
Dendrodoa grossularia (Stylidae) [153, 154], and desmethylgrossularine-1 (II_4) from the 
tunicate Polycarpa aurata [155]. Other natural –carbolines include mescengricin (II_6), 
an inhibitor of L-glutamate excitotoxicity in neurons, isolated from Streptomyces 
griseoflavus [156], and cryptotackieine (II_2) [157], also known as neocryptolepine [158], 
isolated from roots of the West African plant Cryptolepis sanguinolenta [159]. 
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Cryptotackieine, a member of the indolo[2,3-b]quinoline class of heterocycles [160], has 
been shown to be a strong inhibitor of Plasmodium falciparum growth [161]. For example, 
2-Amino--carbolines, such as II_7 and II_8, have also been identified as the mutagens 
produced in the pyrolysis of proteins [162, 163] as well as the pyrolysis of tryptophan 
[164]. Isoeudistomin U, isolated from the Ascidian Lissoclinum fragile, was originally 
reported to have a -carboline skeleton II_9 [165], but this assignment was later shown to 
be incorrect [166], the revised structure was reported as the dihydro--carboline II_10. 
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Figure 2.1 -Carboline Core Structure and Natural Products with -Carboline 
Subunits 
 
 
 
Given their isomeric relationship to β-carbolines, α-carbolines have attracted 
attention from synthetic chemists [167], and more recently from medicinal chemists [168]. 
Synthetic members of this class were shown to have a wide range of activities, including 
topoisomerase II inhibition [169], and 4-amino--carbolines have also been shown to 
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possess anxiolytic properties by stabilization of the open chloride channel [170, 171]. 
Relatively few patents have been granted on the medicinal use of -carbolines, particularly 
in comparison to -carbolines, with recent applications including use as antiviral agents 
[172], inhibitors of ApoB-100 associated lipoprotein production for cholesterol lowering 
[173], and more recently, as inhibitors of CDK1 kinase as potential anti-cancer agents 
[174]. This later filing has triggered investigations into -carbolines as potential 
multikinase inhibitors [175].  
 
Existing synthetic approaches to -carbolines are numerous and often independent 
of a specific target, but rather are methodology oriented. Exceptions include those efforts, 
which have targeted the grossularines [176-182] and the more popular cryptotackieine 
[183-187]. There are two major approaches reported in the literature for the synthesis of 
pyrido[2,3-b]indole cores: construction of the pyridine ring from an existing indole 
framework, such as 2-amino-3substituted indole derivatives or its equivalent, and 
construction of the indole pyrrole ring from an existing pyridine framework via cross 
coupling chemistry between appropriate aniline and pyridine derivatives (Figure 2.2).  
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Figure 2.2 Overview of Literature Synthesis of -Carbolines 
 
 
 
The first reported synthesis of an -carboline by Sir Robert Robinson in 1924 [167, 
188] proceeded through the acid catalyzed decomposition of 1-(2-pyridyl)benzotriazole, a 
modification of the Graebe-Ullmann carbazole synthesis which closes the indole ring 
(Scheme 2.1, Eq 1) [189]. This procedure was improved upon and exploited for decades 
[190-193]. Later, the roles of the benzene and pyridine rings were reversed, with the latter 
bearing the diazonium salt, leading to improved yields in the indole ring closure, as did 
microwave promotion of the original methodology (Scheme 2.1, Eq 2) [194, 195]. Nitrene 
insertion chemistry of appropriately substituted 3-arylpyridines also found application 
(Scheme 2.1, Eq 3) [196, 197], and likewise falls into the category of indole ring closure 
onto an existing substituted pyridine, though in this case with formation of the C-N bond. 
A Fischer indole synthesis route through the 2-pyridylhydrazone of cyclohexanone, 
catalyzed by PPA, followed by dehydrogenation over Pd-C has also been reported to 
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prepare the unsubstituted -carboline [201] (Scheme 2.1, Eq 4), but surprisingly no other 
successful application of this strategy has appeared in the literature. 
 
More recently, the Cuny group has reported two strategies that exploit cross-
couplings to prepare anilinopyridines, with final indole ring closure occurring by either a 
second cross-coupling [198], or a photo-cyclization [199] (Scheme 2.1, Eq 5 and Eq 6). 
The former, sequential cross-coupling strategy closely follows previous work by 
Queguiner [200]. 
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Scheme 2.1 Syntheses of -Carbolines – Construction of Indole Ring 
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A more common strategy to -carbolines closes the pyridine ring onto an existing 
indole framework. In general, applications of this construction sequence fall into two major 
camps: condensations routed through a 2-aminoindole synthon (Scheme 2.2, Eq 1) [202-
209], and those targeting pyridine closures onto a 2-oxindole (Scheme 2.2, Eq 2) [210, 
211]. The C-N bond closures in presumed nitrogen radical processes, constructing -
carbolines, have also been reported by Narasaka (Scheme 2.2, Eq 3) [213, 214].  
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Scheme 2.2 Synthesis of -Carbolines – Construction of Pyridine Ring 
 
 
 
In addition, intramolecular Hartwig-Buchwald cross coupling onto a 2-
bromoindole, with formation of the pyridine was reported by Dodd [212]. In Dodd’s 
synthesis (Scheme 2.3), an intramolecular palladium-catalyzed reaction to construct the 
pyridine ring of the -carboline core by forming a bond between the N1 and C9a positions 
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was utilized. Aldol product II_26 was obtained by first enolization of the -amino-lactone 
II_24 with LiHMDS followed by trapping the enolate with 2-bromo-1-methylindole-3-
carboxaldehyde II_25 in the presence of stannic chloride with 51% yield. Acid catalyzed 
dehydration and deprotection by TFA, SMe2 gave -unsaturated carbonyl compound 
II_27 with 90% yield. Finally, the palladium catalyzed cross coupling chemistry afforded 
the N1-C9a bond formation to close the pyridine ring giving the desired product II_28 in an 
overall yield of 23%. 
 
Scheme 2.3 Dodd’s Synthesis of -Carboline – Construction of Pyridine Ring 
 
 
 
Electrocyclic ring closures forming the pyridine ring from 2-aminoindole-derived 
intermediates are also known [215-217]. Funicello’s synthesis is an example of the N1-C2 
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bond formation to construct the pyridine ring by electrocyclic ring closure (Scheme 2.4). 
2-Azido-1-methyindole II_29 was prepared by azidation of 1-methylindole by azido group 
transfer from tosyl azide. Azide II_29 was then treated with triphenylphosphine affording 
N-(1-methylindol-2-yl)iminotriphenylphosphorane II_30 in 70% yield. Iminophosphorane 
II_30 underwent an aza-Wittig reaction with acrolein, followed by an electrocyclization, 
to close to the pyridine ring giving the corresponding -carboline in 70% yield.  
 
Scheme 2.4 Funicello’s Synthesis of -Carboline – Construction of Pyridine Ring 
by Electrocyclic Ring Closure 
 
 
 
Intramolecular dipolar cycloadditions of 2-azidoindole derivatives have also been 
used to close the pyridine ring (Scheme 2.5, Eq 1) [219], as have intramolecular 
cycloadditions of carbodiimides (Scheme 2.5, Eq 2) [220, 221], to construct -carbolines. 
Recently, in 2010, Kusurkar and co-workers reported cycloadditions of 3-vinyl-7-
azaindoles to construct -carbolines (Scheme 2.5, Eq 3) [218].  
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Scheme 2.5 Syntheses of -Carbolines 
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2.2 An Intramolecular Inverse Electron Demand Diels-Alder Approach to -
Carboline Skeleton 
 
Inverse electron demand Diels-Alder cycloadditions using electron-deficient 
heteroaromatic azadienes are well-established chemistry for the synthesis of heterocyclic 
compounds, and have been previously applied to the synthesis of -carbolines. 
Intramolecular IEDDA chemistry to prepare -carbolines employing 2-N-(o-
alkynylanilino)pyrimidine systems have been successful in a limited number of examples 
(Scheme 2.6, Eq 1) [223, 224]. Hoonaert and co-workers have also employed pyrazinones 
as dienes in IEDDA reactions to prepare -carbolines (Scheme 2.6, Eq 2) [225].  
 
Scheme 2.6 Syntheses of -Carbolines via IEDDA 
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We had envisioned that a library of annulated -carboline structures (II_42) could 
be prepared by intramolecular inverse electron demand Diels-Alder reaction (IEDDA) of 
indole-1,2,4-triazine (II_43), which is derived from condensation with an isatin (II_46), 
with tethered electron rich dienophiles (Scheme 2.7) [222].  
 
Scheme 2.7 Retrosynthetic Analysis of Inverse Electron Demand Diels-Alder 
Approach to -Carbolines 
 
 
Though the existing synthetic routes can readily produce various α-carbolines, the 
intramolecular IEDDA approach, outlined in Scheme 2.7, has several advantages from a 
library synthesis perspective. First, there is a wide selection of commercially available or 
easily synthesized starting materials: isatins, propargylic and homopropargylic amines and 
alcohols. Second, three easily modifiable diversification sites, R1, R2 and R4, can be built 
into the core –carboline structure. Furthermore, construction of the annulated lactam or 
lactone as the fourth ring would be easily accomplished by the IEDDA reactions, thereby 
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adding two more diversification points: R3 as well as lactam/lactone ring size. A particular 
goal in this work was to establish the reaction chemistry and scope in order to build a 
library of -carbolines for biological screening. The targeted -carbolines II_42 (Z = O) 
are similar to those prepared by Dodd applying a rather lengthy route (Scheme 2.3), but 
with a transposed carbonyl group on the lactone ring [212]. 
 
One consideration in this design was the electron donation from the indole nitrogen 
into the indole-triazine ring of II_45, which would result in an elevated LUMO of the 
triazine azadiene, and thereby inhibit the desired cycloaddition. Thus, it was anticipated 
that an electron-withdrawing group R2, which could also serve as a diversification point, 
would be needed on the indole nitrogen.  
 
Feasibility studies began with isatin-derived 1,2,4-triazine II_45a (R1 = H) [226, 
227], which was easily prepared by the condensation of isatin (II_46, R1= H) with ethyl 
oxalamidrazonate [228-231] (II_47) in quantitative yield (Scheme 2.8). The first step in 
the cyclocondensation was accomplished by stirring in ethanol at room temperature for 12 
h and refluxing 20 min, after which the solvent was removed and the cyclocondensation 
completed by refluxing in bromobenzene (bp 156 oC) for 24 h. The two-step condensation 
with different solvents was needed to optimize the triazine formation. Sulfonylation of the 
indole nitrogen also proceeded routinely to give triazine II_44a (R1 = H, R2 = Ts), and 
served two purposes. As noted, reduction of electron donation from this nitrogen into the 
triazine ring was thought to be important in order for the subsequent cycloaddition to 
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proceed, as later studies showed to be correct. Furthermore, sulfonylation greatly improved 
the solubility of the triazines II_44 in organic solvents in comparison to II_45, which 
showed only limited solubility in dichloromethane, chloroform, THF, toluene, methanol 
and acetone. Starting with other 5-substituted isatin derivatives, analogous triazines were 
similarly prepared in good yields (84 - 92%, Table 1). 5-Nitro- and 5-carboxamidoisatins 
also readily participated in the cyclocondensation with the oxalamidrazonate II_47 to form 
the corresponding triazines (II_45, R1 = NO2, CONH2), but due to the electron withdrawing 
nature of the isatin substituents, subsequent sulfonylations were not successful (not 
shown). 
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Table 2.1 Preparation of N-protected indole-1,2,4-triazines II_44 (Scheme 2.8) a 
 
 
 
R2 R1 = H R1 = Me R1 = MeO R1 = F 
p-MePh II_44a, 88% II_44b, 92% II_44c, 89%  II_44d, 85% 
p-MeOPh II_44e, 90% II_44f, 87% II_44g, 84%  II_44h, 88% 
Ph II_44i, 90% II_44j, 88% II_44k, 87%  II_44l, 91% 
a Isolated yield over two steps (Scheme 2.8). 
 
Lewis acid catalyzed amidation of II_44a with methyl propargyl amine (II_48a) 
gave the cycloaddition precursor II_49a in excellent yield when Al(Me)3 was used as 
catalyst (Table 2.2) [234-237]. However, the most convenient procedure for library 
protocols employed 1.2 equivalents of Zr(Ot-Bu)4 [238]. Weinreb amidation with Al(Me)3 
also gave excellent yields, but required the extra step of first mixing Al(Me)3 and the amine, 
then cannulating this amine-AlMe3 complex into the triazine solution in order to avoid 
ketonization of the ester [238]. Not surprisingly, other Lewis acids, MgCl2, Mg(OTf)2, 
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Zn(OTf)2, Yb(OTf)3 and Sc(OTf)3, were not successful in catalyzing the amidation. 
Stoichiometric amounts of catalyst were required for the amidation, presumably due to the 
product itself sequestering the catalyst and preventing efficient turnover. 
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Table 2.2 Lewis Acid Catalyzed Amidation Reaction of Triazine Ester II_44a 
(Scheme 2.9) 
 
 
Entry Catalyst Loading (eq) Solvent (0.1M) Yield (%) a 
1b Al(Me)3 1.5 DCM >95
 
2 Zr(Ot-Bu)4 0.5 toluene 60
 
3 Zr(Ot-Bu)4 1.2 toluene 90
 
4 c Zr(Ot-Bu)4 1.2 DCM >95
 
5 d MgCl2 1.2 DCM < 10 
6 d Mg(OTf)2 1.2 DCM < 10 
7 Zn(OTf)2 1.2 DCM no reaction 
8 Yb(OTf) 1.2 DCM no reaction 
9 Sc(OTf)3 1.2 DCM no reaction 
a All reactions were carried out at rt for 20 hours unless otherwise 
noted; isolated yield.  
b Mix catalyst and amine, then transfer the mixture amine-
aluminum complex into triazine solution via cannula.  
c  Reaction time was 16 hours. 
d Hydrolyzed decomposition product detected (UPLC, NMR). 
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The intramolecular cycloaddition of II_49a, the alkyne tethered triazine, was 
studied under various conditions (Table 2.3). Ultimately it was found that the IEDDA 
reaction proceeded smoothly under microwave irradiation, in diglyme (120 oC, 20 min, 
Entry 3) to give the -lactam annulated α-carboline II_50a in quantitative yield. The 
microwave promoted reaction conditions were preferred over the more traditional heating 
(Entry 1) because of the shorter reaction time, which prevents the possible decomposition 
of other cycloadducts. Attempts to lower the temperature and/or shorten the reaction time 
lead to lower yields (Entry 2, Entry 4 and Entry 5). Little or no reaction occurred in toluene 
under microwave irradiation (Entry 6) unless silicon carbide chips [240] were added as a 
microwave facilitator (Entry 7).  
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Table 2.3 Microwave Promoted IEDDA Reaction Conditions of Isatin Derived 
Triazine II_49a to Give Cycloadduct II_50a (Scheme 2.10) a 
 
 
 
Entry Solvent Temperature (oC) Time Yield 
1b diglyme 164 7 h > 95% 
2 diglyme 100 20 min 40% 
3 diglyme 120 20 min > 95% 
4 diglyme 120 10 min 70% 
5 diglyme 160 10 min 85% 
6 toluene 160 30 min trace 
7c toluene/Si-C 160 30 min 60% 
a IEDDA reactions were carried out under microwave irradiation 
unless otherwise noted. All yields (conversion) were determined by 
UPLC unless otherwise noted. 
b Heating in oil bath. 
c Si-C chip was added to the reaction under microwave irradiation. 
Isolated yield. 
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 Upon further exploring the reaction conditions, it was discovered that the 
amidation-cycloaddition sequence could be accomplished in one pot process (Scheme 
2.11). The Zr(IV)-catalyzed amidation was thus accomplished in tetrahydrofuran (16 h, rt), 
then the reaction mixture was refluxed at 65 ºC for another 24 h to yield cycloadduct 
II_50a. This one-pot procedure gave a yield of 89% for II_50a without isolating the amide 
intermediate, which was comparable to the overall yield (94%) of the corresponding two-
step sequence, in which isolation of the intermediate amide was performed. Control 
experiments were carried out to determine the possible catalytic role of Zr(Ot-Bu)4 in the 
cycloaddition. In two side-by-side reactions, II_49a, one sample with Zr(Ot-Bu)4 and one 
without Zr(Ot-Bu)4 catalyst, were heated to 65 
oC. The two reactions required the same 
amount of time (24 h) to give complete conversions, indicating that the presence of 
amidation catalyst Zr(Ot-Bu)4 in the one pot two step sequence had no effect on the 
cycloaddition of III_49a. For the library synthesis, which will be discussed in the next 
section, the two-step sequence was adopted in order to isolate the triazine intermediates 
II_49, which can also serve as members of a secondary library. 
 
Scheme 2.11 One Pot Process of Amidation /Cycloaddition of Triazine Ester II_44a 
 
 
57 
 
 With the two-step sequence optimized for preparing II_50a, the scope of this 
chemistry was probed with other alkynyl amines II_48. The alkynyl amines were either 
commercially available, or could be easily prepared from simple procedures. Thus, II_48d-
h were prepared via nucleophilic substitutions with propargyl bromide and various primary 
amines (Scheme 2.12, Eq 1). Amines II_48i-l were prepared via reductive aminations of 
the propargyl amine with various aldehydes (Scheme 2.12, Eq 2). Finally, II_48m was 
prepared from 3-butyn-1-ol, after conversion to the mesylate II_51, then refluxing with 
benzylamine in toluene (Scheme 2.12, Eq 3). 
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Scheme 2.12 Preparation of Alkynyl Amines II_48 
 
 
 
 The amidations with the alkynyl amines II_48 with II_44 proceeded in high yields 
under the optimized conditions with Zr(Ot-Bu)4 as catalyst. The cycloaddition precursors 
II_49 were then subjected to the optimized microwave promoted cycloadditions to give 
the final cycloadducts II_50 (Table 2.4). 
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Table 2.4 Amidation-IEDDA Sequence to -Carbolines II_50 from Triazines 
II_44 (Scheme 2.13) a
 
 
Entry Amine 
Cycloaddition precursor 
II_49 (Yield) 
Cycloadduct 
II_50 (Yield)b 
 
1 
 II_49a (98%) 
  
II_50a (96%) 
2c  II_49b (90%) 
  
II_50b (83%) 
3d 
 
II_49c (89%) 
  
II_50c (91%) 
4 
 
II_49d (96%) 
 
II_50d (98%) 
5  II_49e (96%) 
  
II_50e (97%) 
60 
 
6e  
II_49h  
(95%)   
II_50h (93%) 
7f 
 
II_49m (93%) 
  
II_50m (95%) 
8  II_49n (95%) No Rxn 
a Amidation reactions were carried out in DCM, with 1.2 equivalent of 
amine and 1.2 equivalent of Zr(Ot-Bu)4 at rt for 16 hours, 0.25M. 
IEDDA reactions were carried out in diglyme under microwave 
irradiation at 120 oC for 20 minutes, unless otherwise noted. All IEDDA 
reaction concentrations are 0.1M. 
b Isolated yields.  
c IEDDA in DMF at 160 oC for 30 minutes.  
d IEDDA in diglyme at 160 oC for 30 minutes.  
e IEDDA in diglyme at 120 oC for 40 minutes, 0.1M.  
f IEDDA in diglyme at 160 oC for 30 minutes.  
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Tertiary propargyl amides II_49a, II_49d, and II_49e with terminal alkyne 
dienophiles all showed comparable reactivity (Entry 1, Entry 4, and Entry 5), under the 
optimized cycloaddition conditions (diglyme, microwave irradiation, 120 oC, 20 min), 
producing the desired α–carbolines in excellent yields (96 – 98%). However, propargyl 
amide II_49h with the internal alkyne (Entry 6) required a longer reaction time (40 min) 
for the cycloaddition to be completed in a good yield (93%). Increasing the tether length 
between the alkyne group and the amide linkage also decreased the reactivity (Entry 7). 
Thus, the cycloaddition of tertiary propargyl amide II_49m to produce the δ–lactam 
II_49m required higher temperatures (160 oC vs 120 oC) to proceed in high yield, still in 
30 minutes. 
 
In contrast to the tertiary amides, secondary amides II_49b and II_49c (Entry 2 
and Entry 3) showed no or very little reaction under our pre-determined microwave 
conditions. The reason for this lack of reactivity was thought to be a strong intramolecular 
hydrogen bond, which may inhibit the alkyne group from rotating to the proper position 
for the cycloaddition to occur (Scheme 2.14), or a slow cis-trans amide equilibrium. 
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Scheme 2.14 Intramolecular Hydrogen Bonding Preventing IEDDA from 
Affording II_50b 
 
 
 
The NMR spectra supported this hypothesis: as all tertiary amides showed the 
presence of two rotamers in a 1:1 ratio in CDCl3, the secondary amides II_49b and III_49c 
showed only a single rotamer in the NMR spectra. In the 1H NMR spectrum for II_49b, a 
very slowly exchanging proton (48 hours for complete exchange) at δ 8.25 supported the 
presence of a single conformation with strong intramolecular hydrogen bonding. When the 
cycloaddition of II_49b was run in DMF instead of diglyme (160 oC, 20 min), the 
cycloadditions proceeded in good yield to give the desired cycloadduct II_49b (83%, Entry 
3). Presumably the significantly greater hydrogen bond disrupting capabilities of DMF in 
comparison to diglyme enable the cycloaddition to proceed. When II_49c with the gem 
dimethyl substituted propargylic carbon, was run in diglyme at a higher temperature (160 
oC, 30 min), the cycloaddition proceeded in good yield to give the desired product II_50c 
(91%, Entry 3), presumably aided by the Thorpe-Ingold effect [241-243]. No cycloaddition 
occurred with the nitrile as the potential dienophile under any conditions examined (Entry 
8). 
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To confirm the importance of the electron-withdrawing group on the original indole 
nitrogen, the reactivity of amide II_52 (R1 = H) was also examined (Scheme 2.15). As 
expected, no cycloaddition product II_53 was observed under any conditions, presumably 
due to the greater electron donation from the indole nitrogen, which elevates the LUMO of 
the triazine ring, thereby preventing the desired cycloaddition. Additional modification 
such as elevated reaction temperatures or prolonged reaction time all led to decomposition 
of II_52, and a small amount of the decarboxylation product of II_52 was detected in 
UPLC analysis.  
 
Scheme 2.15 Preparation of Unprotected Triazine II_52, and its Reactivity in 
IEDDA 
 
 
In addition to the amide linkage of the alkyne dienophiles, transesterification of 
II_44a with alkynyl alcohols led to tethered alkynyl esters as cycloaddition precursors 
II_54a and II_54b in good yields (Scheme 2.16). Various catalysts for the 
transesterification reaction were screened. Boronic acid [244] and indium (III) iodide [245] 
yielded no transesterification product with propargyl alcohol, while Ti(OiPr)4 [246] gave 
only a trace of desired product, with mostly detosylation resulting. Otera’s catalyst [247] 
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proved optimal, giving cycloaddition precursors II_54a and II_54b in excellent yields 
(84% and 87%, respectively). 
 
Scheme 2.16 Transesterification and IEDDA Sequence affording II_55a 
 
 
 
Cycloaddition precursors II_54a and II_54b showed a much lower reactivity in the 
cycloadditions in comparison to the amides II_49. For ester II_54a, after microwave 
irradiation at 160 ºC for 2 hours, the desired cycloadduct II_55a with the annulated γ-
lactone was produced in good yield (80%). In contrast, II_54b, with the longer tether (n = 
2) failed to produce the desired δ-lactone under any conditions. A sharp decrease in 
reactivity in intramolecular IEDDA reactions of alkynes tethered to 1,2,4-triazines in 
progressing from 5- to 6-membered ring annulations has been previously noted by Taylor 
[248-251], and has been ascribed to the greater entropy loss for the larger rings [252]. 
Indeed, it has been estimated that the effective molarity for 5-membered ring closures can 
be as high as 1,000-fold greater in comparison to 6-membered ring cyclizations [253]. 
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2.3 Preparation of -Carboline Type Library via Amidation/Transesterification 
IEDDA Sequence on Isatin Derived Triazines 
 
 The established amidation/transesterification IEDDA sequence provided a rapid 
and efficient way to prepare lactam and lactone annulated -carbolines, which could 
ultimately be used in chemical library construction. This methodology presented a wide 
range of diversification sites on the final product structure attained in very few steps, as 
shown in Figure 2.3. By using various substituted isatins as starting material, substituents 
in the A ring of the -carbolines can be readily altered. The variation in the ring size in the 
D ring resulting from the final IEDDA reaction can be adjusted by varying the tether length. 
Also in the D ring, by choosing ester tether or amide tether, one can easily interchange the 
nature of the ring as lactone or lactam. Substitutions on the alkyne terminal position or on 
the propargyl position provide two more diversification sites. In the case of the lactam 
annulated cycloadduct, different substituents on the nitrogen can also be introduced via 
various alkynyl amines during the amidation step. Last but not the least, the indole nitrogen 
protecting group can be easily altered. In this fashion, a series of heterocycles can be 
effectively and efficiently synthesized from the inverse electron demand Diels-Alder 
reactions of the tethered alkyne/triazine pairs. 
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Figure 2.3 Possible Carboline Diversification Sites 
 
 
 With these diversifications in mind, a pilot scale library synthesis was designed 
(Figure 2.4).  In this library, four isatins with different substituents at the C5 position were 
selected to prepare the isatin derived triazines. After triazine formation, the original isatin 
nitrogen was then protected with five sulfonyl chlorides. Finally, eight various propargyl 
amines and an alcohol were chosen for the amidation/transesterification and IEDDA to 
construct the -carboline type library with a theoretical production of one hundred and 
eighty unique library members. 
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Figure 2.4 Proposed Library Production 
 
 
 
A work flow was designed and successfully executed for the library production 
(Figure 2.5). The production of the library was carried out in parallel fashion. The isatin 
derived triazines II_45 were prepared individually on a large scale, up to 3 grams. Isatin 
nitrogen protections were run in a reaction block, 12 reactions per set, and the products 
II_44 were purified manually. Subsequent amidations were carried out in a parallel fashion 
in a reaction block, 24 reactions per set, to prepare the cycloaddition precursors II_49, 
which were purified by passing through HydroMatrix plugs saturated with hydrochloride 
solution (1.0 M) to remove the catalyst and unreacted amine. The solvent was removed in 
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a Genevac evaporator ™, and the product residues were transferred into microwave 
reaction vessels and subjected into microwave reactions in parallel fashion, 24 reactions 
per set, to afford -carbolines II_50. The solvent diglyme was removed in the Genevac 
evaporator and the crude products were submitted to CMLD analytical team for 
purification by mass-directed preparative LC-MS, and plating for bio-screening. 
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Figure 2.5 Work Flow for the -Carboline Library Production 
 
 
 Using this optimized two-step amidation or transesterification, then IEDDA 
reaction sequence, following the work flow shown in Figure 2.5, a pilot scale chemical 
library of -carbolines was prepared, from triazine analogues II_44 and alkynyl amines 
II_48 and propargyl alcohol. The library contained 176 members, with 88 being IEDDA 
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-carboline cycloadducts (Table 2.5) and 88 being the corresponding tethered 
alkyne/triazine pair cycloaddition precursors II_49 and II_54a. The library was analyzed 
by using UPLC. The average yield of the library (-carboline cycloadduct) was 94%, with 
90% of the library members produced in yields greater than 85%. Purification by LC-MS 
produced the final library.  
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Table 2.5 Library Synthesis Matrix 
 
 
Library a R1= H R1= Me R1= OMe R1 = F 
         R2 (p-) 
R3     
MeOPh MePh Ph MePh OMePh Ph OMePh Ph OMePh MePh Ph 
 
100 100 100 50  100 50  90 72 100 100 85  
 100 94
b 100 100 100 66 100 100 99 100 100 
 
97 94b 100 77 98 90 100 100 100 98 100 
 
40  100 97 98 90  85  95  97 80  93 96 
 
100 100 100 100 100 95 100 100 100 100 100 
 
100 100 100 100 100 100 100 100 100 100 100 
 
65  100 95  100 100 92 100 100 100 100 100 
 
- c 100 100 100 - c 56 - c - c 94 100 - c 
a UPLC conversions against starting materials.  
b Isolated yields.  
c Members not prepared due to limited amount of the propargyl cyclohexylamine. 
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2.4 Studies toward the Synthesis of Grossularines 

Though natural products grossularine-1 II_3 and grossularine-2 II_5 were isolated 
over 20 years ago, there are still only two total syntheses reported for these two anticancer 
alkaloids, despite of the prominent cytotoxic activity they exhibited toward to murine and 
human L1210 leukemia cells by an intercalative mechanism: ID50 6 and 4 g/mL, 
respectively [254]. In 1995, Hibino and co-workers reported the first total synthesis of 
grossularine-1 and grossularine-2 [178, 179]. Their synthetic strategy fell into the 
subcategory of closing the pyridine ring onto a functionalized existing indole framework. 
The synthesis started with iodoindole II_59 and the stannylated imidazole II_58 
undergoing a Stille cross-coupling, producing ester II_60. Hydrolysis of the ester II_60 
gave the corresponding acid II_61. Curtius rearrangement, upon treating the acid II_61 
with diphenyl phosphorazide (DPPA) yielded isocyanate II_62. The final construction of 
the pyridine ring of the grossularines was achieved by bond formation across C2 – C3 via 
an intramolecular thermal electrocyclization between the azahexatriene of isocyanate and 
imidazole substituent, affording the tetracyclic imidazo[4’,5’:3,4]pyrido[2,3-b]indole core 
structure II_63. Conversion of II_63 to the grossularines was uneventful. Both structures, 
grossularine-1 and grossularine-2, were synthesized in 10 steps each from imidazole II_56 
in 28-33% overall yield (Scheme 2.17). 
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Scheme 2.17 Hibino’s Total Synthesis of Grossularine-1 and Grossularine-2 
 
 
 
More recently in 2005, Horne and co-workers published a biomimetic synthesis of 
grossularine-1 (Scheme 2.18) [182]. The synthesis began with the preparation of 2-
aminoimidazoles II_65 by the cyclocondensation of -amino carbonyl compound II_64 
with dimethyl cyanamide. The 2-amino-imidazole II_65 hydrochloride salt was then 
dissolved in a methanol solution saturated with ammonia, precipitating the dimer II_66 as 
a dark violet solid. Collection and resubjection of the dimer II_66 back into the identical 
reaction conditions afforded -carboline II_70. Finally the hydrolysis of imide II_70 
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afforded grossularine-1 as a yellow solid. The synthesis required only two steps from II_65 
to give natural product with an overall yield of 57%.  
 
Scheme 2.18 Horne’s Biomimetic Synthesis of Grossularine-1 
 
 
 
In addition to these two syntheses, several synthetic approaches that achieved the 
basic imidazo[4’,5’:3,4]pyrido[2,3-b]indole skeleton of the grossularines were published 
over the past several years. For example, Molina reported a straightforward synthesis of 
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the heterocyclic core of the grossularines by construction of the pyridine and imidazole 
rings in single step [180, 181]. The MOM protected 2,3-substituted indole II_71 was 
transformed into II_72 in 4 steps with decent yields. Then, indole derivative II_72 was 
treated with N,N-dimethyl guanidine to afford the complete grossularine core II_73 in good 
yield at room temperature. The simultaneous closure of both imidazole and pyridine rings 
in a single step made this approach rapid and efficient (Scheme 2.19). 
 
Scheme 2.19 Molina’s Synthesis of Imidazo[4’,5’:3,4]pyrido[2,3-b]indole Skeleton 
of Grossularines 
 
 
 
Achab and co-workers also published a synthesis of the 
imidazo[4’,5’:3,4]pyrido[2,3-b]indole skeleton via palladium catalyzed cross coupling 
chemistry (Scheme 2.20). [176, 177] Their approach started with the construction of the 
imidazole functionality on an existing substituted pyridine ring II_74, and completed the 
relatively lengthy synthesis with final closure of the indole ring system. The imidazole[4,5-
c]pyridine II_75 was prepared from the diaminodichloro pyridine II_74 and 
(dicholoromethylene)dimethyliminium chloride. Following bromination and SEM 
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protection of II_75, intermediate II_76 was obtained. Coupling II_76 with aniline derived 
stannane II_77 via palladium catalyzed cross coupling chemistry afforded the precursor 
II_78 for the final indole ring closure. The final intramolecular cyclization of II_78, which 
was triggered by the deprotection of the aniline, gave the grossularine core structure II_79 
in an acceptable 45% yield.  
 
Scheme 2.20 Achab’s Synthesis of Imidazo[4’,5’:3,4]pyrido[2,3-b]indole Skeleton 
 
 
 
Previously in our group, Dr. Grace Woo initiated an investigation of the 
grossularines synthesis via an intermolecular IEDDA approach between isatin derived 
triazines II_44 and imidazoles. Unfortunately, all attempts failed, affording little or no 
desired cycloadduct, as summarized in Table 2.6. In addition to the ethyl ester group, 
different electro-withdrawing substituents on triazine II_44 were tested as well, including 
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the corresponding methyl ketone, phenyl ketone and aldehyde. None of these structures 
afforded the desired cycloadduct.  
 
Table 2.6 Intermolecular Cycloaddition of Triazines II_44 with Imidazoles  
by Woo (Scheme 2.21) 
 
 
Entry II_44 (P) II_80 (R) Time (h) II_81 (%) 
1 Ts Ph 12 0 
2 Ts SMe 12 0 
3 SO2Ph SMe 12 0 
4 MOM SMe 24 0 
5 Ts NMe2 12 10 
6 MOM NMe2 24 0 
7 Ts (Me)2NCH=N 12 0 
a All reactions performed in refluxing diglyme (162 °C). 
b Isolated yield after chromatography on SiO2.  
 
 Since this investigation of the IEDDA reaction was exclusively promoted by 
thermal conditions, with the success of the construction of the -carboline library by the 
microwave irradiation, the possibility of achieving an intermolecular cycloaddition with 
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triazine II_44 and a range of selected dienophiles using microwave irradiation was 
investigated. Unfortunately, the same disappointing results were observed. Intermolecular 
IEDDA reactions of II_44a with ethyl ethynyl ether, enamines (E)-1-N-propenyl-
pyrrolidine and 1-pyrrolidino-1-cyclohexene, and 2-(dimethylamino)imidazole [231-233], 
all of which have been shown to react quite well with triazines and tetrazines in 
intermolecular IEDDA cycloadditions, were investigated. Unfortunately, II_44a showed 
no reactivity with any of the selected dienophiles under thermal or microwave assisted 
conditions, further confirming the importance of the previously established intramolecular 
strategy used in -carboline synthesis.  
 
Our focus then returned to the intramolecular approach, linking the imidazole 
functionality onto the triazine system via an amidation or transesterification reaction, then 
generating the desired grossularine core structure by an intramolecular IEDDA reaction. 
First, imidazole alcohol II_82 was prepared for transesterification onto II_44a to link the 
imidazole and triazine subunits. However, no desired ester II_83 was detected applying 
the Oterra catalyst (Scheme 2.22). The major products of the reaction were a mixture of 
decomposition products of imidazole alcohols and the detosylated triazine.  
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Scheme 2.22 Transesterification to Install the Imidazole to Triazine II_44a 
 
 
 
Imidazole amines II_84 were prepared as well for the amidation reaction with 
triazine II_44a to tether the imidazole subunit via an amide linkage. In the case of II_85a, 
no desired amide II_85a was found in the reaction mixture. When amine II_84b was 
applied, the desired amide II_85b was separated with a 65% yield (Scheme 2.23).  
 
Scheme 2.23 Amidation to Install the Imidazoles to Triazine II_44a 
 
 
 
 Amide II_85b was then subjected to the optimized IEDDA reaction condition 
(Scheme 2.24), using DMF as solvent. All attempts were unsuccessful, with either no 
reaction or substrate decomposition, using different solvents (diglyme, THF, and diphenyl 
ether), reaction times, promotion energy sources (thermal and microwave), and reaction 
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temperatures (See details in Chapter V, section 5.2). A successful cycloaddition of II_85b 
would have required formation of an 8-member ring. Also the transition state is high energy 
since aromatic imidazole would be disrupted and later rearomatize to access II_86. Such 
intramolecular IEDDA reactions are quite rare, and Seitz has shown these to be highly 
unfavorable. Details about the reaction conditions were described in Chapter V. 
 
Scheme 2.24 Intramolecular IEDDA Reaction of Amide III_85ba 
 
 
 
Since tertiary amides had higher activity in the intramolecular IEDDA reactions, 
another imidazole amine II_87 was made for the amidation/IEDDA sequence (Scheme 
2.25). The yield of the amidation reaction was very low, with only 20% yield of desired 
amide II_88 achieved. The majority of the product was II_89, with loss of the imidazole 
ring in a presumed retro conjugate addition/acyl enamine hydrolysis sequence. The tertiary 
amide II_88 underwent decomposition under relatively mild reaction conditions, 80 °C in 
diglyme, giving no desired cycloadduct. 
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Scheme 2.25 Intramolecular IEDDA of Tertiary Amide II_88 
 
 
 
The amidation/transesterification IEDDA sequence was a failure for achieving the 
intramolecular cyclization between triazine and tethered imidazole. The low activity of the 
amides in the cycloadditions is likely due to the tether length between the triazine and the 
imidazole dienophile. Amides II_85b and II_88, would be required to close an 8-member 
and 7-member ring, respectively, if the cyclization did occur, requiring much higher 
activation energy, which eventually decomposed the compounds. So in order to reduce the 
tether length, installation of the imidazole during the process of constructing the triazine 
instead of following the amidation/transesterification approach was undertaken (Scheme 
2.26). Amidrazone II_91 was prepared over two steps from II_90, followed by 
condensation with isatin affording the imidazole with the built in triazine II_92 in excellent 
yield over three steps (90%). Tosylation of II_92 gave the cyclization precursor II_93.  
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Scheme 2.26 Preparation of Imidazole Substituted Triazine II_93 
 
 
 
 Triazine II_93 was then investigated for the intramolecular IEDDA reaction 
(Scheme 2.27). Unfortunately, the intramolecular IEDDA reaction did not occur under any 
conditions. Different solvents (diglyme, DMF, and diphenyl ether), reaction times, 
promotion energy sources (thermo and microwave), and reaction temperatures (See details 
in Chapter V) were explored, but no desired grossularine core cycloadduct II_94 was 
observed. The low activity of triazine II_93 in the cyclization reaction could be explained 
by removing the electro-withdrawing carbonyl functionality from the triazine ring 
substituent compared to previous triazines II_44. The triazine ring system in II_93 was not 
electron deficient enough to allow the IEDDA to occur. At this point, further pursuit of the 
grossularines by this intramolecular IEDDA strategy was abandoned.  
  
83 
 
Scheme 2.27 Intramolecular IEDDA Reaction of Triazine II_93 
 
 
 
2.5 Summary 
 
Isatin-derived 1,2,4-triazines have proven to be excellent heteroaromatic azadienes 
for intramolecular inverse electron demand Diels-Alder reactions with tethered alkynyl 
dienophiles. These cycloadditions led to lactam-annulated α-carbolines in excellent yields 
under microwave promotion. The scope of the chemistry was probed using various alkynyl 
amines, alkynyl alcohols, and variation of the tether length between the aminoalkyne and 
the triazine. The triazines with ester linkages showed significantly less reactivity in 
cycloadditions compared to those with amide linkages. Increasing tether length also led to 
a decrease in cycloaddition reactivity. This chemistry was subsequently applied to a library 
synthesis, producing a focused library of eighty-eight -carboline members. Diversity was 
introduced using a combination of four substituted isatin-derived triazines, with four 
sulfonylations of the indole nitrogen, and several propargyl amine derivatives as 
dienophiles. Efforts toward to the total synthesis of grossularines were also made but all 
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were unsuccessful. Neither inter- or intra- molecular approach granted us the access of the 
grossularine core structures via IEDDA reaction of the triazine/imidazole pairs. 
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Chapter III 
 
 
 
 
An Intramolecular Inverse Electron Demand Diels-Alder Approach to 
Carbazoles and Carbazole Type Library Synthesis 
 
 
3.1 Introduction 
 
More than two decades ago, our group reported the inverse electron demand Diels-
Alder reaction of indole (III_1a) with dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate (III_2) 
[255, 256], which afforded dimethyl 5H-pyridazino[4,5-b]indole-1,4-dicarboxylate (III_4) 
(Scheme 3.1) [257-265]. In the presence of 1.9 equivalents of III_2, indole underwent a 
[4+2] cycloaddition with the tetrazine III_3, with immediate release of gaseous dinitrogen 
to produce the dimethyl 5H-pyridazino[4,5-b]indole-1,4-dicarboxylate (III_4). 
Dihydrotetrazine III_5, the penultimate intermediate in the synthesis of the tetrazine III_2, 
was also produced, presumably from the dehydrogenation of the intermediate III_3 by 
tetrazine III_2. Though the original yield of this [4+2] cycloaddition reported earlier by 
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Seitz and coworkers was only 30%, in our hands upon optimization, an excellent yield of 
greater than 95% was achieved preparing 5H-pyridazino[4,5-b]indole-1,4-dicarboxylate 
(III_4) routinely at large scales (up to 50 grams). 
 
Scheme 3.1 Preparation of Dimethyl 5H-Pyridazino[4,5-b]indole-1,4-
dicarboxylate III_4 
 
 
 
 Given the easy preparation of dimethyl 5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_4) in high yield, we sought to use III_4 and its analogues prepared from 
substituted indole derivatives as the starting point for the synthesis of several heterocyclic 
frameworks in library preparations. In order to achieve these goals, distinguishing the two 
ester groups of dimethyl 5H-pyridazino[4,5-b]indole-1,4-dicarboxylate (III_4) via 
regioselective manipulations was crucial.  
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Over the years, several protocols to regioselectively modify the two ester groups of 
III_4 have been explored. For example, a direct conversion of the “top” C1 ester of 
pyridazinoindole III_4 to methyl ketone III_6 utilizing trimethylaluminum was reported 
in 1997 (Scheme 3.2) [266-270]. Thus, upon treating pyridazinoindole III_4 with 4 
equivalents of trimethylaluminum in anhydrous methylene chloride, conversion of the C1 
ester group to the methyl ketone was predominant, affording III_6. Regioselective addition 
to this more electron deficient C1 ester group is easily rationalized through basic resonance 
considerations: electron donation from the N5 indole nitrogen renders the C4 carboxyl 
group less electron deficient than the C1 carboxylate, resulting in lower reactivity of the C4 
ester. However, the C4 ester was still reactive enough for conversion into methyl ketone. 
Further treatment of III_6 with excess (4 to 6 equivalents) trimethylaluminum afforded 
diketone III_7 in modest yield (41%). One problem with this methodology, however, was 
the variation in the number of equivalents of the trimethylaluminum required, which varied 
from batch to batch depending on the quality of the reagent. 
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Scheme 3.2 Regioselective Ketonization of Esters on Pridazinoindole III_4 
 
 
 
Another example was the regioselective amidation of the ester groups on 
pyridazinoindole III_4, which was first reported by our group in 1998 (Scheme 3.3) [271, 
272]. Tosylation of III_4 afforded III_8 with indole nitrogen protected. Weinreb amidation 
of III_8 with N-methylpropargylamine hydrochloride salt, to introduce the acetylenic 
dienophile onto the pyridazine ring, occurred exclusively on the C1 ester position to give 
the monoamide III_9 in 90% yield. Sonogashira coupling with o-bromoiodobenzene 
yielded III_10. Subsequent cycloaddition and further transformations led to staurosporine 
aglycone III_12.  
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Scheme 3.3 Regioselective Amidation on Pyridazinoindole III_4 
 
 
 
Given these highly encouraging preliminary results of the regioselective 
ketonization and regioselective amidation, coupled with the possibility of attaining 
diversified product structures through variations of the indole starting material and 
amidation amine partners, a more thorough investigation of the regioselective amidations 
on III_4 was initiated. 
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3.2 Regioselective Amidations of Dimethyl 5H-Pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_4) 
 
Based on early studies on the regioselective ketonization and Weinreb amidation 
of III_4 with trimethylaluminum, and trimethylaluminum/amine complexes, we had 
considered that nucleophilic addition to the C1 ester group would dominate the amidation 
of the ester substituents of III_4. Work began with a model study of the Weinreb amidation 
of III_4 with N-methylbenzylamine (III_13a). Following Weinreb’s procedure [273-275], 
trimethylaluminum was added to a solution of N-methylbenzylamine in anhydrous 
methylene chloride at 0 °C. The reaction mixture was stirred for 30 minutes, then slowly 
cannulated into a solution of III_4. Surprisingly, instead of amidation occurring at the C1 
ester position, the amidation exclusively occurred at the C4 ester position, affording 
monoamide III_17 (Scheme 3.4, Eq 1). This regioselectivity could be explained by 
coordination of the alkylaluminum amide III_14, generated in situ, with the indole nitrogen 
N5 of the pyridazinoindole III_4, forming the intermediate III_15. Then, the amino group 
was delivered intramolecularly to the C4 ester group to afford the bottom monoamide 
III_17.  
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Scheme 3.4 Regioselective Amidation of III_4 with N-Methylbenzylamine – 
Trimethylaluminum 
 
 
 
 
An excess of the alkylaluminum reagent (more than 3 equivalents) led to amidation 
at both ester groups, generating diamide III_18 (Scheme 3.4, Eq 2). The operational details 
were crucial for yielding the exclusive, regioselective monoamide product III_17. The 
optimized procedure required injecting 1.4 equivalent of trimethylaluminum into the 
solution of 1.5 equivalent of amine to form the alkylaluminum reagent. The slightly lower 
amount of trimethylaluminum, compared to the amine, was necessary to ensure that no 
excess trimethylaluminum existed to react with the diester III_4, which leads to 
ketonization. The injection of trimethylaluminum was best done underneath the surface of 
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the amine solution to avoid decomposition of trimethylaluminum contacting with air. The 
in situ generated alkylaluminum reagent then was slowly cannulated into the solution of 
III_4, applying the same subsurface injection technique. 
 
With this optimized procedure, primary benzylamine (III_13b) was then tested for 
the regioselective amidation reaction of pyridazinoindole III_4. However, the amidation 
with the primary benzylamine afforded different results (Table 3.1, Scheme 3.5). The 
anticipated regioselective C4 ester amidation was not observed. Instead, a mixture of all 
three possible amidation products was produced with no preference: monoamide at C1 
position III_19, monoamide at C4 position III_20 and diamide III_21. Other aluminum 
Lewis acid catalysts were also tested for the regioselective amidation but showed no desire 
selectivity (Entry 2 and Entry 3). Various sequences of adding reagents were tested as well, 
but no selectivity was observed. Regioselectivity was finally achieved when the reaction 
was carried out at a lower temperature, -50 °C, and with a lower loading of 1.1 equivalent 
of alkylaluminum and amine, affording monoamide III_19 with the amidation occurring 
at the C1 position (Entry 5) in an acceptable 50% yield. When the reaction was run at an 
even lower temperature, -78 °C, the reaction ceased to give any products (Entry 6). 
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Table 3.1 Regioselective Amidation of III_4 with Benzylamine – 
Trimethylaluminum (Scheme 3.5) a 
 
 
Entry 
Aluminum 
Cat. 
Eq. (amine/aluminum) Temp. Products 
(III_19):(III_20):(III_21) 
1 Al(Me)3 1.5 / 1.4 0 - rt 1:1:trace 
2 Al(Me)2Cl 1.5 / 1.4 0 - rt 1:1:trace 
3 Al(Me)Cl2 1.5 / 1.4 0 - rt 1:1:trace 
4 Al(Me)3 1.5 / 1.4 - 50 °C 2:1:trace 
5 b Al(Me)3 1.1 / 1.0 - 50 °C 50%:trace:trace 
6 Al(Me)3 1.1 / 1.0 - 78 °C no reaction 
a NMR analysis, unless otherwise noted.  
b Isolated yield. 
 
An explanation for the regioselectivity change when benzylamine, a primary amine, 
was applied in the amidation compared to secondary amine N-methylbenzylamine, may be 
in the identity of the aluminum-amine complex. With a primary amine, higher order 
aggregates of aluminum and amine, which were not identified, might have more likely been 
generated in the process [276, 277]. These aluminum-amine complexes may function as 
direct amidation reagents rather than undergoing a pre-amidation chelation between indole 
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N5 nitrogen and the C4 ester carbonyl group, which was the key for high regioselectivity at 
C4 with secondary amine. These complexes would more likely approach the more electron 
deficient C1 ester group, affording “top” monoamide III_19 as the major product.  
 
In order to accomplish a regioselective amidation that would exclusively occur at 
the C4 position on the pyridazinoindole III_4 when the primary benzylamine was applied, 
other possible Lewis acid catalysts were tested for the reaction (Table 3.2, Scheme 3.6). 
Lewis acids Mg(OTf)2, Yb(OTf)3, and Sc(OTf)3 catalyzed the amidation reactions without  
showing any regioselectivity, giving both monoamides and the diamide as a mixture. With 
Zr(Ot-Bu)4, a mixture of all three amides as well as decarboxylation products were 
produced (Entry 5). By comparison, Zn(OTf)2 did not catalyze the amidation at either ester 
position, causing only decomposition of the starting material (Entry 6). No reaction 
occurred with BF3/Et2O. MgCl2 did not promote the amidation at room temperature, 
however when the reaction temperature was elevated, refluxing in DCM, regioselectivity 
was finally achieved (Entry 8). Though the reaction only afforded a very low 12% yield, 
the amidation occurred exclusively at the C4 position, affording the “bottom” monoamide 
III_20. Higher loading of the catalyst (3.0 eq, Entry 9) did not significantly improve the 
yield (15%). Ester-activating reagents HOAT (0.1 eq), HOBT (0.1 eq) and DMAP (0.1 eq) 
were added to the reaction with MgCl2 in order to improve the overall yield. Though HOAT 
and HOBT improved the amidation conversion, these reactions showed no regioselectivity. 
The addition of DMAP (0.1 eq), however, improved the yield dramatically without 
scarifying regioselectivity, affording the monoamide III_20 in a 76% yield, with only a 
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trace amount of the other monoamide III_19 and diamide III_20 detected in the reaction 
mixture. To confirm that the regioselectivity indeed required MgCl2, a control reaction, 
applying DMAP (0.1 eq) without MgCl2, was carried out, yielding only trace amounts of 
all three products with no regioselective preference. Most of the starting pyridazinoindole 
was recovered (Entry 11). These results confirmed that DMAP did not account for the 
regioselectivity but only activated the ester groups. The regioselectivity presumably came 
from the coordination of the magnesium with N5 nitrogen and C4 carbonyl, directing the 
amidation to occur exclusively at the C4 ester on the pyridazine ring.  
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Table 3.2 Lewis Acid Catalyst Screening for Regioselective Amidation of III_4 
with Benzylamine (Scheme 3.6) a 
 
 
Entry Catalyst Eq. (cat./amine) Temp. 
Products 
(III_19):(III_20):(III_21) 
1 Mg(OTf)2 1.5 / 1.2 rt 1:1:trace 
2 MgCl2 1.5 / 1.2 rt NR 
3 Yb(OTf)3 1.5 / 1.2 rt 1:1:trace 
4 Sc(OTf)3 1.5 / 1.2 rt 1:1:trace 
5 Zr(Ot-Bu)4 1.5 / 1.2 rt 1:1:trace 
6 Zn(OTf)2 1.5 / 1.2 rt decomposition  
7 BF3-Et2O 1.5 / 1.2 rt NR 
8 b MgCl2 1.5 / 1.2 reflux  trace:12%:trace 
9 b MgCl2 3.0 / 1.2 reflux trace:15%:trace 
10 b MgCl2, DMAP 1.5 / 1.2 / 0.1 reflux trace:76%:trace 
11 DMAP 0.1 / 1.2 reflux trace:trace:trace  
a NMR analysis, unless otherwise noted. 
b Isolated yield. 
 
In summary, with the model studies completed, a collection of protocols was 
established for amidations to precisely differentiate the C1 and C4 ester groups on the 
pyridazinoindole III_4 with good to excellent regioselectivity, with both primary amines 
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and secondary amines (Figure 3.1). For primary amines, regioselective amidation at the 
C1 position could be achieved by using trimethylaluminum, and regioselective amidation 
at the C4 position could be achieved by using magnesium chloride with DMAP. For 
secondary amines, regioselective amidation at the C1 position could be achieved by 
protecting the pyridazinoindole N5 nitrogen first, then applying the trimethylaluminum 
catalyzed Weinreb amidation. Regioselective amidation at C4 position could be achieved 
with secondary amines by a direct Weinreb amidation reaction. To obtain diamides with 
both C1 and C4 esters transformed, both trimethylaluminum and magnesium chloride, 
excess amount, with excess amine could be used to afford the desired products in excellent 
yields.  
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Figure 3.1 Summary of Regioselective Amidation Reactions on  
Pyridazino[4,5-b]indole III_4 
 
 
 
Over the years, a diversity collection of compounds was made by the Center for 
Chemical Methodology and Library Development at Boston University (CMLD-BU). This 
diversity collection, which was assembled from various organic labs in the chemistry 
department at Boston University, consisted of unrelated structure types that had been 
prepared as part of various research projects in different organic groups. During the 
screening of this diversity collection of compounds against West Nile virus, 
pyridazinoindole III_22 emerged as a compound of interest showing promising 
bioactivity. In order to optimize the bioactivity of the pyridazinoindole structures against 
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West Nile virus, a small pilot scale library was proposed with III_22 as the lead structure, 
applying the established regioselective amidation methodology (Figure 3.2). 
 
Figure 3.2 Pyridazinoindole Library and Leading Structure III_22 
 
 
 
Therefore, the scope of the chemistry was examined on the established 
regioselective amidation with various dimethyl 5H-pyridazino[4,5-b]indole-1,4-
dicarboxylates, primary amines and secondary amines. A small collection of compounds 
was prepared for bioactivity screening against West Nile virus replication, some 
representative compounds are shown in Figure 3.3. This collection of compounds are 
currently being tested for bioactivity against West Nile virus as well as other bioactivity 
screening. Compound III_31 and its analogues have shown some promising activities. 
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Figure 3.3 Representative Amide Products of Regioselective Amidation 
Reactions 
III_21, 97% 
Method E 
 
III_19, 50% 
Method C 
III_20, 76% 
Method A 
 
III_17, 93% 
Method B 
 
III_23, 47% 
Method C 
 
III_24, 81% 
Method A 
 
III_25, 42% 
Method A 
 
III_26, 71% 
Method B 
 
III_27, 95% 
Method B 
 
III_28, 97% 
Method A 
 
III_29, 95% 
Method B 
 
III_30, 95% 
Method B 
 
III_31, 95% 
Method B 
 
III_32, 93% 
Method B 
 
III_33, 92% 
See experimental 
for details. 
 
III_34, 83% 
Method B 
 
III_35, 83% 
Method B 
 
III_36, 78% 
Method B 
 
III_37, 62% 
Method B 
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3.3 Intramolecular IEDDA Approach to Lactam Annulated Carbazole Structures 
 
We envisioned that pyridazino[4,5-b]indoles could participate as electron deficient 
diene systems in intramolecular inverse electron demand Diels-Alder reactions with 
tethered alkynyl dienophiles to form carbazole structures III_38. This could be achieved 
via either the “bottom approach”, where the dienophile is tethered to the pyridazinoindole 
from the C4 ester, or the “top approach”, where the dienophile is tethered from the C1 ester. 
With the success of regioselective amidations described in the previous section, tethering 
the alkynyl dienophiles to the pyridazinoindole via an amide linkage with precise regio-
control to prepare the IEDDA cycloaddition precursors should be achievable. The IEDDA 
cycloadducts of the tethered pyridazinoindole/alkyne pairs would possess unique lactam 
annulated carbazole structures, which would also make an excellent core structure with 
several diversification sites easily modified for further library synthesis (Figure 3.4).  
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Figure 3.4 Carbazole Structure via Regioselective Amidation – “Top Approach” 
vs. “Bottom Approach” 
 
 
Similar to the IEDDA cycloaddition that led to -carbolines as described in 
Chapter II, one consideration in these designs was electron donation from the indole 
nitrogen into the pyridazine ring, which would result in an elevated LUMO of the azadiene, 
and thereby inhibit the desired cycloaddition. Thus, it was anticipated that an electron-
withdrawing group, which could also serve as a diversification point, would be needed on 
the indole nitrogen atom.  
 
Feasibility studies started with dimethyl 5H-pyridazino[4,5-b]indole-1,4-
dicarboxylates (III_4), following the “top approach”, which required the protection of the 
indole nitrogen followed by the installation of alkynyl dienophiles at the C1 ester via 
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regioselective amidation. The tosylation of the indole nitrogen on III_4 encountered 
unexpected difficulties. Various bases and conditions were tested but initial efforts proved 
to be fruitless. It was eventually found that the combination of triethylamine and sodium 
hydride as base in refluxing tetrahydrofuran for 2 days afforded the desired tosylated 
pyridazine III_8 in an excellent yield (Table 3.3). We suspected that the requirement of 
the combination of triethylamine and NaH could be because the tosylation of III_4 was 
extremely moisture sensitive. A certain amount of NaH removed any water content without 
further hydrolyzing the starting material, and the triethylamine deprotonated the indole 
nitrogen and promoted the tosylation reaction. No reaction occurred with either NaH (Entry 
3-5) or triethylamine (Entry 1, 2) alone. 
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Table 3.3 Tosylation of Pyridazinoindole III_4 (Scheme 3.7) a 
 
 
Entry Base Eq. Temp. Time Result 
1 TEA 3.0 rt overnight NR 
2 TEA 3.0 reflux overnight NR 
3 NaH 1.5 rt 3 h NR 
4 NaH 3.0 rt 3 h NR 
5 NaH 3.0 reflux overnight decomposition 
6 KOtBU 1.2 reflux overnight 10% conv. 
7 DIPEA 3.0 reflux overnight NR 
8 b NaH/TEA 2.0/2.0 reflux 1 day 67% 
9 b NaH/TEA 2.0/2.0 reflux 2 days 95% 
 a All reactions were run in anhydrous THF. 
 b Isolated yield. 
 
 With success of the nitrogen protection, subsequent trimethylaluminum catalyzed 
Weinreb amidation of III_8 with N-methyl propargylamine afforded monoamide 
cycloaddition precursor III_9 with exclusive regioselectivity at the C1 ester position in an 
excellent yield (92%). The intramolecular IEDDA cycloaddition of precursor III_9 was 
then studied under various conditions (Table 3.4, Scheme 3.8). In contrast to the 
preparation of -carbolines, initial attempts with microwave promotion failed to yield the 
desired cycloadducts, even at much higher reaction temperatures (Entry 1 to Entry 4). 
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Heating in diglyme (165 °C) only led to decomposition (Entry 5). Relatively high dilution 
of the reaction (0.008 M) and the presence of BHT were required to prevent decomposition 
of the starting material (Entry 9-14). Without BHT, the reaction was very messy, producing 
numerous decomposition products (Entry 6). The lower concentration was also critical 
(Entry 7). Screening reaction time indicated that precise control was needed to prevent the 
eventual decomposition of the cycloadduct. The ideal reaction time was from 7 hours to 9 
hours, which gave clean total conversion without any decomposition (Entry 8 to 14). It was 
ultimately found that with the presence of BHT (1.05 eq.), the cycloaddition proceeded 
smoothly in refluxing diglyme (0.008 M, 165 °C) for 7 hours, affording the lactam 
annulated carbazole III_39 in 88% isolated yield (Entry 12).  
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Table 3.4 Intramolecular Cycloaddition of III_9 to Form Carbazole III_39 
(Scheme 3.8) a 
 
 
Entry Temp. Solvent Time Result 
1 W, 120 °C diglyme 20 min NR 
2 W, 170 °C o-dichlorobenzene 30 min NR 
3 W, 210 °C o-dichlorobenzene 20 min NR 
4 W, 170 °C o-dichlorobenzene 30 min NR 
5 b, c 165 °C diglyme 7 h messy, decomp. 
6 b 165 °C diglyme 5 h messy, decomp. 
7 c 165 °C diglyme 5 h decomp. 
8  165 °C diglyme 1 h NR 
9 165 °C diglyme 2 h 30% conv. 
10 165 °C diglyme 4 h 60% conv. 
11 165 °C diglyme 5 h 80% conv. 
12 165 °C diglyme 7 h 100% conv. 
13 165 °C diglyme 9 h 100% conv. 
14 165 °C diglyme 11 h 70% conv. decomp. 
a All reaction were run with the presence of 1.05 eq. of BHT, 0.1 M in o-dichlorobenzene 
or 0.008 M in diglyme unless otherwise noted. Analyzed by UPLC. 
 b Without 1.05 eq. of BHT.  
 c With a concentration of 0.1 M in diglyme.  
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With the two-step sequence optimized for the preparation of carbazole III_39, the 
scope of this chemistry was then explored with other alkynyl amines. The amidations all 
proceeded in excellent yields, affording III_40 under the optimized conditions with 
trimethylaluminum as the catalyst. The cycloaddition precursors III_40 were then 
subjected to the optimized cycloaddition conditions to give the final cycloadducts III_41 
(Table 3.5, Scheme 3.9). 
 
Scheme 3.9 Chemistry Scope of Amidation/IEDDA Sequence 
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Table 3.5 Chemistry Scope of Amidation/IEDDA Sequence 
 
Entry Amine 
Cycloaddition 
precursor (Yield) 
Cycloadduct 
(Yield) a 
 
1  
III_9 (92%) 
  
III_39 (96%) 
2  III_40a (94%)  NR 
3 
 
III_40b (90%) NR 
4 
 
III_40c (93%) 
 
III_41c (97%) 
5  III_40d (95%) 
  
III_41d (93%) 
6e 
 
III_40e  
(95%) 
  
III_41e (94%) 
7 
 
III_40f (92%) NR  
8 
 
III_40g (88%) 
 
III_41g (87%) 
 a Isolated yields. 
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Tertiary propargyl amides III_9, and III_40c, d, e, g with terminal or internal 
alkyne dienophiles all showed comparable reactivity (Table 3.5, Entry 1, 4, 5, 6, 8), under 
the optimized cycloaddition conditions (diglyme, BHT, 165 °C, 7 h), producing the 
corresponding carbazoles in excellent yields. Tertiary amide III_40f was prepared as an 
effort to study the tether length between the amide and the alkyne functionality. As 
anticipated, increasing the tether length by an additional methylene unit, which would 
produce a -lactam with a successful cycloaddition, resulted in no reactivity. No 
cycloaddition was observed under any conditions (Entry 7).  
 
Secondary monoamides III_40a and III_40b were also prepared as cycloaddition 
precursors starting with primary propargylamines. In contrast to tertiary amides, no 
cycloadditions occurred to form the corresponding carbazoles under the optimized 
cycloaddition conditions (Entry 2, 3). Elevated temperatures did not promote the 
cycloaddition either. Refluxing in diphenyl ether for 12 hours led to decomposition of the 
amide precursors. Introducing the Thorpe-Ingold effect in substrate III_40b did not 
enhance the cycloaddition to yield the desired product either. These results were consistent 
with earlier observations in the -carboline work. Presumably an intramolecular hydrogen 
bond in III_40a and III_40b prevented the alkyne dienophile from rotating into the proper 
conformation necessary for the cycloaddition (Scheme 3.10). DMF was also used as the 
solvent attempting to disrupt the intramolecular hydrogen bond that prevents the proper 
conformation allowing cycloaddition to occur, as described in the -carboline work 
(Chapter II), but there was still no cycloaddition occurred. Therefore, using secondary 
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alkynyl amines to prepare tertiary amides as cycloaddition precursors was crucial for the 
subsequent intramolecular IEDDA cycloaddition.  
 
Scheme 3.10 Intramolecular Cycloadditions of Secondary Amides III_40a, b 
 
 
 
The route to lactam-annulated carbazoles following the “bottom approach” was 
also investigated (Figure 3.4), starting with III_4. Direct trimethylaluminum catalyzed 
Weinreb amidation of III_4 with N-methyl propargyl amine afforded monoamide III_42 
with exclusive regioselectivity at C4 ester position in an excellent yield (96%). 
Unexpectedly, all attempts to protect the indole nitrogen of III_42 failed. Numerous bases 
and conditions were tested, and all failed to afford desired protected product (Table 3.6, 
Scheme 3.11).  
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Table 3.6 Tosylation of Monoamide III_42 (Scheme 3.11) a 
 
 
 
Entry Base Eq. Temp. Time Result 
1 TEA 3.0 reflux overnight NR 
2 DIPEA 3.0 reflux overnight NR 
3 NaOH, Bu4NHSO4 2.0/2.0 rt 3 h NR 
4  NaH 1.5 reflux overnight NR 
5  NaH 3.0 reflux overnight NR 
6  KH 1.5 reflux overnight NR 
7 KOtBu 2.0 reflux overnight NR 
8  NaH/TEA 2.0/2.0 reflux 2 days NR 
 a All reactions were run in anhydrous THF. 
 
Without success in protecting the indole nitrogen of monoamide III_42, the 
intramolecular cycloadditions of unprotected III_42 were attempted (Table 3.7, Scheme 
3.12). As expected, no cycloaddition was observed under thermal (Entry 2 and Entry 3) or 
microwave conditions (Entry 1). Lewis acid catalysts, which could catalyze the 
cycloaddition by binding to the pyridazine, thereby lowering the LUMO of the diene 
system, were also tested. However, no desired cycloadduct was afforded, resulting in only 
decomposition of the starting material III_42 (Entry 4 to Entry 6). This confirmed the 
earlier assumption that the electron donation from the indole nitrogen into the pyridazine 
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ring, which elevates the LUMO of the azadiene, and inhibits the desired cycloaddition. 
Therefore, an electron-withdrawing group was indeed needed at N5 position for the 
cycloaddition to succeed. And since all attempts protecting the indole nitrogen of III_42 
failed, this “bottom approach” to carbazoles was abandoned for further applications.  
 
Table 3.7 Intramolecular Cycloaddition of Unprotected Monoamide III_42 
(Scheme 3.12) 
 
 
Entry Temp. Solvent Lewis Acid Time Result 
1 W, 170 °C o-dichlorobenzene none 30 min NR 
2 165 °C diglyme none 7 h NR 
3 200 °C diphenyl ether none 7 h NR 
4  165 °C diglyme Ni(COD)2 12 h decomp. 
5  165 °C diglyme Zn(OTf)2 12 h decomp. 
6 165 °C diglyme Sc(OTf)3 12 h decomp. 
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3.4 Preparation of Carbazole Type Library via Regioselective Amidation IEDDA 
Sequence on Pyridazino[4,5-b]indoles 
 
With the model studies completed, a regioselective amidation/IEDDA sequence 
was established to provide a rapid and efficient way to prepare a lactam annulated carbazole 
library using the “top down” approach. Several diversification sites would be introduced 
into the carbazole core structure in very few steps via this robust methodology (Figure 
3.5).  
 
Figure 3.5 Possible Carbazole Diversification Sites 
 
 
 
 Starting with various substituted indoles, substituents in the A-ring (R1) of the 
carbazole core structure could be readily introduced. Different electro-withdrawing groups 
(R2) could be introduced during the indole nitrogen protecting step. Substituents on the 
lactam nitrogen in the D-ring (R3) could be introduced from the various propargylamines 
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during the regioselective amidation step. Also, the substituents on the alkyne terminal 
position (R4) would diversify the C-ring, while the D-ring substituents (R5), originated 
from substitution on the propargylic position, provide more diversification. Furthermore, 
the remaining ester group on the C-ring could be transformed into different functionalities 
via subsequent chemical manipulations. In this fashion, a series of carbazole structures 
could be effectively and efficiently prepared from the inverse electron demand Diels-Alder 
reactions of the tethered alkyne/pyridazine pairs (Scheme 3.13).  
 
Scheme 3.13 Retrosynthesis of Carbazole Type Library 
 
 
 
A carbazole library production plan was designed, starting with 6 indoles with 
different substituents at C5 position, eight electron-withdrawing nitrogen protecting 
groups, and twelve propargylamines with various substituents on nitrogen or alkyne 
terminal positions, as shown in Figure 3.6. The preparation of the pyridazinoindoles was 
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straightforward. In parallel format, two equivalents of dimethyl 1,2,4,5-tetrazine-3,6-
dicarboxylate III_2 in DCM was added into solutions of the indoles slowly at 0 °C using 
a syringe pump. Starting with six 5-substituted indoles and following the optimized 
procedure, six pyridazinoindole analogues, III_4 and III_43-47, were prepared in good to 
excellent yields (Table 3.8, Scheme 3.14). 
 
Figure 3.6 Proposed Carbazole Type Library Production 
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Table 3.8 Preparation of Pyridazinoindole Analogues (Scheme 3.14) 
 
 
 
R1 = H Me OMe F CN NO2 
Product III_4 III_43 III_44 III_45 III_46 III_47 
Yield 96% 93% 88% 90% 77% 85% 
 
 Protections of indole nitrogen of the pyridazinoindole analogues III_4 and III_43-
47 proceeded smoothly with various sulfonyl and acylchlorides, applying the optimized 
procedure to afford N-protected pyridazinoindoles III_8 and III_48-70 in good to excellent 
yields (Table 3.9). In test runs, mesyl, nosyl and p-fluorobenzenesulfonyl protected 
pyridazinoindoles showed very poor stabilities, and the protecting groups cleaved easily 
under the subsequent IEDDA cycloaddition condition, producing messy mixture products. 
Therefore, these protecting groups were removed from the library production plan. Also, 
the solubility of 5-cyano and 5-nitro pyridazinoindoles were extremely poor, which limited 
their appearance in the subsequent library synthesis.  
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Table 3.9 Preparation of N-protected Pyridazinoindole Analogues  
(Scheme 3.15) 
 
 
R2 R1 H Me OMe F CN 
 
III_8 
95% 
III_48 
92% 
III_49 
94% 
III_50 
95% 
III_51 
75% 
 
III_52 
91% 
III_53 
89% 
III_54 
93% 
III_55 
88% 
--- 
 
--- --- 
III_56 
73% 
--- 
III_57 
79% 
 
III_58 
90% 
III_59 
88% 
III_60 
88% 
III_61 
84% 
--- 
 
III_62 
92% 
III_63 
90% 
III_64 
95% 
III_65 
85% 
--- 
 
III_66 
88% 
III_67 
85% 
III_68 
90% 
III_69 
79% 
III_70 
72% 
 
Similar to the production of the -carboline library, a workflow was deliberated 
and successfully executed for the carbazole library synthesis (Figure 3.7). The production 
of the library was carried out in a parallel fashion to achieve maxim efficiency.  
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Figure 3.7  Workflow for the Carbazole Library Production 
 
 
 
Following the workflow shown above and the established two-step regioselective 
amidation/IEDDA sequence protocol, a chemical library of carbazoles from 
pyridazino[4,5-b]indole analogues III_8, III_48-70 and various propargylamines was 
produced. There were two parts in this library, one was a collection of IEDDA 
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cycloaddition precursors, the pyridazinoindoles with tethered alkynyl dienophiles (188 
members); the other was a collection of the corresponding IEDDA cycloaddition 
cycloadduct, the carbazoles (188 members). Upon the completion the library production, 
the library was submitted to CMLD-BU analytical team for purification, characterization 
and high-throughput screening for bioactivities.  
 
3.5 Summary 
 
Lewis acid catalyzed regioselective amidation of dimethyl 5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate was established to direct the amidation to occur at the C1, C4 or 
both ester positions. The regioselective amidation at the C1 ester group was then applied to 
tether various dienophiles to the pyridazinoindole ring system via an amide linkage. Inverse 
electron demand Diels-Alder cycloaddition of these C1 tethered 
pyridazinoindole/dienophile pairs afforded annulated carbazoles, after the protection of the 
indole nitrogen with electron withdrawing groups. The amide linkage were also installed 
at C4 position applying the regioselective Amidation chemistry. However the 
pyridazinoindole/dienophile pairs failed in both indole N5 protection and IEDDA reaction, 
providing no desired carbazoles. The scope of the chemistry was probed using different 
alkynyl amines and tether length. In contrast to tertiary amides, which afforded desired 
cycloadducts in excellent yields, secondary amides showed no reactivity under any 
conditions, and produced no cycloadducts. Three-atom tethers proved to be the maximum 
length between the pyridazinoindole and alkyne that underwent the cycloaddition, 
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producing -lactams. A carbazole type library of one hundred and eighty-eight members 
was prepared employing this methodology, starting with various indoles, indole nitrogen 
protection groups and propargylamine derivatives.  
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Chapter IV 
 
 
 
 
Diels-Alder/retro-Diels-Alder Sequence on Anthrone and its Application 
 
 
4.1 Introduction 
 
In 1928, Otto Paul Hermann Diels and Kurt Alder first published the novel [4+2] 
cycloaddition using cyclopentadiene (IV_1) and acrolein (IV_2) to generate 
bicyclo[2.2.1]hept-5-ene-2-carbaldehyde (IV_3) (Scheme 4.1, Equation 1). The reaction 
was named Diels-Alder reaction their honor, and in 1950, they were awarded the Nobel 
Prize in chemistry for their discovery [278]. One year later in 1929, Kurt Alder reported 
the reversibility of the Diels Alder reaction as the Rickert-Alder reaction. In this reaction, 
with the driving force toward aromatization, the oxidized cycloadduct of quinone and 1,3-
cyclohexadiene IV_4 released gaseous ethylene and anthraquinone at elevated 
temperatures (Scheme 4.1, Equation 2). This reversibility of the Diels-Alder reaction was 
termed the retro-Diels-Alder reaction [279]. Since then, a variety of substrates have been 
subjected to the retro-Diels-Adler reaction, yielding numerous different dienes and 
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dienophiles [280]. In 1963, Moffett reported another well-known example of the retro-
Diels-Alder reaction, in which the neutral-Diels-Alder cycloadduct dicyclopentadiene 
regenerated two cyclopentadiene molecules under thermal conditions. (Scheme 4.1, 
Equation 3) [281]. 
 
Scheme 4.1 First Reports of Diels-Alder and retro-Diels-Alder Reaction 
 
 
 
 
In 1938, Diels reported the first Diels-Alder/functional group transformation/retro-
Diels-Alder (DA/FGT/rDA) sequence (Scheme 4.2) [282],  a strategy that served as a 
double bond protection protocol, employing anthracene (IV_7) as the cycloaddition diene 
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component in the preparation of the acid chloride of acetylene dicarboxylic acid (IV_10). 
In this sequence, maleic anhydride, the more reactive dienophile compared to IV_10, was 
used as a scavenger to trap the anthracene, thereby preventing reformation of the 
cycloadduct IV_9. Since then, this novel concept of a DA/FGT/rDA sequence, in which a 
cycloadduct is selectively transformed prior to cycloreversion, has established itself as a 
versatile and important synthetic method [283]. 
 
Scheme 4.2 First Example of a Diels-Alder/retro-Diels-Alder Sequence 
 
 
 
4.1.1 Diels-Alder/retro-Diels-Alder Sequence in Organic Synthesis 
 
The Diels-Alder reaction and its reverse process, the retro-Diels-Alder reaction, 
should go through the same transition state. Therefore, fragmentation of the initial [4+2] 
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cycloadduct should regenerate the reaction partners. However, structural characteristics of 
the dienes and dienophiles often make the retro-Diels-Alder reaction more complicated and 
less predictable (Scheme 4.3). An examples is the Diels-Alder reactions of butadiene, 
where an alkene is applied as the dienophile, and the reaction generates cyclohexene. 
Cyclohexene has only one possible pathway for the retro-Diels-Alder reaction, reverting 
along the original pathway and regenerating the original diene and dienophile (Eq 1). 
However, when an alkyne is applied as the dienophile, the reaction yields 1,4-
cyclohexadiene as cycloadduct, which has two possible pathways for the retro-Diels-Alder 
reaction. The reverse pathway generates the original diene and dienophile, while an 
alternative cycloreversion generates a new diene and dienophile pair, with the dienophile 
participating in the original Diels-Alder reaction incorporated in the newly formed diene 
cycloreversion product (Eq 2). A more complicated example is the Diels-Alder reaction of 
1,3-cyclohexadiene. When an alkene is used as the dienophile, the cycloadduct has two 
possible pathways for the retro-Diels-Alder reaction. The reverse pathway regenerates the 
original diene and dienophile, while the forward reaction fragments a new diene and 
dienophile pair with the original dienophile incorporated in the newly formed diene system 
(Eq 3). When an alkyne is used as the dienophile with 1,3-cyclohexadiene, the cycloadduct 
has three possible pathways for the cycloreversion: the first two are the same as the ones 
discussed before, but the third pathway in this case releases an alkene and an aromatic ring 
as cycloreversion products, and this third pathway is the most favorable pathway due to 
the aromatization driving force (Eq 4). 
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Scheme 4.3 DA/rDA of Butadiene and 1,4-Cyclohexadiene with Dienophiles 
 
 
 
Though there may be several possible pathways for the cycloreversion, there are 
only two general outcomes regarding the products. One regenerates the original diene and 
dienophile, and the other generates a new diene and dienophile pair. The potential of 
producing two different outcomes in a highly controlled fashion makes the Diels-
Alder/retro-Diels-Alder sequence a versatile, promising tool in organic synthesis. If the 
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retro-Diels-Alder reaction predominantly reverts along the original direction, regenerating 
the original diene and dienophile, the DA/rDA sequence could be designed and applied as 
a reactive double bond protecting group, or as a stereocontrol element, featuring the Diels-
Alder and retro-Diels-Alder reactions as the protection and deprotection steps, 
respectively. On the other hand, if the retro-Diels-Alder reaction follows a pathway other 
than the reversal along the original Diels-Alder reaction, generating a new diene and 
dienophile pair, the DA/rDA sequence could be developed as a synthetic method to convert 
cyclic frameworks into new structures. Thus, depending on the pathways that the retro-
Diels-Alder reaction follows, and the purpose of the DA/rDA sequence, the application of 
DA/rDA can be generally classified in three categories. The first category is the 
construction of new cyclic structures, examples are the synthesis of -carbolines, 
previously talked in Chapter II and other heterocyclic compounds. The second category 
is the protection/deprotection of Dienophile. This strategy was quite often used in organic 
synthesis, [284-289] one example is the first practical synthesis of the coenzyme Q1 
reported by Chen’s group is an example of applying the DA/rDA sequence as a dienophile 
protecting group (Scheme 4.4). [284] The Diels-Alder reaction of quinone IV_12 with 
cyclopentadiene afforded cycloadduct IV_13 in quantitative yield with acetic acid as 
catalyst at room temperature. The enolate of this cycloadduct was then allylated with 1-
bromo-3-methyl-2-butene to generate compound IV_14. The subsequent retro-Diels-Alder 
reaction proceeded readily at 85 °C to give coenzyme Q1 IV_15 in 60% overall yield in 5 
steps. This DA/rDA sequence transformed the double bond dienophile of quinone IV_12 
into an enolizable group with high regio-control, thereby allowing the other 
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transformations to proceed for practical synthetic purposes. Subsequent cycloreversion 
then regenerated the double bond. 
 
Scheme 4.4 DA/rDA as Protecting/Deprotecting Functions in the Synthesis of 
Coenzyme Q1 
 
 
 
The third category is the stereocontrol of functional group transformations by 
applying the DA/rDA sequence. And this category will be the focus in the rest of this 
chapter, featuring our work using anthracenes and anthrones as stereocontrol elements in 
functional group transformations in DA/FGT/rDA sequences. In this manner, the 
anthracene moiety serves both as a double bond protecting element and as the source of 
chirality in asymmetric synthesis.  
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4.1.2 DA/rDA Sequence as Stereocontrol Element in Asymmetric Synthesis 
 
The process of applying the DA/rDA sequence as a stereocontrol feature in 
asymmetric synthesis includes three steps: the initial Diels-Alder reaction, the functional 
group transformation of the cycloadduct, and the retro-Diels-Alder reaction. Since the last 
step is a cycloreversion, introduction of new chirality into the final products can only occur 
after the cycloaddition, but before the cycloreversion. There are two possible approaches 
to introduce the chirality into an achiral dienophile or diene to produce an enantioenriched 
cycloadduct, the process may proceed via either substrate or catalyst control, or asymmetric 
functional group transformation of the initial cycloadduct. There are five approaches to 
introduce new chirality into the final products by the DA/FGT/rDA sequence: 1) chiral 
dienes in a stereoselective Diels-Alder reaction; 2) chiral dienophiles in a stereoselective 
Diels-Alder reaction; 3) chiral catalysts in a stereoselective Diels-Alder reaction; 4) chiral 
resolution of achiral, racemic cycloadducts; 5) asymmetric functional group transformation 
on achiral cycloadducts. There are a number of reports in the literature successfully 
demonstrated the use of chiral dienes, chiral dienophiles, chiral resolution and asymmetric 
functional group transformation on achiral cycloadducts in DA/FGT/rDA sequence [290, 
291]. However, the use of chiral catalysts for the asymmetric catalytic Diels-Alder reaction 
has not yet been documented for the application in this sequence. In the following sections, 
the applications of chiral dienes, chiral dienophiles, chiral resolution and asymmetric 
functional group transformation on achiral cycloadducts in the DA/FGT/rDA sequence are 
briefly reviewed. The main goal of our research is to establish a catalytic stereoselective 
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Diels-Alder reaction and applying this strategy to the DA/FGT/rDA sequence in 
asymmetric organic synthesis. 
 
4.1.2a Chiral Dienes in a Stereoselective Diels-Alder Reaction 
 
The possibility of using a chiral diene component as the stereocontrol element in 
synthetic DA/rDA sequences with an achiral dienophile was explored, most notably, by 
Winterfeldt and coworkers over the past three decades [292-298]. Their chiral 
cyclopentadiene derivatives, which functioned as chiral auxiliaries as well as a double bond 
protecting groups, were successfully employed in the syntheses of the agelorins [299, 300], 
wistarin [301], strigol and sorgolactine [302, 303], using the DA/FGT/rDA sequence. In 
the course of these syntheses, several chiral cyclopentadiens were developed for the 
application of this strategy. An early example of their work is the synthesis of chiral -
lactones (Scheme 4.5) [293]. The cycloaddition of enantiopure chiral cyclopentadiene 
IV_16 and maleic anhydride yielded cycloadduct IV_17 in quantitative yield with high 
diastereoselectivity (>98%) via an asymmetric Diels-Alder reaction, which requires high 
pressure despite the highly reactive nature of maleic anhydride. Subsequent regioselective 
Grignard addition occurred to the least hindered carbonyl group from the top face, followed 
by reduction to lactones IV_19. After the retro-Diels-Alder reaction at elevated 
temperatures, chiral lactones IV_20 were released and purified in excellent yields and 
enantiopurity (>95 ee). Michael addition onto the chiral ,-unsaturated lactones was 
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directed by the newly formed stereocenter and proceeded with excellent stereoselectivity 
to give IV_21.  
 
Scheme 4.5 Example of Winterfeldt’s Chiral Diene as Stereocontrol Element in 
DA/rDA Sequence 
 
 
 
Another example of the application of Winterfeldt’s chiral cyclopentadiene strategy 
is the synthesis of indoloquinolizinone building blocks reported in 2001 [304] (Scheme 
4.6). This chemistry featured a new, cyclopentadienyl auxiliary IV_22 and the intermediate 
4-system IV_23, which worked reliably for a whole series of compounds. The initial 
cycloadduct intermediate IV_23 was designed to enable polycyclic compounds to be 
“grown” on the butadiene moiety in reactions subsequent to the cycloaddition in a 
diastereoselective manner. Iminium ion salt IV_24 underwent a diastereoselective Diels-
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Alder reaction with butadiene IV_23, affording cycloadduct IV_25 in excellent yield and 
enantiopurity, though high pressure (14 kbar) was required for this reaction. Thermally 
promoted retro-Diels-Alder reaction of IV_25 yielded the enantiopure (>98% ee) 
indoloquinolizinone building block IV_26 [305, 306]. 
 
Scheme 4.6 Winterfeldt’s Chiral Diene as Stereocontrol Element in DA/rDA 
Sequence for the Synthesis of Indoloquinolizinone Building Block 
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4.1.2b Chiral Dienophiles in a Stereoselective Diels-Alder Reaction 
 
A chiral dienophile may also be used to introduce stereochemistry in the initial 
Diels-Alder reaction in the DA/FGT/rDA sequence. However, since the dienophilic 
subunit of the cycloadduct usually is incorporated into the final synthetic target, the use of 
chiral dienophiles to introduce chirality is less common in the literature since these subunits 
often already bears the necessary chirality. Nonetheless, there are some successful 
applications of chiral dienophiles for diastereoselective cycloadditions in the DA/rDA 
sequence. The Helmchen group demonstrated an effective DA/rDA strategy using chiral 
dienophiles in the synthesis of the (R)- and (S)-Matsutake alcohols, and the antibiotic 
Sarcomycin [307]. For example, in the synthesis of the (R)- and (S)-Matsutake alcohols, 
chiral dienophile IV_27 and anthracene were used in the initial Diels-Alder reaction 
(Scheme 4.7). The enantiopure cycloadduct IV_28 (96.5:3.5 d.r.) was modified after 
auxiliary cleavage to form two diastereomers IV_29. Subsequent retro-Diels-Alder 
reactions via flash vacuum pyrolysis and deprotection gave the (R)- and (S)-Matsutake 
alcohols in 95% and 89% yields, respectively.  
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Scheme 4.7 Chiral Dienophile as Stereocontrol Element in DA/rDA Sequence by 
Helmchen 
 
 
 
Another example of chiral dienophiles in the DA/FGT/rDA sequence is 
Sotomayor’s enantiodivergent synthesis of pyrrolo[2,1-a]isoquinolines (Scheme 4.8) [290, 
291]. Enantiopure maleimide IV_35 was prepared from maleimide IV_31 over 3 steps in 
70% overall yield. The Diels-Alder reaction of IV_35 with cyclopentadiene afforded 
cycloadduct IV_36 as a single diastereomer. Addition of lithium reagents or reduction of 
the enantiopure norbornenedicarboximide IV_36 occurred regioselectively on the carbonyl 
remote to the chiral sulfoxide substituent and from the convex face. Intramolecular Friedel-
Crafts alkylations of the acyl iminium ion intermediates generated from IV_36 afforded 
IV_37. Removal of the chiral substituent was carried out with SmI2, and the final retro-
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Diels-Alder reaction afforded desired enantiopure products IV_39 through flash vacuum 
pyrolysis.  
 
Scheme 4.8 Chiral Dienophile as Stereocontrol Element in DA/rDA Sequence by 
Sotomayor 
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Other strategies, such as chiral resolution of racemic achiral cycloadduct [301, 310-
315] and asymmetric functional group transformation on achiral cycloadducts [308, 309] 
were also frequently used as the stereocontrol element in the DA/rDA sequence in the 
literature.  
 
4.1.3 Chiral Anthracenes as a Stereocontrol Element in the DA/rDA Sequence  
 
As illustrated in Schemes 4.2 and 4.7, the use of anthracene as the diene in the 
DA/FGT/rDA was successfully applied in natural product synthesis. The Thebtaranonth 
group has applied the DA/FGT/rDA strategy with anthracene as the diene in the synthesis 
of several natural -methylene cyclopentenones, including -methylene bis--
butyrolactones [318], methylenomycin B [319] and others [320-322]. For example, 
cycloadduct IV_41 was readily prepared via a Diels-Alder reaction of anthracene and 
methyl acrylate (IV_40). Enolate allylation of cycloadduct IV_41 and subsequent 
cyclization yielded IV_43. Final retro-Diels-Alder reaction of IV_43 using FVP afforded 
methylenomycin IV_44 in quantitative yield (Scheme 4.9).  
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Scheme 4.9 Anthracene in DA/rDA Sequence for the Synthesis of 
Methylenomycin B by Thebtaranonth 
 
 
 
Though it seems logical to extend the ideas of Winterfeldt’s chiral diene concept 
by using a chiral anthracene as the diene, no reports of using such a template in Diels-Alder 
chemistry appeared in literature prior to the work of our group. In the mid-1990s, our group 
initiated an investigation into the use of homochiral anthracenes with stereogenic centers 
at the C9 position as diene templates in asymmetric synthesis (Scheme 4.10) [323]. Chiral 
anthracenes IV_45a and IV_45b underwent asymmetric Diels-Alder reactions with maleic 
anhydride, maleimide and N-methyl maleimide with complete diastereoselectivity, 
exclusively producing single isomers IV_46 in high yields. 
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Table 4.1 Stereoselective Diels-Alder Reaction of Chiral Anthracenes and 
Dienophiles by the Snyder Group (Scheme 4.10) 
 
 
 
Entry IV_45 a/b X Yield (%) a dr b 
1 a O 89 > 99:1 
2 a NH 88 > 99:1 
3 a NMe 92 > 99:1 
4 b O 75 > 99:1 
5 b NMe 76 > 99:1 
  a Isolated yield; b Chiral HPLC. 
With the success of these initial asymmetric Diels-Alder reactions using chiral 
anthracenes as templates for the DA/rDA sequence, over the past decade, our group has 
championed the application of chiral anthracene templates as regio- and stereocontrol 
elements in the enantioselective preparation of butenolides, ,-unsaturated -lactams, and 
polycyclic alkaloidal core structures [324-326]. The general strategy begins with a 
completely diastereoselective cycloaddition using chiral anthracene as the diene 
component, followed by highly regioselective functional group transformations of one 
carbonyl group of the anthracene-mounted dienophiles. The cycloreversion, which 
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proceeds without racemization, subsequently produces the targeted asymmetric products 
(Scheme 4.11). 
 
Scheme 4.11 General Strategy of DA/FGT/rDA Sequence by the Snyder Group 
 
 
 
In 2009, Xiang Liu from our group reported the synthesis of several enantiopure 
tricyclic alkaloid framework utilizing chiral anthracenes as diene templates (Scheme 4.12) 
[327]. Enantiopure chiral anthracene IV_45b was chosen for this work since its 
cycloadduct underwent the cycloreversion with relative ease. In these sequences, IV_45b 
participated in completely diastereoselective cycloadditions with maleimide to yield 
enantiopure cycloadduct IV_47. An electron rich aryl ring was then tethered to the 
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maleimide nitrogen via Mitsunobu reaction, yielding IV_48. Grignard addition occurred 
exclusively at the carbonyl remote to the original anthracene chiral substituent, producing 
IV_49. Acid catalyzed generation of the acyl iminium ion IV_50 led to the key 
intramolecular Friedel-Crafts cyclization product IV_51 [328-331]. The stereochemistry 
of this cyclization was anticipated to be controlled by the chiral anthracene template, with 
exclusive approach of the nucleophilic aryl ring from the top face, away from the 
anthracene-derived benzene rings, which blocks the bottom face of the acyl iminium ion. 
The cycloreversion promoted by simple microwave irradiation in DMSO then generated 
the enantiopure tricyclic alkaloid cores IV_52 with the ABC-ring system found in 
Erythrina and homoerythrina alkaloids. 
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Scheme 4.12 Application of DA/FGT/rDA Sequence using Chiral Anthracene 
Templates in Synthesis by the Snyder Group  
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More recently, in 2010, the Jones group independently reported the synthesis 
towards to crispine A employing the same strategy using chiral anthracene templates 
(Scheme 4.13) [332]. They used a different chiral anthracene, analogue IV_53, as the diene 
component in the initial cycloaddition. Reduction of the cycloadduct IV_54 provided 
hydroxy-lactam IV_55 as a single diastereoisomer with reduction occurring exclusively on 
the carbonyl remote to the chiral substituent on the anthracene template. Subsequent 
intramolecular Friedel-Crafts reaction of the hydroxy-lactam IV_55 with excess TFA 
afforded IV_56. However, when the retro-Diels-Alder reaction was performed on amide 
IV_56 utilizing the typical flash vacuum pyrolysis protocols at 520 °C, 0.005 mm Hg, a 
rapid isomerization of the product to the more thermodynamically stable alkene ensured, 
giving the achiral isomer IV_57. Finally, hydrogenation and lithium aluminum hydride 
reduction of IV_57 afforded racemic crispine A IV_58. The racemization during FVP 
negated the principle of an asymmetric anthracene template.  
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Scheme 4.13 Synthesis of Crispine A Applying DA/FGT/rDA Sequence by the 
Jones Group 
 
 
 
As discussed previously, a major issue with this strategy is that the cycloreversion 
step often requires very harsh conditions (high reaction temperatures), which can lead to 
decomposition or isomerization of the products. Furthermore, the chiral anthracene 
templates are not commercially available, or are very expensive, and usually take many 
steps to prepare [333]. With these challenges in mind, other possible templates were 
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sought, which are easily accessed, bench stable and able to achieve cycloreversion under 
milder conditions. We therefore turned our attention to using anthrone and related 
analogues for this DA/rDA sequence strategy.  
 
4.1.4 Chiral Anthrone as Diene Template in DA/rDA Sequence  
 
Rickborn’s extensive investigation into the cycloadditions of anthrone [334, 335], 
coupled with Knapp’s and Nicolaou’s synthetic applications [336, 337] of anthracene in 
DA/rDA sequences,  demonstrated success with the oxyanion promoted cycloreversion of 
9-hydoxyanthracene cycloadducts. These encouraging results, coupled with our success 
with chiral anthracenes, led us to initiate an investigation into chiral anthrones as diene 
components in asymmetric Diels-Alder reactions for the DA/FGT/rDA sequence. Over the 
past few years, our effort mainly focused on the application of chiral anthrone IV_61, 
which could be prepared by two routes (Scheme 4.14) [327, 333]. Route 1, anthrone 
acetylation followed by asymmetric reduction, proved to be troublesome during the final 
methylation step due to competing alkylation at the anthrone carbonyl oxygen atom. Route 
2 started with the known chiral anthracene IV_45b, which we are able to prepare on a gram 
scale, and this route was more practical for preparing the chiral anthrone on a larger scale.  
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Scheme 4.14 Preparation of Chiral Anthrone 
 
 
 
In the past work, 1-methoxyethyl stereogenic substituent had proven to be effective 
in exerting excellent stereocontrol over the asymmetric cycloaddition of chiral anthracene 
IV_45a and further functional group transformations in the DA/FGT/rDA sequence (see 
Scheme 4.10). However, the application of anthrone IV_61, which carries the same chiral 
substituent, in the same DA/FGT/rDA sequence, was largely disappointing. [327, 333] 
Anthrone IV_61 indeed underwent a Diels-Alder reaction with N-methyl maleimide to give 
cycloadduct IV_63 in quantitative yield and complete diastereoselectivity (Scheme 4.15, 
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A). However, in the cycloreversion step, the basic reaction conditions led to rapid 
racemization of the -hydroxy-lactams IV_65. Attempts to use the acyliminium ion 
cyclization, which was successful with chiral anthracene IV_45a discussed previously in 
Scheme 4.12, with chiral anthrone IV_61, were disappointing as well (Scheme 4.15, B). 
The attempted acid catalyzed cyclization of IV_66 led only to ring-opened product IV_68 
as a diastereomeric mixture. Production of IV_68 was likely due to the hyper-conjugative 
continuum extending from the alcohol oxygen lone pair through the -framework to the 
acyliminium ion in the transition state IV_67.  
 
Scheme 4.15 Application of Chiral Anthrone in DA/rDA Sequence 
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Supporting this conclusion, using achiral anthrone as the diene component, the 
Grignard addition occurred at the alternative carbonyl group, which is remote to the 
hydroxyl group on anthrone cycloadduct IV_69 in comparison to IV_66 (Scheme 4.16). 
With the acyliminium ion generated at this different carbonyl position, the continuum does 
not exist, and the ring opening process was no longer a competitive pathway. The base 
induced cycloreversion of IV_70 gave the racemic product IV_71 without consequence, 
in near quantitative yield. 
 
Scheme 4.16 Model Study on Achiral Anthrone 
 
 
 
With the problems encountered with chiral anthrone IV_61 and the successful 
model study on achiral anthrone in the DA/FGT/rDA sequence, our attention turned to the 
investigation of an asymmetric cycloaddition between achiral anthrone itself and 
maleimides, promoted by a chiral catalyst, which could be further applied to the 
DA/FGT/rDA sequence. There will be three major challenges, which are also the 
objectives of the research describe in the rest of this chapter, in this DA/FGT/rDA strategy. 
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First, can excellent enantioselectivity be achieved in the initial cycloaddition using 
anthrone as the diene component with a chiral catalyst? Second, does the anthrone template 
have sufficient chemistry tolerance, with excellent regioselectivity in the carbonyl 
transformations, in reactions subsequent to the initial cycloaddition? Finally, can mild 
conditions be achieved for the cycloreversion to prevent decomposition and/or 
isomerization of the cycloreversion products, as occurred in Jones’ crispine A synthesis? 
 
4.2 Asymmetric Diels-Alder Reaction of Anthrone 
 
The catalytic asymmetric Diels-Alder reaction is a powerful method to construct 
complex molecular structures [338]. In this regard, organocatalysis has been successful in 
several Diels-Alder and hetero-Diels-Alder reactions over the past decade [339-347]. In 
the Diels-Alder reaction of anthrone, the active diene, the 9-hydroxyanthracene tautomer, 
can be generated using a catalytic amount of a base. A chiral organobase, associating with 
the active phenolate intermediate in the form of its conjugated acid, could generate 
enantioselectivity in the subsequent Diels-Alder reaction with dienophiles [348-352]. 
There are several reports in the literature successfully applying chiral organobases as 
catalysts to achieve enantioselective Diels-Alder reactions of anthrone. 
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4.2.1 Previous Asymmetric Cycloaddition between Anthrone and Maleimides 
 
The first asymmetric Diels-Alder reaction of anthrone was reported by the Kagan 
group in 1989 using cinchona alkaloids as organobase catalysts [348, 349]. Kagan’s work 
used N-methyl maleimide as the benchmark dienophile to evaluate the enantioselectivity 
of the organobase catalyzed asymmetric Diels-Alder reaction shown in Scheme 4.17. The 
best result, 61% ee and 97% yield, was produced using quinidine as the chiral organobase 
catalyst, at -50 °C in chloroform.  
 
Scheme 4.17 First Asymmetric Diels-Alder Reaction of Anthrone by Kagan 
 
 
 
After Kagan’s pioneering work, the Yamamoto group investigated this asymmetric 
Diels-Alder reaction of anthrone using C2-chiral pyrrolidines as organobase catalysts [350, 
351]. Yamamoto’s work is summarized in Scheme 4.18. The best asymmetric induction of 
87% ee was attained when IV_76, with an N-4-pyridylmethyl substituent, was used as the 
catalyst in the reaction with the bulky N-2-t-butylphenyl maleimide. Less hindered 
dienophiles were not as selective. For example, for benchmark N-methyl maleimide, 
asymmetric induction was achieved using the same catalyst IV_76, but in only 74% ee, 
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and only slightly better than Kagan’s results. Yamamoto concluded that the hydroxyl 
groups on the catalysts and aprotic solvents were crucial in attaining higher selectivity and 
proposed a transition state model IV_73 of bifunctional activation to explain the selectivity. 
The basic nitrogen of the catalyst interacts with the anthrone tautomer via hydrogen 
bonding, while one of the hydroxyl groups on the catalyst binds to one of the dienophile 
carbonyl oxygen atoms, directing the approaching of the dienophile. This model might be 
also applicable to Kagan’s original results given the quinidine has a similar aminol 
substructure. 
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Scheme 4.18 Asymmetric Diels-Alder Reaction of Anthrone by the Yamamoto 
Group 
 
 
 
Dr. Liu from our group also examined various chiral amino-alcohols and diamines 
as chiral organobase catalysts for the asymmetric Diels-Alder reaction of anthrone using 
N-methyl maleimide, as summarized in Scheme 4.19 [327]. These efforts were mostly 
unsuccessful, the best enantiomeric excess of 50% was attained using prolinol IV_78a 
[351] as the catalyst. The proline amide catalysts IV_79 showed very limited reactivity and 
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selectivity presumably due to low basicity, while their reduced diamine analogues IV_80 
gave better yields but the same level of low enantioselectivity.  
 
Scheme 4.19 Asymmetric Diels-Alder Reaction of Anthrone and N-Methyl 
Maleimide by the Snyder Group 
 
 
 While we were screening organobase catalysts for the asymmetric Diels-Alder 
reaction of anthrone, the Tan group reported a chiral guanidine-catalyzed diastereoselective 
Diels-Alder reaction of anthrone and its analogues IV_85, as summarized in Table 4.2 
[353]. The reaction of anthrone and phenylmaleimide IV_86c (R = Ph) was efficiently 
152 
 
catalyzed by the chiral bicyclic guanidine IV_87, affording a result of 90% yield and 81% 
ee. When substituents were introduced either on anthrone itself or on the o-position of the 
maleimide N-aryl groups, the selectivities were dramatically enhanced, up to 99% ee, 
which was consistent with Yamamoto’s observations.  
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Table 4.2 Asymmetric Diels-Alder Reaction of Anthrone by the Tan Group 
(Scheme 4.20) 
 
 
 
IV_85 [R1, R2, R3, R4] R5 IV_88 yield/% a ee% b 
IV_85a [H, H, H, H] Ph (IV_86c) IV_88a 90 81 
IV_85a [H, H, H, H] 2-NO2C6H4 (IV_86j) IV_88b 87 98 
IV_85a [H, H, H, H] 2,5-Cl2C6H3 (IV_86k) IV_88c 88 95 
IV_85b [Cl, Cl, H, H] Bn (IV_86d) IV_88d 92 95 
IV_85b [Cl, Cl, H, H] c-hexyl (IV_86l) IV_88e 88 98 
IV_85b [Cl, Cl, H, H] 4-ClC6H5CH2 (IV_86m) IV_88f 85 98 
IV_85c [H, H, Cl, Cl] Ph (IV_86c) IV_88g 92 99 
IV_85c [H, H, Cl, Cl] 2,6-F2C6H3 (IV_86n) IV_88h 92 99 
IV_85d [H, Cl, Cl, H] Ph (IV_86c) IV_88i 87 99 
IV_85d [H, Cl, Cl, H] 2,4,6-Me3C6H2 (IV_86o) IV_88j 85 99 
IV_85e [H, H, NHMe, 
H] 
c-hexyl (IV_86l) IV_88k 96 85 
 a Isolated yield. b Chiral HPLC. 
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More recently, the Moyano group published a bifunctional thiourea-catalyzed 
asymmetric cycloaddition of anthrone and maleimides [354]. In their research, Takemoto’s 
bifunctional amino thiourea IV_89 was applied as the catalyst [355], providing a very 
similar activation mode for the asymmetric cycloaddition of anthrone as Yamamoto’s 
catalyst. The protonated chiral amino nitrogen was thought to bond to the anthrone 
phenolate oxygen, while the thiourea moiety, which has stronger hydrogen-bonding ability 
than the alcohol in Yamamoto’s model, directs the dienophile to the top face in transition 
state IV_90. The asymmetric Diels-Alder reactions of anthrone and N-aryl maleimides 
catalyzed by IV_89 produced desired cycloadducts with both excellent yield and 
enantioselectivity, as summarized in Scheme 4.21. However, the dienophiles were limited 
to maleimides with N-aryl substituents, no N-alkyl substituted maleimides were reported 
in this work. 
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Table 4.3 Asymmetric Diels-Alder Reaction of Anthrone by the Moyano Group 
(Scheme 4.21) 
 
 
 
 R Yield (%) a ee (%) b 
1 Ph 91 90 
2 Bn 92 83 
3 m-Cl-C6H4 92 90 
4 p-OMe-C6H4 90 97 
   a Isolated yield. b Chiral HPLC. 
 
 
4.2.2 Chiral Anthracene Cycloadduct Derived Catalysts for Asymmetric 
Cycloaddition of Anthrone 
 
 After examining the reaction transition states proposed by both the Yamamoto and 
Moyano groups, and analyzing previous results from our group’s research, we developed 
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a transition state model for the asymmetric Diels-Alder reaction of anthrone, trying to 
rationalize the origin of the selectivity, as illustrated in Figure 4.1 [327]. 
 
Figure 4.1 Transition State Analysis 
 
 
 
Since 9-hydroxylanthracene is planar, there are four quadrants from which 
dienophiles can approach the aromatic plane, generating two enantiomers. When catalyst 
IV_78 was applied, the maleimide should favor approach from the top right quadrant, with 
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the ammonium group hydrogen bonding to the phenolate oxygen to activate the Diels-
Alder reaction, and the hydroxyl group from the catalyst directing the maleimide to the top 
face (Quadrant I) by hydrogen bonding to the carbonyl from the maleimide. The approach 
from the bottom left, Quadrant III, would occur in the same manner, generating the same 
enantiomer. The other two approaches, from Quadrant II and IV, would have to occur 
without the hydroxyl directing hydrogen bond, thereby decreasing the overall 
enantioselectivity of the reaction process. Catalyst IV_89 is argued to work in the same 
manner. Presumably the greater enantioselectivity in comparison to IV_78, is a 
consequence of the stronger hydrogen bonding with the thiourea. When catalysts IV_75 
and IV_76 were applied, the two hydroxyl groups from the catalysts are able to direct the 
two diagonal quadrants I and III simultaneously, which led to a higher selectivity. For the 
N-substituted pyrrolidine IV_76, a calculated stable conformation reported by Yamamoto 
suggested that the bottom left (Quadrant III) was blocked by the tethered pyridine moiety, 
which further improved the selectivity.  
 
 With this model in mind, we turned our attention to potential use of homochiral 
cycloadducts of chiral anthracene and maleimide as organocatalysts. In the proposed 
reaction process model, the anthracene part of the molecule could block two quadrants 
from the top face (or bottom face) simultaneously, leaving the two quadrants from the 
opposite bottom face (or top face), for the dienophile to approach the anthrone aromatic 
plane. By manipulating the carbonyl groups on the anthracene-mounted maleimide subunit 
of the catalyst, we could either use steric groups to block one of the remaining two 
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quadrants leaving only one pathway available for the dienophiles to approach, or install a 
hydroxyl-containing moiety as directing group to differentiate the two unhindered 
quadrants.  
 
The preparation of the new catalysts started with the Diels-Alder reaction of chiral 
anthracene IV_45b and maleimide, giving cycloadduct IV_47 as the single 
diastereoisomer with excellent yield. Following DIBAL-H reduction, allyl installation onto 
the acyl iminium produced from IV_121 gave IV_122 in 87% yield over two steps. The 
DIBAL-H reduction proceeded with complete regioselectivity as expected. After Boc-
protection, reduction of IV_124, then Boc-deprotection, gave IV_125a as the target 
catalyst candidate (Scheme 4.22). Using a similar sequence, several homochiral 
anthracene/maleimide cycloadduct derived catalysts IV_125 were prepared for the 
asymmetric Diels-Alder reaction of anthrone and maleimides. 
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Scheme 4.22 Preparation of Chiral Anthracene Cycloadduct Derived Catalysts 
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Attempts to use the newly prepared chiral anthracene derived catalysts in 
asymmetric cycloadditions failed, none of the catalysts produced encouraging results. 
Candidates IV_96 a-c, g did not catalyze the Diels-Alder reaction between anthracene and 
N-methylmaleimide at all within a reasonable time period. Though catalysts IV_96 d-f, h 
were able to activate the cyclization to give corresponding cycloadducts, no 
enantioselectivity was achieved in any of these cases as determined by chiral HPLC. The 
poor ability to activate the cycloadditions could be a consequence of the steric crowding of 
the nitrogen, but when the catalysts did initiate the cycloaddition, neither the blocking 
substituents nor the directing hydroxyl groups seemed to effect the stereochemical outcome 
whatsoever. 
 
Using Moyano’s protocol with thiourea IV_89 as the catalyst, the 
enantioselectivities of asymmetric Diels-Alder reactions between anthrone and several 
maleimides, in addition to the ones reported in the literature were examined (Table 4.1, 
Scheme 4.23). Combined with the data reported in their work, various substituents on 
maleimide nitrogen resulted very different enantioselectivities. The selectivity dropped 
dramatically, vanished completely in some cases, when the substituents on maleimide 
nitrogen were not aryl groups. Maleimide (Entry 5) and N-methyl maleimide (Entry 6) 
were completely nonselective. Also if there were one, (benzyl maleimide, Entries 2 and 9) 
or more (Entry 7) methylene groups between the nitrogen atom and aromatic ring, a great 
amount of enantioselectivity was lost.  
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Table 4.4 Asymmetric Diels-Alder Reaction of Anthrone Using Thiourea 
Catalyst IV_89 (Scheme 4.23) 
 
 
 
 R Yield (%) c ee (%) d 
1a Ph 91 90 
2a Bn 92 83 
3a m-Cl-C6H4 92 90 
4a p-OMe-C6H4 90 97 
5b H 42 < 10 
6b Me 78 < 10 
7b (CH2)2-3,4-(OMe)2-C6H3 83 32 
8b Ph 90 > 99 
9b Bn 80 50 
a Data reported in literature [354]. b Data obtained in our experiments.  
           c Isolated yield. d Chiral HPLC. 
 
  
These results indicated that the maleimide nitrogen substitution plays a very 
important role in achieving enantioselectivity in the asymmetric Diels-Alder reaction of 
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anthrone and maleimides. The originally proposed model for the reaction process had 
neglected the dienophile effect in this transition state complex. We suspected that the steric 
effect or -stacking effect of the nitrogen substituent might be a key issue. When the 
immediate space around the maleimide nitrogen atom gets more crowded, the 
enantioselectivity increases. In Yamamoto’s result (Scheme 4.18), the 2-tert-butylphenyl 
substituted maleimide was necessary to achieve high enantioselectivity among all 
maleimides. A complete picture of optimal enantioselectivity in this reaction is still 
unclear. More thorough investigations into both catalyst structures and maleimide nitrogen 
substituents are needed in order to fully understand the nature of the enantioselectivity 
origin in this reaction.  
 
4.2.3 BINOL Type Catalysts for Asymmetric Cycloaddition of Anthrone 
 
Since the chiral anthracene derived catalysts IV_96 gave only disappointing results, 
our attention turned to 2,2’-binaphthol and 2,2’-binaphthyldiamine structures as potential 
catalysts for this asymmetric cycloaddition of anthrone. Feasibility studies used N-methyl 
maleimide as the dienophile (Scheme 4.24). The S-1,1’-bi-2-naphthol IV_97 alone did not 
catalyze the cycloaddition reaction at all, with 100% starting material recovered after three 
days. S-1,1’-Bi-2-naphthylamine gave a messy reaction mixture with little desired 
cycloadduct observed by UPLC, probably due to the decomposition of anthrone under 
basic conditions. However, when the unreacted reaction mixture containing S-1,1’-bi-2-
naphthol IV_97 was treated with 10 mol% of triethylamine, a surprising 95% yield of 
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cycloadduct with 85% ee resulted. This promising observation led to further exploration of 
this BINOL-TEA catalytic system.  
 
Scheme 4.24 Asymmetric Diels-Alder Reaction of Anthrone Using bi-2-Naphthol 
and TEA as Catalyst 
 
 
 
The fact that BINOL IV_97 alone did not catalyze the cycloaddition can be 
explained by the lack of a basic moiety on the ligand to generate the hydroxy-anthracene 
tautomer, the active diene for the cycloaddition. After addition of triethylamine, 
tautomerization of anthrone to the deprotonated phenolate, which complexes with BINOL 
by hydrogen bonding, generates the active diene. The other BINOL phenol group remains 
intact, acting as a directing group for the dienophile via hydrogen bonding. 
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Figure 4.2 Proposed Transition State Model of BINOL/TEA Catalysis of 
Asymmetric Diels-Alder Reaction of Anthrone 
 
 
 
Reaction conditions using the BINOL/TEA catalytic system were then further 
investigated to optimize the yield and enantioselectivity of this asymmetric cycloaddition 
(Table 4.5). Premixing of S-BINOL, anthrone and maleimide prior to the addition of 
triethylamine turned out to be critical for maximizing the enantioselectivity. When S-
BINOL, anthrone, maleimide and triethylamine were all mixed together at time zero, or 
when a pre-mixed solution of S-BINOL and triethylamine was transferred to a reaction 
mixture of anthrone and maleimide, no enantioselectivity was observed (Entry 1 and Entry 
2). Furthermore, premixing required several hours of equilibration (Entry 3-7), and a higher 
temperature of the premixing did not shorten the time required for achieving the same 
enantioselectivity (Entry 8). Different amines, the amount of amine, reaction temperature 
and solvent were examined as well. Though DIPEA gave similar enantioselectivity, the 
yield dropped to 65% due to the decomposition of the cycloadduct IV_101 (Entry 10). The 
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enantioselectivity also declined when the amount of amine was increased (Entry 11 and 
Entry 12), presumably due to background reaction of anthrone with the maleimide 
catalyzed by triethylamine. The inorganic base K2CO3 was also tested and resulted in good 
enantioselectivity (Entry 9), illustrating that TEA functions only as a base instead of 
forming a more complex catalysis system with BINOL The reaction temperature did not 
affect the enantioselectivity but the cycloaddition slowed significantly when lower 
temperatures were applied, resulting in lower yields (Entry 13 and Entry 14). When the 
reaction was carried at -78 °C, there was no reaction even after three days. Finally, 
chloroform and 1,2-dichloroethane proved to be better solvents for this asymmetric 
cycloaddition compared to toluene and hexane (Entries 15-17). Attempts using visible and 
UV light, instead of base, to activate the Diels-Alder reaction were unsuccessful. The best 
enantioselectivity (85% ee) was achieved by premixing S-BINOL, anthrone and maleimide 
for 24 hours, followed by addition of 10 mol% of triethylamine in chloroform for 24 hours 
(95% yield). 
 
Scheme 4.25 Optimization of BINOL/TEA Catalytic System  
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Table 4.5 Optimization of Binol/TEA Catalytic System 
 
Entry Base (eq.) 
Premix/RXN 
Time 
Solvent Temp. Yield a ee b 
1 TEA (10%) 0/24 h CHCl3 rt >95% 0 
2 TEA (10%) 0/24 h CHCl3 rt 40% 
<10
% 
3 TEA (10%) 30 min/24 h CHCl3 rt >95% 0 
4 TEA (10%) 2 h/24 h CHCl3 rt >95% 
<10
% 
5 TEA (10%) 6 h/24 h CHCl3 rt >95 20% 
6 TEA (10%) 24 h/24 h CHCl3 rt >95 85% 
7 TEA (10%) 72 h/24 h CHCl3 rt >95 85% 
8 TEA (10%) 30 min 40 oC/24 h CHCl3 rt >95 0 
9 K2CO3 (10%) 24 h/24h CHCl3 rt 90% 70% 
10 DIPEA (10%) 24 h/24h CHCl3 rt 65% 80% 
11 TEA (25%) 24 h/24 h CHCl3 rt 95% 30% 
12 TEA (50%) 24 h/8h CHCl3 rt 95% 0 
13 TEA (10%) 24 h/24 h CHCl3 -30 °C 50% 85% 
14 TEA (10%) 24 h/72 h CHCl3 -78 °C NR -- 
15 TEA (10%) 24 h/24 h toluene rt 60% 80% 
16 TEA (10%) 24 h/24 h DCE rt 95% 85% 
17 TEA (10%) 24 h/24 h hexane rt 45% 50% 
 a UPLC conversion. b Chiral HPLC. 
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Other BINOL derivatives [356] were also examined under the optimized reaction 
conditions (Scheme 4.26). All catalytic systems gave greater than 95% conversion, but 
with poor or no enantioselectivity, presumably because of direct catalysis of the reaction 
with triethylamine. A background reaction was conducted using TEA (10%) without any 
BINOL derivatives, affording a greater than 95% conversion and no ee in the same reaction 
time. 
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Scheme 4.26 Enantioselectivity of BINOL Derivatives as Catalysts 
 
 
With the model studies completed, the S-BINOL IV_97 and triethylamine catalytic 
system was then tested with other maleimides with different substituents on the nitrogen 
(Table 4.6). When N-methyl IV_86b, N-phenyl IV_86c and N-benzyl IV_86d maleimides 
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were used for the cycloaddition, the BINOL/TEA system gave good to excellent 
enantioselectivities (Entries 2-4). When maleimide IV_86a (R = H) was used in the 
cycloaddition, the selectivity was reduced to74% ee (Entry 1), and the extremely poor 
solubility of the cycloadduct IV_91a made it impossible to perform Mitsunobu reactions 
to install other nitrogen substituents in parallel fashion for further diversification.  
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Table 4.6 Effects of N-Substituents on the cycloadditions of Maleimides in 
BINOL/TEA Catalytic System (Scheme 4.27) 
 
 
 
Entry R Product Yield a ee b 
1 H (IV_86a) IV_91a 76% 74% 
2 Me (IV_86b) IV_91b 98% 85% 
3 Ph (IV_86c) IV_91c 99% 99% 
4 Bn (IV_86d) IV_91d 92% 90% 
5 
 -
(IV_86e) 
IV_91e 98% 45% 
a Isolated yield. b Chiral HPLC. 
 
In order to pursue the original synthetic goal of alkaloid synthesis, the route was 
therefore modified to allow the installation of the aromatic substituent before the 
asymmetric cycloaddition, thereby requiring the preparation of the substituted maleimide 
IV_86e. However, the S-BINOL/TEA catalytic system did not effectively control the 
enantioselectivity of the asymmetric cycloaddition of anthrone with the substituted 
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maleimide IV_86e, giving only 45% ee (Entry 5). This was also consistent with earlier 
observations, which increasing the number of methylene groups between the maleimide 
nitrogen atom and the aromatic functionality lead to a decreasing enantioselectivity. 
Therefore, finding a catalyst capable of providing good enantioselectivity in the 
asymmetric cycloadditions of anthrone and a wide variety of N-substituted maleimides like 
IV_86e remained a challenge. 
 
In conclusion, the newly established S-BINOL (IV_97) and triethylamine catalytic 
system gave as good as or better enantioselectivity in the asymmetric cycloadditions of 
anthrone and maleimides compared to data reported in the literature using other 
organocatalysts. This improvement in enantioselectivity was most significant for the N-
methyl maleimide, whereby the BINOL/TEA catalytic system gave an 85% ee, which is 
the best enantioselectivity obtained to date for the reaction. 
 
4.2.4 Prolinol Derived Ligands as Catalysts for Asymmetric Cycloadditions of 
Anthrone 
Given the failure of maleimide to participate in an enantioselective cycloaddition 
with anthrone above 74% ee, and the general insolubility of cycloadduct IV_91a, the 
aromatic substituents on the maleimide needed to be installed prior to the asymmetric 
cycloaddition with anthrone in order to prepare alkaloidal core structures. The challenge in 
this project thus remained to find a catalyst capable of providing good enantioselectivity 
for the asymmetric cycloadditions of anthrone and various N-substituted maleimides. 
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Unfortunately, the BINOL/TEA catalytic system did not provide the desired level of 
enantioselectivity with maleimides which have the aryl ring substituents removed from the 
maleimide nitrogen by more than one methylene group. 
The literature, combined with our own experience, indicated that for the 
asymmetric cycloaddition between anthrone and maleimides, there is no single catalyst that 
works well for all maleimides, but enantioselectivity is very substrate specific. We 
therefore initiated a screening of several catalysts to achieve high enantioselectivity in the 
cycloaddition between anthrone and the maleimide IV_86e, which was of particular 
interest in for further synthetic applications (Table 4.7). In the first round of screening, the 
catalyst IV_102 (Entry 6) provided good enantioselectivity for the asymmetric 
cycloaddition of anthrone and maleimide IV_86e, affording the corresponding 
enantiomerically enriched cycloadduct IV_91e in 83% ee. Two related catalysts IV_78a 
and IV_103 were also tested to optimize the enantioselectivity (Entry 7 and Entry 8), but 
did not show improvement. 
 
Scheme 4.28 Catalyst Screening for the Asymmetric Cycloaddition between 
Anthrone and Maleimide IV_86e 
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Table 4.7 Catalysts Screening for the Asymmetric Cycloaddition between 
Anthrone and Maleimide IV_86e 
Entry Catalyst Time Yield a ee b 
1 
  
48 h 95% 9% 
2 
 
24 h 98% 
45% 
(S, S) 
3 
 
14 h 90% 34% 
4 
 
48 h 48% 10% 
5 
 
12 h 92% 10% 
6 
 
12 h 98% 83% 
7 
 
12 h 95% 72% 
8 
 
72 h trace -- 
a Isolated yield. b Chiral HPLC. 
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Reaction conditions were then examined to optimize the enantioselectivity in this 
asymmetric cycloaddition of anthrone with maleimide IV_86e, using catalyst IV_102 
(Table 4.8). The initial reaction conditions employed proved to give the highest 
enantioselectivity (83% ee, with 98% yield), at room temperature in chloroform with 0.1 
M concentration on a 20 mg scale (Entry 1). When the reaction was scaled to 500 mg, the 
enantioselectivity dropped significantly, to 39% (Entry 9). A lower concentration for the 
reaction seemed to be crucial when larger scale reactions were applied, as in Entry 11, 500 
mg scale reaction with a 0.05 M concentration gave a much better selectivity (82% ee) 
compared to 0.1 M concentration (entry 9). The choice of solvent was also consistent with 
Yamamoto’s finding [351], a moderately polar aprotic solvent, chloroform, was best for 
selectivity. Surprisingly, the enantioselectivity dropped as the temperature decreased from 
room temperature to -78 °C, probably due to the temperature-sensitive solubility of one of 
the reaction components, which could potentially disturb the coordination dynamic within 
the reaction mixture (Entries 6-8). Increasing the reaction temperature to 40 °C did not 
improve the selectivity either (Entry 5). The elevated temperature caused the cycloadduct 
to undergo a cycloreversion, leading to a lower 74% yield. While the selectivity also 
dropped significantly to 42% (Entry 5). The loading of the catalyst did not change the 
selectivity, at 10 %, 20%, 50% and 100% mol of the catalyst, all reactions yielded the same 
selectivity around 80% ee. 
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Table 4.8 Optimization of Catalyst IV_102 for Asymmetric Cycloaddition of 
Anthrone (Scheme 4.29) 
 
 
Entry Time Solvent Concentration Temp. Yield a ee b 
1 12 h CHCl3 0.1 M rt 98% 83% 
2 12 h CH2Cl2 0.1 M rt 95% 60% 
3 12 h toluene 0.1 M rt 88% 75% 
4 12 h hexane 0.1 M rt 86% 21% 
5 5 h CHCl3 0.1 M 40 °C 74% 42% 
6 12 h CHCl3 0.1 M 0 98% 56% 
7 72 h CHCl3 0.1 M -30 °C 88% 38% 
8 72 h CHCl3 0.1 M -78 °C 56% 15% 
9 12 h CHCl3 0.1 M (500 mg) rt 98% 39% 
10 12 h CHCl3 0.2 M rt 98% 52% 
11 12 H CHCl3 0.05 M (500 mg) rt 98% 82% 
a Isolated yield. b Chiral HPLC. 
176 
 
The prolinol catalyst IV_102 was then tested in the asymmetric cycloadditions of 
anthrone and other maleimides (Table 4.9). Catalyst IV_102 did not give useful level of 
selectivities for N-methyl, N-phenyl or N-benzyl maleimides (Entries 1-3), confirming the 
assumption that the organocatalitic asymmetric cycloadditions of anthrone are very 
sensitive to substrate structure. Subsequently, the catalyst IV_102 was applied in anthrone 
cycloadditions with maleimides IV_86e-i bearing different aryl ethyl substituents to 
explore the substrate scope (Entries 4-8). The enantioselectivity was approximately the 
same for the different aryl groups, except in the case of maleimide IV_86i, which has one 
more methylene group between the maleimide nitrogen atom and the indole subunit. 
Particularly informative was the decrease of 78% ee to 8% ee upon this increased tether 
length (Entry 7 and 9). 
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Table 4.9 Catalyst IV_102 for Asymmetric Cycloaddition of Anthrone with 
Different Maleimides (Scheme 4.30) 
 
 
 
Entry R Yield (IV_91) a ee b 
1 Me IV_86b 98% 32% 
2 Ph IV_86c 99% 42% 
3 Bn IV_86d 96% 47% 
4 
 
98% 83% 
5 
 
95% 80% 
6 
 
98% 78% 
7 
 
96% 78% 
8 
 
95% 8% 
a Isolated yield. b Chiral HPLC. 
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In conclusion, the substituted prolinol catalyst IV_102 was able to catalyze the 
asymmetric cycloadditions between anthrone and maleimides with N-arylethyl substituents 
IV_86e-i in excellent yields and good enantioselectivity. No other organocatalysts 
approached this level of enantioselectivity with N-arylethyl maleimide dienophiles in 
cycloadditions with anthrone. The level of the enantioselectivity and the unique structure 
of these specific maleimides allowed the application of this asymmetric cycloaddition in 
the DA/FGT/rDA sequence for further synthetic purposes.  
 
 
4.3 Application of the DA/rDA Sequence Using Anthrone as Template in the 
Synthesis of Alkaloidal Core Structures  
 
Having established good an enantioselectivity in the asymmetric cycloadditions 
between anthrone and maleimides IV_86e-h using prolinol catalyst IV_102, studies were 
directed toward applying the DA/rDA sequence in the synthesis of the alkaloidal 
frameworks, which form the structural fragment of Erythrina alkaloids that have been 
shown to elicit significant pharmacological activity [357]. 
 
Model studies began using maleimide IV_86e (Scheme 4.31). The synthesis of the 
tricyclic alkaloidal core structure was undertaken beginning with the asymmetric 
cycloaddition of anthrone and maleimide IV_86e to produce cycloadduct IV_91e in 
quantitative yield with 83% ee. Regioselective methyl Grignard addition produced a single 
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diastereoisomer IV_104a (phenyl, IV_104b), with the methyl group adding to the 
maleimide carbonyl group remote to the anthrone hydroxyl group. The following TFA 
catalyzed Friedel-Crafts cyclization of the crude Grignard addition product IV_104a gave 
cycloadduct IV_105a in an excellent 97% yield over two steps. The cycloreversion of the 
cyclized product IV_105a was promoted by potassium hydride in THF at room 
temperature in quantitative yield in a short period of reaction time (5 minutes) to yield the 
desired alkaloid structure IV_106. Notably, the cycloreversion was very solvent specific. 
In the process of optimizing the reaction conditions for the cycloreversion, THF was the 
only solvent that allowed the cycloreversion to occur. Other solvents, DMSO, DCM, 
chloroform, dichlorobenzene, and toluene, were tested with various bases under a wide 
range of different temperatures, thermal and microwave irradiated, and none of them gave 
any cycloreversion product. 
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Scheme 4.31 Preparation of Alkaloidal Core Structures Applying the DA/rDA 
Sequence 
 
 
 
With the model study of the DA/rDA sequence completed, the substrate scope of 
the DA/rDA sequence was explored with other maleimides IV_86 with different aryl ethyl 
substituents to prepare a collection of tricyclic alkaloidal core structures (Table 4.6). In 
addition to the diversification introduced by the variety of maleimides substituents, 
different Grignard reagents, methyl and phenyl, were also used to diversify the structure. 
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The established DA/FGT/rDA protocols in the model study in Scheme 4.31 transferred 
well to all substrates. Regioselective Grignard additions followed by Friedel-Crafts 
cyclizations of the crude addition products IV_104 gave cycloadducts IV_105 in excellent 
yields (84-97%). The Friedel-Crafts cyclizations producing cycloadduct IV_105c,d 
required significantly longer reaction times than other substrates, presumably due to the 
steric effect at the newly formed quaternary carbon center. The potassium hydride 
promoted cycloreversions of methoxy substituted aryl rings IV_86a-f gave the desired 
lactams IV_106a-f in quantitative yields. For the indole derivatives IV_105g,h (Entries 7 
and 8), the cycloreversions also gave the desired lactams IV_106g,h in excellent yields 
(90-94%), though not quantitatively. 
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Table 4.10 Preparation of Alkaloidal Core Structures Applying the DA/rDA 
Sequence a 
Entry R  Grignard (R’)/ FC Yield b, c rDA Yield b, e 
1 
 
 
R= Me, IV_105a, 97% 
 
> 99% 
2 R= Ph, IV_105b, 92% > 99% 
3 d 
 
 
R= Me, IV_105c, 94% 
 
> 99% 
4 R= Ph, IV_105d, 87% > 99% 
5 
 
 
R= Me, IV_105e, 95% 
 
> 99% 
6 R= Ph, IV_105f, 89% > 99% 
7 
 
 
R= Me, IV_105g, 91% 
 
91% 
8 R= Ph, IV_105h, 84% 90% 
a For yields and enantioselectivities for Diels-Alder reactions, see Table 4.5. b Isolated 
yields, two steps. c Grignard additions were run in THF (0.1 M in imide) at -78 °C to room 
temperature for 14-18 hours, monitored by TLC. Friedel-Crafts cyclization were run in 
dichloroethane (DCE), 0.1 M in acyl aminal with 20 eq TFA at room temperature for 30 
minutes unless otherwise note. d Friedel-Crafts cyclization were run for 7 hours. e 
Cycloreversion were run in THF (0.1 M in cycloadduct) with 5 eq of KH for 5 minutes.  
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4.4 Studies toward to the Syntheses of Crispine A, Harmicine and Analogues 
 
The chemistry used to prepare alkaloidal core structures IV_106a and IV_106b 
(Scheme 4.31) could also be applied to the synthesis of the antitumor alkaloid crispine A 
[358] in a highly enantiomerically enriched form. The synthesis would require a 
regioselective reduction of the maleimide cycloadducts rather than a Grignard addition. 
 
Applying the same DA/rDA sequence established previously, the asymmetric 
Diels-Alder reaction of anthrone and maleimide IV_86e afforded cycloadduct IV_91e in 
excellent yield (Scheme 4.32). Reduction of the cycloadduct IV_91e with DIBAL-H 
provided hydroxy lactam IV_107 as a single diastereoisomer in quantitative yield. 
Subsequent TFA catalyzed intramolecular Friedel-Crafts cyclization of hydroxyl lactam 
IV_107 afforded cycloadduct IV_108 in excellent yield after purification by flash column 
chromatography (94%, 2 steps). The retro-Diels-Alder reaction was performed on IV_108 
with potassium hydride and sodium hydride in THF. Unfortunately, the cycloreversion of 
IV_108 did not afford any desired product but only decomposition. Weaker bases were 
then examined for the cycloreversion. While potassium carbonate did not trigger the 
cycloreversion, giving back starting material IV_137, sodium hydroxide was the only base 
that afforded the desired cycloreversion product IV_109, but with a low 15% yield after 
flash column chromatography. The cycloreversion product IV_109 decomposed rapidly in 
CDCl3 within 2 hours. In this case, a retro-Diels-Alder reaction clearly had occurred, but 
either the cycloreversion product IV_109 decomposed immediately under the basic 
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conditions, or it might have undergone a rapid isomerization to the more 
thermodynamically stable IV_110 [332]. 
 
Scheme 4.32 Synthesis towards to Crispine A 
 
 
 
Similar attempts were made to synthesize harmicine starting with maleimide 
IV_86h. The chemistry proceeded uneventfully, and in high yield, to cycloreversion 
precursor IV_112. Once again, total decomposition in the final retro-Diels-Alder step 
resulted, even using sodium hydroxide as the base (Scheme 4.33). 
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Scheme 4.33 Synthesis towards to Harmicine 
 
 
 
Though attempts toward the synthesis of crispine A and harmicine were 
unsuccessful due to the failed cycloreversion, reduction of the alkene and carbonyl group 
on the alkaloidal core structure IV_106a afforded crispine A analogue IV_114 with good 
yields (Scheme 4.34). Presumably, the instability of crispine A and harmicine to the 
cycloreversion conditions is a consequence of the acidity of the angular hydrogen. 
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Scheme 4.34 Synthesis of Crispine A Analogue 
 
 
 
 
4.5 Summary 
 
In summary, a BINOL/TEA catalytic system was established for the asymmetric 
cycloaddition between anthrone and specific maleimides (N-methyl IV_86b, N-phenyl 
IV_86c, and N-benzyl IV_86d) affording excellent yields and good enantioselectivities of 
the cycloadducts. Of note is the cycloaddition between anthrone and N-methyl maleimide 
IV_86b, in which the BINOL/TEA catalytic system gave 85% ee (95% yield), the best 
enantioselectivity achieved to date for this dienophile with anthrone. Asymmetric 
cycloadditions of anthrone with N-aryl ethyl substituted maleimides (IV_86e-i) using 
prolinol catatlyst IV_102 with good enantioselectivity were also established. Using 
IV_102 catalyzed asymmetric Diels-Alder reactions as the key stereocontrol element, we 
successfully applied the DA/FGT/rDA sequence to the synthesis of alkaloidal core 
frameworks, including crispine A analogue IV_114. Notably, this is also the first time, 
applying the DA/rDA sequence in synthesis, that chirality was transferred from the chiral 
catalyst for the initial Diels-Alder reaction to the final enantiomerically enriched product. 
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Chapter V 
 
 
 
 
Experimental  
 
 
5.1 General Methods 
 
Melting points were determined on a capillary melting point apparatus and are 
uncorrected. The 1H NMR and 13C NMR spectra were recorded at 117.42 kG (1H 500 MHz, 
13C 125 MHz), 93.94 kG (1H 400 MHz, 13C 100 MHz), or 70.50 kG (1H 300 MHz, 13C 75 
MHz) at ambient temperature as noted. Hydrogen chemical shifts are expressed in parts 
per million (ppm) relative to the residual protio solvent resonance: CDCl3 δ 7.24, DMSO 
δ 2.50. All exchangeable protons in non-exchanging solvents were confirmed as such by 
the addition of D2O. For 
13C spectra, the centerline of the solvent signal was used as internal 
reference: CDCl3 δ 77.16, DMSO δ 39.52. Unless otherwise noted, each carbon resonance 
represents a single carbon (relative intensity). Inverse gated decoupled spectra using 10 
second delays between transients were used for carbon resonance integration to establish 
relative intensities greater than 1 carbon when not obvious. All pulse sequence employed 
for ID NMR experiments were of standard software (Varian Unity Plus v5.1a, and Gemini 
188 
 
NMR Spectrometer System) supplied by the manufacturers. Infrared spectra were recorded 
on an FTIR spectrometer by depositing one drop of a sample solution in a volatile solvent 
(typically CHCl3) directly onto the reflective plate, followed by evaporation of the solvent. 
For infrared spectra, only diagnostic bands (including, but not limited to: OH, carbonyl and 
SO2 stretching frequencies) are reported. High resolution mass spectrometric data were 
obtained on a QToF (hybrid quadrapolar/time-of-flight) API US system by electrospray 
(ESI) in the positive ion mode. Mass correction was done by an external reference using a 
lockspray accessory. Mobile phases were water and acetonitrile (1:9) with 0.1% formic 
acid. With a flow rate of 0.2 mL/min. The MS settings were: capillary voltage 3kV, cone 
voltage 45, source temperature 120 ⁰C and desolvation temperature 350 ⁰C. Optical 
rotations were obtained on a Rudolph Autopol III polarimeter (concentration: g/100 mL). 
All reactions were carried out under an argon atmosphere as noted, in oven-dried (100 – 
110 oC) glassware. Temperatures below room temperature were maintained using the 
appropriate bath (-78 oC, dry ice/acetone; 0 oC, ice/water). All microwave reactions were 
run in sealed 10 mL thick-walled microwave pressure tubes in a microwave reactor. 
Microwave reaction temperatures were measured using a volume-independent infrared 
temperature sensor located within the microwave cavity. An “HM/HCl plug” refers to a 
Hydromatrix SPE column saturated with 1.0 M HCl water solution. Flash chromatography 
was performed on silica gel-60 (43-60 μm). Diethyl ether, tetrahydrofuran (THF), 1,4-
dioxane, toluene, and benzene, were distilled from sodium/benzophenone immediately 
prior to use; dichloromethane (CH2Cl2), chloroform (CHCl3), 1,2-dichloroethane and 
DMSO were distilled from calcium hydride immediately prior to use. Ethanol and 
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methanol were distilled from magnesium and iodine immediately prior to use. 
Bromobenzene was dried over sodium sulfate prior to use. Triethylamine (C6H15N) was 
distilled from potassium hydroxide. Commercially available chemical reagents were used 
without further purification or purified following literature purification procedure if needed 
[359].  
 
 
5.2 Experimental for Chapter II 
 
General Procedure A, 
Preparation of Isatin-
Derived Triazines II_45: 
Freshly prepared ethyl oxalamidrazonate (II_47) [360] was dissolved in anhydrous EtOH 
(0.1 M), and the isatin (1.0 eq) was added at room temperature with stirring. The reaction 
mixture was stirred at room temperature for 12 hours, and then refluxed for 20 minutes. 
After removal of the EtOH in vacuo, the residue was dissolved in anhydrous bromobenzene 
(0.2 M) and refluxed for 24 hours. After removal of the solvent in vacuo, the residue was 
dried by addition and subsequent evaporation of toluene three times, and used directly for 
the next step without any further purification.  
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General Procedure B, 
Preparation of Sulfonamides 
II_46: The isatin-derived 
triazine II_45 was suspended in THF (0.25 M) and triethylamine (2.0 eq) was added into 
the solution at room temperature. The reaction mixture was stirred at room temperature for 
30 minutes until dissolution was complete, then p-toluenesulfonyl chloride (2.0 eq) was 
added at room temperature, and the reaction mixture was stirred at room temperature for 7 
hours. After removal of the solvent in vacuo, the residue was purified by flash 
chromatography to yield desired triazine II_44.  
 
 
General Procedure C, 
Amidation of II_44a to 
Amides II_49: To a 
solution of triazine II_44a (1.0 eq) and propargyl amine (1.2 eq) in CH2Cl2 (0.25 M) was 
added Zr(Ot-Bu)4 (1.2 eq) at room temperature. The reaction mixture was stirred at room 
temperature for 16 hours, then the mixture was diluted with CH2Cl2 (2 ml) and passed 
through an HM/HCl plug (hydro-matrix plug saturated with 0.1M HCl aqueous solution) 
eluting with CH2Cl2. The filtrate was dried over sodium sulfate, and then the solvent was 
removed in vacuo. The residue was purified by flash chromatography to yield the desired 
amide II_49. 
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General Procedure D, Cycloaddition 
of II_49 to II_50: A solution of the 
amide II_49 in diglyme (0.1 M) was 
placed in a thick-walled microwave 
tube, then the reaction mixture was subjected to microwave irradiation at 160 °C for 20 
minutes with stirring unless otherwise noted. After the irradiation the solvent was removed 
in vacuo and the residue was purified by flash chromatography to yield the cycloadducts 
II_50. 
 
 
General Procedure E, 
Transesterification of II_44 to 
II_54 using Otera Catalyst: To a 
solution of triazine carboxylate (1.0 eq) and the Otera catalyst (0.1 eq) [361] in toluene (0.1 
M) was added the alkynyl alcohol (excess, greater than 5 eq) at room temperature. The 
reaction mixture was heated and stirred at 105 °C for 12 hours. The reaction was filtered 
through Celite, then the solvent and excess alcohol were removed in vacuo. The residue 
was purified by flash chromatography to yield the desired esters. 
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General Procedure F, Preparation of 
Alkynylamines: Propargylamine (1.0 eq) 
and the aldehyde (2.0 eq) were mixed in EtOH and the reaction mixture was refluxed for 
18 hours. The reaction mixture was allowed to cool to room temperature, then NaCNBH2 
(3.0 eq) was added to the reaction at room temperature and continued to stir for 3 hours. 
Water was added to quench the reaction, adjust the pH to neutrality, the mixture was 
extracted with EtOAc and DCM for 3 times. Organic extracts were combined and the 
solvent was removed in vacuo, the residue was purified by chromatography to yield the 
desired alkynylamines. 
 
 
Ethyl 5-[(4-Methylbenzene)sulfonyl]-5H-[1,2,4]triazino[5,6-
b]indole-3-carboxylate (II_44a). Prepared according to General 
Procedures A and B, beginning with ethyl oxalamidrazonate (II_47, 
311 mg, 2.38 mmol, 1.0 eq), isatin (350 mg, 2.38 mmol, 1.0 eq) and 4-
methylbenzenesulfonyl chloride (907 mg, 4.76 mmol, 2.0 eq). Purification by flash 
chromatography (hexanes:EtOAc, 1:1, Rf 0.68) gave II_44a (827 mg, 2.09 mmol, 88% 
yield) as a yellow solid: mp 145-146 °C; IR (neat) 2982, 1742, 1379, 1191, 1180, 671, 579 
cm-1; 1H NMR (400 MHz, CDCl₃) δ 1.54 (t, J = 7.0 Hz, 3H), 2.36 (s, 3H), 4.60 (q, J = 7.0 
Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 7.58 (ddd, J = 8.0, 7.4, 0.8 Hz, 1H), 7.83 (ddd, J = 8.6, 
7.4, 1.0 Hz, 1H), 8.20 (d, J = 8.4 Hz, 2H), 8.49 (ddd, J = 8.0, 0.8, 0.8 Hz, 1H), 8.52 (ddd, 
J = 8.6, 1.0, 0.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 14.4, 21.9, 63.1, 115.1, 118.9, 
 
 
 
193 
 
123.4, 125.8, 128.8 (2C), 130.1 (2C), 133.7, 134.4, 140.5, 145.0, 146.8, 146.9, 152.6, 
162.7; HRMS (ESI) m/z 419.0770 ([M + Na]+, 100%), calc’d for C19H16N4O4SNa 
419.0790. 
 
 
Ethyl 8-Methyl-5-[(4-methylbenzene)sulfonyl]-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_44b). Prepared 
according to General Procedures A and B, beginning with ethyl 
oxalamidrazonate (II_47, 243 mg, 1.86 mmol, 1.0 eq), 5-methylisatin (300 mg, 1.86 mmol, 
1.0 eq) and 4-methylbenzenesulfonyl chloride (710 mg, 3.72 mmol, 2.0 eq). Purification 
by flash chromatography (DCM:EtOAc, 10:1, Rf 0.70) gave II_44b (700 mg, 1.71 mmol, 
92% yield) as a  yellow solid: mp 164-165 °C; IR (neat) 2984, 2925, 1743, 1192, 1179, 
579 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.53 (t, J = 7.2 Hz, 3H), 2.35 (s, 3H), 2.54 (s, 3H), 
4.60 (q, J = 7.2 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 7.63 (dd, J = 8.6, 0.9 Hz, 1H), 8.16 (d, J 
= 8.4 Hz, 2H), 8.28 (d, J = 0.9 Hz, 1H), 8.38 (d, J = 8.6 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 14.4, 21.4, 21.9, 63.1, 114.8, 119.0, 123.2, 128.7 (2C), 130.1 (2C), 134.4, 135.0, 
136.1, 138.7, 145.0, 146.8, 146.9, 152.5, 162.8; HRMS (ESI) m/z 433.0939 ([M + Na]+, 
100%), calc’d for C20H18N4O4SNa 433.0939. 
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Ethyl 8-Methoxy-5-[(4-methylbenzene)sulfonyl]-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_44c). Prepared 
according to General Procedures A and B, beginning with ethyl 
oxalamidrazonate (II_47, 306 mg, 2.34 mmol, 1.0 eq), 5-methoxyisatin (415 mg, 2.34 
mmol, 1.0 eq) and 4-methylbenzenesulfonyl chloride (894 mg, 4.69 mmol, 2.0 eq). 
Purification by flash chromatography (DCM:EtOAc, 10:1, Rf 0.68) gave II_44c (890 mg, 
2.09 mmol, 89% yield) as a yellow solid: mp 136-138 °C; IR (neat) 2893, 1741, 1493, 
1180, 581 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.54 (t, J = 7.1 Hz, 3H), 2.35 (s, 3H), 3.94 
(s, 3H), 4.61 (q, J = 7.1 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 7.40 (dd, J = 9.3, 2.2 Hz, 1H), 
7.91 (d, J = 2.2 Hz, 1H), 8.15 (d, J = 8.6 Hz, 2H), 8.41 (d, J = 9.3 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 14.3, 21.8, 56.1, 63.0, 104.6, 116.2, 119.7, 122.9, 128.5 (2C), 130.0 (2C), 
134.3, 134.8, 144.9, 146.7, 146.8, 152.4, 157.9, 162.6; HRMS (ESI) m/z 449.0885 ([M + 
Na]+, 100%), calc’d for C20H18N4O5SNa 449.0896. 
 
 
Ethyl 8-Fluoro-5-[(4-methylbenzene)sulfonyl]-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_44d). Prepared 
according to General Procedures A and B, beginning with ethyl 
oxalamidrazonate (II_47, 278 mg, 2.12 mmol, 1.0 eq), 5-
fluoroisatin (350 mg, 2.12 mmol, 1.0 eq) and 4-methylbenzenesulfonyl chloride (809 mg, 
4.24 mmol, 2.0 eq). Purification by flash chromatography (hexanes:EtOAc, 1:1, Rf 0.80) 
gave II_44d (740 mg, 1.79 mmol, 85% yield) as a yellow solid: mp 155-157 °C; IR (neat) 
 
 
195 
 
2984, 1744, 1489,  1192, 1179,  579 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.54 (t, J = 7.2 
Hz, 3H), 2.36 (s, 3H), 4.61 (q, J = 7.2 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 7.56 (ddd, JHF = 
9.0 Hz, J = 9.0, 2.8 Hz, 1H), 8.15 (dd, JHF = 7.6 Hz, J = 2.8 Hz, 1H), 8.18 (d, J = 8.2 Hz, 
2H), 8.51 (dd, J = 9.0 Hz, JHF = 4.2 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 14.4, 21.9, 
63.2, 109.4 (d, 2JCF = 24.4 Hz), 116.8 (d, 
3JCF = 8.4 Hz), 120.2 (d, 
3JCF = 9.9 Hz), 121.4 (d, 
2JCF = 14.4 Hz), 128.7 (2C), 130.2 (2C), 134.1, 136.6, 144.6 (d, 
4JCF = 3.8 Hz), 147.09, 
147.13, 152.8, 160.4 (d, 1JCF = 245.4 Hz), 162.5; HRMS (ESI) m/z 437.0683 ([M + Na]
+, 
100%), calc’d for C19H15FN4O4SNa 437.0696. 
 
 
Ethyl 5-[(4-Methoxybenzene)sulfonyl]-5H-[1,2,4]triazino[5,6-
b]indole-3-carboxylate (II_44e). Prepared according to General 
Procedures A and B, beginning with ethyl oxalamidrazonate (II_47, 
284 mg, 2.17 mmol, 1.0 eq), isatin (320 mg, 2.17 mmol, 1.0 eq) and 
4-methoxybenzenesulfonyl chloride (899 mg, 4.35 mmol, 2.0 eq). 
Purification by flash chromatography (hexanes:EtOAc, 1:1, Rf 0.62) gave II_44e (810 mg, 
1.96 mmol, 90% yield) as a yellow solid: mp 185-187 °C; IR (neat) 2983, 1742, 1593, 
1380, 1190, 1174, 579 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.53 (t, J = 7.1 Hz, 3H), 3.80 
(s, 3H), 4.60 (q, J = 7.1 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 7.58 (dd, J = 7.8, 7.6 Hz, 1H), 
7.83 (ddd, J = 8.4, 7.6, 1.2 Hz, 1H), 8.26 (d, J = 8.8 Hz, 2H), 8.49-8.53 (overlap, 2H); ¹³C 
NMR (100 MHz, CDCl3) δ 14.4, 55.9, 63.1, 114.7 (2C), 115.1, 118.9, 123.4, 125.7, 128.6, 
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131.3 (2C), 133.6, 140.6, 145.0, 146.7, 152.6, 162.7, 165.1; HRMS (ESI) m/z 435.0743 
([M + Na]+, 100%), calc’d for C19H16N4O5SNa 435.0739. 
 
Ethyl 5-[(4-Methoxybenzene)sulfonyl]-8-methyl-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_44f). Prepared 
according to General Procedures A and B, beginning with ethyl 
oxalamidrazonate (II_47, 261 mg, 1.99 mmol, 1.0 eq), 5-
methylisatin (320 mg, 1.99 mmol, 1.0 eq) and 4-
methoxybenzenesulfonyl chloride (821 mg, 3.97 mmol, 2.0 eq). Purification by flash 
chromatography (DCM:EtOAc, 10:1, Rf 0.71) gave II_44f (730 mg, 1.71 mmol, 87% 
yield) as a yellow solid: mp 173-174 °C; IR (neat) 2892, 1741, 1192, 1167, 670 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 1.53 (t, J = 7.1 Hz, 3H), 2.55 (s, 3H), 3.80 (s, 3H), 4.61 (q, J = 
7.1 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 7.64 (d, J = 8.6 Hz, 1H), 8.24 (d, J = 9.0 Hz, 2H), 
8.30 (s, 1H), 8.39 (d, J = 8.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 14.4, 21.3, 55.9, 
63.1, 114.6 (2C), 114.8, 118.9, 123.2, 128.6, 131.2 (2C), 134.9, 135.9, 138.7, 145.0, 146.8, 
152.4, 162.8, 165.1; HRMS (ESI) m/z 449.0880 ([M + Na]+, 100%), calc’d for 
C20H18N4O5SNa 449.0896. 
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Ethyl 8-Methoxy-5-[(4-methoxybenzene)sulfonyl]-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_44g). 
Prepared according to General Procedures A and B, beginning 
with ethyl oxalamidrazonate (II_47, 296 mg, 2.26 mmol, 1.0 
eq), 5-methoxyisatin (400 mg, 2.26 mmol, 1.0 eq) and 4-
methoxybenzenesulfonyl chloride (934 mg, 4.52 mmol, 2.0 eq). Purification by flash 
chromatography (DCM:EtOAc, 10:1, Rf 0.65) gave II_44g (835 mg, 1.89 mmol, 84% 
yield) as a yellow solid: mp 163-165 °C; IR (neat) 2893, 1742, 1593, 1495, 1191, 1170, 
579, 554 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.53 (t, J = 7.2 Hz, 3H), 3.80 (s, 3H), 3.94 
(s, 3H), 4.60 (q, J = 7.2 Hz, 2H), 6.92 (d, J = 9.0 Hz, 2H), 7.39 (dd, J = 9.2, 2.8 Hz, 1H), 
7.90 (d, J = 2.8 Hz, 1H), 8.22 (d, J = 9.0 Hz, 2H), 8.40 (d, J = 9.2 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 14.3, 55.8, 56.0, 63.0, 104.6, 114.5 (2C), 116.1, 119.6, 122.7, 128.4, 131.0 
(2C), 134.7, 144.8, 146.6, 152.3, 157.7, 162.7, 164.9; HRMS (ESI) m/z 465.0848 ([M + 
Na]+, 100%), calc’d for C20H18N4O6SNa 465.0845. 
 
 
Ethyl 8-Fluoro-5-[(4-methoxybenzene)sulfonyl]-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate II_44h. Prepared 
according to General Procedures A and B, beginning with ethyl 
oxalamidrazonate (II_47, 278 mg, 2.12 mmol, 1.0 eq), 5-
fluoroisatin (350 mg, 2.12 mmol, 1.0 eq) and 4-
methoxybenzenesulfonyl chloride (876 mg, 4.24 mmol, 2.0 eq). Purification by flash 
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chromatography (hexanes:EtOAc, 1:1, Rf 0.72) gave II_44h (795 mg, 1.85 mmol, 88% 
yield) as a yellow solid: mp 165-167 °C; IR (neat) 2984, 1743, 1593, 1489, 1267, 1193, 
1170, 1155, 579 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.52 (t, J = 7.2 Hz, 3H), 3.79 (s, 3H), 
4.59 (q, J = 7.2 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 7.53 (ddd, JHF = 9.1 Hz, J = 8.8, 2.4 Hz, 
1H), 8.10 (dd, JHF = 7.2 Hz, J = 2.4 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.48 (dd, J = 9.1 Hz, 
JHF = 4.2 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 14.4, 55.9, 63.1, 109.3 (d, 2JCF = 24.4 
Hz), 114.7 (2C), 116.7 (d, 3JCF = 8.4 Hz), 120.1 (d, 
3JCF = 9.9 Hz), 121.3 (d, 
2JCF = 24.4 
Hz), 128.3, 131.2 (2C), 136.6 (d, 4JCF = 1.5 Hz), 144.5 (d, 
4JCF = 3.8 Hz), 147.0, 152.7, 
160.3 (d, 1JCF = 245.4 Hz), 162.5, 165.2; HRMS (ESI) m/z 453.0642 ([M + Na]
+, 100%), 
calc’d for C19H15FN4O5SNa 453.0645. 
 
 
Ethyl 5-(Benzenesulfonyl)-5H-[1,2,4]triazino[5,6-b]indole-3-
carboxylate (II_44i). Prepared according to General Procedures A 
and B, beginning with ethyl oxalamidrazonate (II_47, 302 mg, 2.31 
mmol, 1.0 eq), isatin (340 mg, 2.31 mmol, 1.0 eq) and 
benzenesulfonyl chloride (816 mg, 4.62 mmol, 2.0 eq).  Purification 
by flash chromatography (hexanes:EtOAc, 1:1, Rf 0.68) gave II_44i (795 mg, 2.08 mmol, 
90% yield) as a yellow solid: mp 192-193 °C; IR (neat) 2985, 1742, 1449, 1379, 1190, 727, 
588 cm-1; 1H NMR (400 MHz, CDCl₃) δ 1.53 (t, J = 7.1 Hz, 3H), 4.60 (q, J = 7.1 Hz, 2H), 
7.51 (dd, J = 8.2, 7.8 Hz, 2H), 7.59 (dd, J = 7.8, 7.4 Hz, 1H), 7.63 (tt, J = 8.2, 1.2 Hz, 1H), 
7.84 (ddd, J = 8.6, 7.4, 1.0 Hz, 1H), 8.32 (dd, J = 8.2, 1.2 Hz, 2H), 8.48 (dd, J = 7.8, 1.0 
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Hz, 2H), 8.52 (d, J = 8.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 14.4, 63.1, 115.1, 118.9, 
123.5, 125.9, 128.7 (2C), 129.5 (2C), 133.7, 135.4, 137.4, 140.5, 145.1, 146.8, 152.6, 
162.6; HRMS (ESI) m/z 405.0634 ([M + Na]+, 100%), calc’d for C18H14N4O4SNa 
405.0633. 
 
 
Ethyl 5-(Benzenesulfonyl)-8-methyl-5H-[1,2,4]triazino[5,6-
b]indole-3-carboxylate (II_44j). Prepared according to General 
Procedures A and B, beginning with ethyl oxalamidrazonate 
(II_47, 243 mg, 1.86 mmol, 1.0 eq), 5-methylisatin (300 mg, 1.86 
mmol, 1.0 eq) and benzenesulfonyl chloride (658 mg, 3.72 mmol, 
2.0 eq). Purification by flash chromatography (DCM:EtOAc, 10:1, Rf 0.74) gave II_44j 
(645 mg, 1.63 mmol, 88% yield) as a yellow solid: mp 171-173 °C; IR (neat) 2985, 1743, 
1193, 729, 591 cm-1; 1HNMR (400 MHz, CDCl3) δ 1.53 (t, J = 7.1 Hz, 3H), 2.55 (s, 3H), 
4.60 (q, J = 7.1 Hz, 2H), 7.50 (dd, J = 8.0, 7.6 Hz, 2H), 7.60-7.65 (overlap, 2H), 8.29-8.31 
(overlap, 3H), 8.39 (d, J = 8.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 14.3, 21.2, 63.0, 
114.7, 118.9, 123.1, 128.5 (2C), 129.4 (2C), 134.8, 135.2, 136.0, 137.3, 138.5, 144.9, 
146.8, 152.4, 162.6; HRMS (ESI) m/z 419.0777 ([M + Na]+, 100%), calc’d for 
C19H16N4O4SNa 419.0790. 
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Ethyl 5-(Benzenesulfonyl)-8-methoxy-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_44k). 
Prepared according to General Procedures A and B, beginning 
with ethyl oxalamidrazonate (II_47, 296 mg, 2.26 mmol, 1.0 
eq), 5-methoxyisatin (400 mg, 2.26 mmol, 1.0 eq) and 
benzenesulfonyl chloride (798 mg, 4.52 mmol, 2.0 eq). Purification by flash 
chromatography (DCM:EtOAc, 10:1, Rf 0.65) gave II_44k (805 mg, 1.95 mmol, 87% 
yield) as a yellow solid: mp 154-155 °C; IR (neat) 2982, 1740, 1492, 1187, 1161, 727, 585  
563 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.53 (t, J = 7.1 Hz, 3H), 3.93 (s, 3H), 4.60 (q, J = 
7.1 Hz, 2H), 7.39 (dd, J = 9.2, 2.6 Hz, 1H), 7.49 (dd, J = 7.8, 7.2 Hz, 2H), 7.61 (t, J = 7.2 
Hz 1H), 7.89 (d, J = 2.6 Hz, 1H), 8.28 (d, J = 7.8 Hz, 2H), 8.40 (d, J = 9.2 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 14.4, 56.2, 63.1, 104.8, 116.2, 119.9, 123.0, 128.6 (2C), 129.5 
(2C), 134.8, 135.3, 137.4, 145.0. 146.9, 152.5, 158.0, 162.7; HRMS (ESI) m/z 435.0727 
([M + Na]+, 100%), calc’d for C19H16N4O5SNa 435.0739. 
 
 
Ethyl 5-(Benzenesulfonyl)-8-fluoro-5H-[1,2,4]triazino[5,6-
b]indole-3-carboxylate (II_44l). Prepared according to General 
Procedures A and B, beginning with ethyl oxalamidrazonate 
(II_47, 262 mg, 2.00 mmol, 1.0 eq), 5-fluoroisatin (330 mg, 2.00 
mmol, 1.0 eq) and benzenesulfonyl chloride (706 mg, 4.00 mmol, 
2.0 eq). Purification by flash chromatography (hexanes:EtOAc, 1:1, Rf 0.76, 725 mg) gave 
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II_44l (1.81 mmol, 91% yield) as a yellow solid: mp 190-192 °C; IR (neat) 2985, 1743, 
1489, 1450, 1191, 1155, 585 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.53 (t, J = 7.1 Hz, 3H), 
4.60 (q, J = 7.1 Hz, 2H), 7.52 (dd, J = 8.0, 7.9 Hz, 2H), 7.57 (dd, J = 9.2, 2.8 Hz, 1H), 7.64 
(t, J = 7.9 Hz, 1H), 8.15 (dd, JHF = 7.6, J = 2.8 Hz, 1H), 8.31 (d, J = 8.0 Hz, 2H), 8.52 (dd, 
J = 9.2, JHF = 4.4 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 14.4, 63.3, 109.5 (d, 2JCF = 24.4 
Hz), 116.7 (d, 3JCF = 8.4 Hz), 120.3 (d, 
3JCF = 9.1 Hz), 121.5 (d, 
2JCF = 25.2 Hz), 128.7 
(2C), 129.6 (2C), 135.6, 136.5 (d, 4JCF = 1.5 Hz), 137.2, 144.7 (d, 
4JCF = 3.9 Hz), 147.2, 
152.8, 160.5 (d, 1JCF = 246.1 Hz), 162.5; HRMS (ESI) m/z 423.0534 ([M + Na]
+, 100%), 
calc’d for C18H13FN4O4SNa 423.0539. 
 
 
Ethyl 5-(methoxymethyl)-5H-[1,2,3]triazino[5,4-b]indole-4-
carboxylate. Prepared according to General Procedures A and B, 
beginning with ethyl 5H-[1,2,3]triazino[5,4-b]indole-4-
carboxylate (200 mg, 1.0 eq, 0.83 mmol), and chloro(methoxy)methane (133 mg, 2.0 eq, 
1.65 mmol). Purification by flash chromatography (DCM:EtOAc, 2:1, Rf = 0.56, 198 mg) 
gave desired product (0.70 mmol, 84% yield) as a white solid: mp, 157-158 oC; IR (neat) 
2991, 1736, 1726, 1430, 1299, 1195, 1074, 912, 735 cm-1; 1H NMR (400 MHz, CDCl3) δ 
1.51 (t, J =  7.0 Hz, 3H), 3.34 (s, 3H), 7.56 (d, J = 7.6 Hz, 1H), 7.73-7.80 (overlap, 2H), 
8.59 (d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 14.4, 57.1, 63.2, 72.9, 111.9, 
118.0, 123.7, 124.2, 132.8, 142.2, 144.5, 147.1, 152.3, 163.7; HRMS (ESI) not obtained.  
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N-(Furan-2-ylmethyl)prop-2-yn-1-amine (II_48d). To a solution of 
2-furfurylamine (1.0 g, 10.3 mmol, 1.2 eq) and triethylamine (1.04 g, 
10.30 mmol, 1.2 eq) in THF (12 ml, 0.80 M) at 0 was added propargyl 
bromide (1.28 g, 8.58 mmol, 1.0 eq, 80% wt. in toluene) dropwise over 30 minutes. The 
reaction was allowed to warm to room temperature and stirred for 4 hours. The mixture 
was then filtered to remove the salt, then the solvent was then removed in vacuo. The crude 
residue was purified via flash chromatography to give N-(furan-2-ylmethyl)prop-2-yn-1-
amine (DCM:EtOAc, 5:1, Rf  0.38, 0.82 g, 71% yield) as a yellow oil: IR (neat) 3293, 2921, 
2836, 1148, 1102, 1010, 736 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.53 (br s, NH2), 2.21 (t, 
J = 2.4 Hz, 1H), 3.39 (d, J = 2.4 Hz, 2H), 3.84 (s, 2H), 6.18 (dd, J = 3.2, 0.8 Hz, 1H), 6.27 
(dd, J = 3.2, 1.6 Hz, 1H), 7.33 (dd, J = 1.6, 0.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
37.2, 44.7, 71.8, 81.7, 107.6, 110.2, 142.1, 153.0; HRMS was not obtained.   
 
 N-(4-(Trifluoromethyl)benzyl)prop-2-yn-1-amine (II_48n). 
Prepared according to General Procedure F, starting with 
propargylamine (200 mg, 3.63 mmol, 1.0 eq) and 4-
(trifluoromethyl)benzaldehyde (1.26 g, 7.26 mmol, 2.0 eq), and NaCNBH3 (4.0 eq). The 
crude residue was purified via flash chromatography to give  II_48n (hexanes:EtOAc, 2:1, 
Rf  0.33, 0.77 g, 87% yield) as a yellow oil: IR (neat) 3307, 2921, 1620, 1328, 1124 1076, 
650 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.26 (t, J = 2.4 Hz, 1H), 3.41 (d, J = 2.4 Hz, 2H), 
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3.93 (s, 2H), 7.46 (d, J = 10.4 Hz, 2H), 7.57 (d, J = 10.4 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ 37.5, 51.7, 72.0, 81.8, 123.0, 125.5 (q, JCF = 3.8 Hz), 128.7 (4C), 143.7; HRMS 
(ESI) m/z 214.0825 ([M + H]+, 100%), calc’d for C11H10F3N 214.0844. 
 
 
N-(3-Fluorobenzyl)prop-2-yn-1-amine (II_48o). Prepared 
according to General Procedure F, starting with propargylamine 
(300 mg, 5.45 mmol, 1.0 eq) and 3-fluorobenzaldehyde (1.35 g, 10.89 mmol, 2.0 eq), and 
NaCNBH3 (4.0 eq). The crude residue was purified via flash chromatography to give  
II_48o (hexanes:EtOAc, 2:1, Rf  0.32, 0.77 g, 86% yield) as a yellow oil: IR (neat) 3301, 
2918, 1615, 1590, 1256, 1139, 785, 656 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.25 (t, J = 
2.4 Hz, 1H), 3.41 (d, J = 2.4 Hz, 2H), 3.87 (s, 2H), 6.93 (ddd, J = 8.8, 8.8, 2.4 Hz, 1H), 
7.05-7.11 (overlap, 2H), 7.24-7.29 (overlap, 2H); 13C NMR (100 MHz, CDCl3) δ 37.4, 
51.7, 71.8, 82.0, 114.1, 115.2, 124.0, 130.0, 142.2, 163.1 (d, JCF = 244.6 Hz); HRMS (ESI) 
m/z 164.0884 ([M + H]+, 100%), calc’d for C10H10FN 164.0876. 
 
 
N,N-Dimethyl-4-((prop-2-yn-1-ylamino)methyl)aniline 
(II_48p). Prepared according to General Procedure F, starting 
with propargylamine (250 mg, 4.54 mmol, 1.0 eq) and 4-(dimethylamino)benzaldehyde 
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(1.35 g, 9.08 mmol, 2.0 eq), and NaCNBH3 (4.0 eq). The crude residue was purified via 
flash chromatography to give  II_48p (hexanes:EtOAc, 2:1, Rf  0.28, 0.80 g, 94% yield) as 
a pale yellow oil: IR (neat) 3288, 2884, 2842, 2803, 1615, 1523, 1348, 804, 647 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 2.24 (t, J = 2.4 Hz, 1H), 2.92 (s, 6H), 3.39 (d, J = 2.4 Hz, 2H), 
3.77 (s, 2H), 6.70 (dd, J = 6.8, 2.0 Hz, 2H), 7.20 (dd, J = 6.8, 2.0 Hz, 2H) ; 13C NMR (100 
MHz, CDCl3) δ 37.2, 40.8 (2C), 51.8, 71.4, 82.4, 112.8 (2C), 127.3, 129.5 (2C), 150.0; 
HRMS (ESI) m/z 189.1392 ([M + H]+, 100%), calc’d for C12H16N2 189.1392. 
 
 
N-(2-Methoxybenzyl)prop-2-yn-1-amine (II_48q). Prepared 
according to General Procedure F, starting with propargylamine 
(300 mg, 5.45 mmol, 1.0 eq) and 2-methoxybenzaldehyde (1.48 g, 
10.89 mmol, 2.0 eq), and NaCNBH3 (4.0 eq). The crude residue was purified via flash 
chromatography to give  II_48q (hexanes:EtOAc, 2:1, Rf  0.25, 0.76 g, 80% yield) as a 
colorless oil: IR (neat) 3291, 2937, 2836, 1602, 1493, 1242, 1029, 755 cm-1; 1H NMR (400 
MHz, CDCl3) δ 2.25 (t, J = 2.4 Hz, 1H), 3.42 (d, J = 2.4 Hz, 2H), 3.85 (s, 3H), 3.88 (s, 
2H),  6.88 (d, J = 8.4 Hz, 1H), 6.93 (dd, J = 7.6, 7.6 Hz, 1H), 7.27 (d, J = 7.6 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 37.6, 48.1, 55.4, 71.4, 82.4, 110.4, 120.5, 127.6, 128.5, 130.2, 
157.8; HRMS (ESI) m/z 176.1083 ([M + H]+, 100%), calc’d for C11H13NO 176.1075. 
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N-(4-Methylbenzyl)prop-2-yn-1-amine (II_48r). Prepared 
according to General Procedure F, starting with propargylamine 
(250 mg, 4.54 mmol, 1.0 eq) and 2-methoxybenzaldehyde (1.09 g, 9.08 mmol, 2.0 eq), and 
NaCNBH3 (4.0 eq). The crude residue was purified via flash chromatography to give  
II_48r (hexanes:EtOAc, 2:1, Rf  0.30, 0.64 g, 88% yield) as a pale yellow oil: IR (neat) 
3292, 2921, 2841, 1515, 1451, 1102, 804, 642 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.24 (t, 
J = 2.4 Hz, 1H), 2.32 (s, 3H), 3.40 (d, J = 2.4 Hz, 2H), 3.83 (s, 2H),  7.12 (d, J = 8.0 Hz, 
2H), 7.22 (d, J = 8.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 21.2, 37.4, 52.1, 71.6, 82.3, 
128.5, 129.3, 136.5, 136.9; HRMS (ESI) m/z 160.1132 ([M + H]+, 100%), calc’d for 
C11H13N 160.1126. 
 
N-Methyl-5-[(4-methylbenzene)sulfonyl]-N-(prop-2-yn-1-
yl)-5H-[1,2,4]triazino[5,6-b]indole-3-carboxamide (II_49a). 
Prepared according to General Procedure C, starting with 
II_44a (80 mg, 0.20 mmol, 1.0 eq) and N-methyl-
propargylamine (16.7 mg, 0.24 mmol, 1.2 eq). Purification by flash chromatography 
(DCM:EtOAc, 10:1, Rf 0.54) gave II_49a (79 mg, 0.19 mmol, 93% yield) as brown orange 
oil: IR (neat) 2933, 1655, 1370, 1192, 1178, 732, 666 cm-1; 1H NMR (400 MHz, CDCl3) δ 
2.31 (t, J = 2.4 Hz, 0.37H, minor rotamer), 2.35 (s, 3H), 2.35 (overlap t, J = 2.4 Hz, 0.63H, 
major rotamer), 3.12 (s, 1.89H, major rotamer), 3.31 (s, 1.11H, minor rotamer), 4.22 (d, J 
= 2.4 Hz, 0.74H, minor rotamer), 4.52 (d, J = 2.4 Hz, 1.26H, major rotamer), 7.29 (d, J = 
8.6, 2H), 7.57 (dd, J = 8.0, 8.0 Hz, 1H), 7.81 (dd, J = 8.3, 8.0 Hz, 1H), 8.10 (d, J = 8.6 Hz, 
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1.26H, major rotamer)  8.12 (d, J = 8.6 Hz, 0.74H, minor rotamer), 8.44 (d, J = 8.0 Hz, 
1H), 8.49 (d, J = 8.3 Hz, 1H); 13C NMR (75 MHz, CDCl3, assumed rotamer pairs in 
parentheses) δ 21.9, (33.2, 36.0), (36.6, 40.9), (73.1, 73.9), (77.4, 77.9), 115.0, 119.1, 
123.0, 125.8, 128.3 (2C), 130.3 (2C), 133.3, 134.4, 139.9, 144.3, 146.8, 147.0, (156.6, 
156.8), 164.6; HRMS (ESI) m/z 442.0935 ([M + Na]+, 100%), calc’d for C21H17N5O3SNa 
442.0950. 
5-[(4-Methylbenzene)sulfonyl]-N-(prop-2-yn-1-yl)-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxamide (II_49b). 
Prepared according to General Procedure C, beginning with 
II_44a (80 mg, 0.2 mmol, 1.0 eq) and propargylamine (14 mg, 
97% weight, 0.24 mmol, 1.2 eq). Purification by flash chromatography (DCM:EtOAc, 
10:1, Rf 0.43) gave II_49b (73 mg, 0.18 mmol, 90% yield) as a white yellow solid: mp 
244-245 °C; IR (neat) 3296, 2928, 1675, 1380, 1176 cm-1; ¹H NMR (400 MHz, CDCl3) δ 
2.33 (t, J = 2.4 Hz, 1H), 2.36 (s, 3H), 4.39 (dd, J = 5.3, 2.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 
2H), 7.60 (ddd, J = 7.8, 7.7, 0.8 Hz, 1H), 7.84 (ddd, J = 8.3, 7.7, 1.2 Hz, 1H), 8.19 (d, J = 
8.4 Hz, 2H), 8.25 (br t, J = 5.3 Hz, NH), 8.49 (dd, J = 7.8, 1.2 Hz, 1H), 8.53 (dd, J = 8.3, 
0.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 21.9, 29.9, 72.3, 79.0, 115.2, 118.9, 123.3, 
125.9, 128.7 (2C), 130.3 (2C), 133.7, 134.5, 140.6, 145.0, 147.0, 147.2, 152.7, 160.8; 
HRMS (ESI) m/z 428.0778 ([M + Na]+, 45%), calc’d for C20H15N5O3SNa 428.0793. 
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5-[(4-Methylbenzene)sulfonyl]-N-(2-methylbut-3-yn-2-yl)-
5H-[1,2,4]triazino[5,6-b]indole-3-carboxamide (II_49c). 
Prepared according to General Procedure C, beginning with 
II_44a (80 mg, 0.2 mmol, 1.0 eq) and 2-methyl-3-butyn-2-amine (22 mg, 95% weight, 
0.24 mmol, 1.2 eq). Purification by flash chromatography (DCM:EtOAc, 10:1, Rf 0.35) 
gave II_49c (77 mg, 0.18 mmol, 89% yield) as yellow oil: IR (neat) 3387, 3293, 2981, 
1700, 1513, 1376, 1193, 1179, 1087, 672 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.84 (s, 6H), 
2.35 (s, 3H), 2.44 (s, 1H), 7.31 (d, J = 8.2 Hz, 2H), 7.58 (ddd, J = 8.0, 7.6, 0.8 Hz, 1H), 
7.83 (ddd, J = 8.8, 7.6, 1.6 Hz, 1H), 8.22 (d, J = 8.2 Hz, 2H), 8.30 (br s, NH), 8.46 (br d, J 
= 8.0 Hz, 1H), 8.52 (d, J = 8.8 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 21.8, 28.9 (2C), 
48.1, 69.8, 86.6, 115.1, 118.7, 123.1, 125.6, 128.6 (2C), 130.1 (2C), 133.4, 134.4, 140.3, 
144.6, 146.8, 147.3, 153.1, 159.5; HRMS (ESI) m/z 456.1095 ([M + Na]+, 38%), calc’d 
for C22H19N5O3SNa 456.1106. 
 
 
N-(Furan-2-ylmethyl)-5-[(4-methylbenzene)sulfonyl]-N-
(prop-2-yn-1-yl)-5H-[1,2,4]triazino[5,6-b]indole-3-
carboxamide (II_49d). Prepared according to General 
Procedure C, starting with II_44a (80 mg, 0.20 mmol, 1.0 eq) 
and (furan-2-ylmethyl)(prop-2-yn-1-yl)amine (41 mg, 0.30 mmol, 1.5 eq). Purification by 
flash chromatography (DCM:EtOAc, 10:1, Rf 0.67) gave II_49d (94 mg, 0.19 mmol, 96% 
yield) as brown orange oil: IR (neat) 2952, 2833, 1661, 1450, 1373, 1179, 1035, 665 cm-1; 
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1H NMR (400 MHz, CDCl3) δ 2.25 (t, J = 2.4 Hz, 0.42H, minor rotamer), 2.34 (s, 3H) 2.35 
(overlap t, J = 2.4 Hz, 0.58H, major isomer), 4.21 (d, J = 2.4 Hz, 0.84H, minor rotamer), 
4.48 (d, J = 2.4 Hz, 1.16H, major rotamer), 4.73 (s, 1.16H, major rotamer), 5.00 (s, 0.84H, 
minor rotamer), 6.27 (dd, J = 2.8, 1.2 Hz, 0.58H, major rotamer), 6.32 (d, J = 2.8 Hz, 
0.58H, major rotamer), 6.39 (dd, J = 2.8, 1.2 Hz, 0.42H, minor rotamer), 6.48 (d, J = 2.8 
Hz, 0.42H, minor rotamer), 7.27 (d, J = 8.2 Hz, 1.16H, major rotamer), 7.28 (d, J = 8.2 Hz, 
0.84H, minor rotamer) 7.32 (d, J = 1.2 Hz, 0.58H, major rotamer), 7.45 (d, J = 1.2 Hz, 
0.42H, minor rotamer), 7.58 (dd, J = 7.9, 7.8 Hz, 1H), 7.81 (dd, J = 8.3, 7.9 Hz, 1H), 8.11 
(d, J = 8.2 Hz, 1.16H, major rotamer), 8.13 (d, J = 8.2 Hz, 0.84H, minor rotamer), 8.46 (d, 
J = 7.8 Hz, 1H), 8.50 (d, J = 8.3 Hz, 1H); 13C NMR (125 MHz, CDCl3, assumed rotamer 
pairs in parentheses) δ 21.9, (34.3, 38.3), (41.2, 44.6), (73.1, 73.8), (77.6, 77.8), (109.7, 
109.9), 110.7, 115.1, 119.1, 123.1, 125.9, 128.4 (2C), 130.3 (2C), 133.3, 134.4, 140.0, 
143.0, 144.3, 146.7, 146.9, (148.8, 149.4), (156.3, 156.6), (164.3, 164.5); HRMS (ESI) m/z 
508.1034 ([M + Na]+, 100%), calc’d for C25H19N5O4SNa 508.1055. 
 
 
N-(2-Methoxyethyl)-5-[(4-methylbenzene)sulfonyl]-N-
(prop-2-yn-1-yl)-5H-[1,2,4]triazino[5,6-b]indole-3-
carboxamide (II_49e). Prepared according to General 
Procedure C, beginning with II_44a (80 mg, 0.20 mmol, 1.0 
eq) and (2-methoxyethyl)(prop-2-yn-1-yl)amine [362] (35 mg, 0.30 mmol, 1.5 eq). 
Purification by flash chromatography (DCM:EtOAc, 20:1, Rf = 0.32) gave II_49e (89 mg, 
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0.19 mmol, 96% yield) as brown orange oil: IR (neat) 2946, 2834, 1652, 1372, 1191, 1178, 
1034, 666 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.22 (t, J = 2.4 Hz, 0.37H, minor rotamer), 
2.33 (s, 3H), 2.34 (overlap t, J = 2.4 Hz, 0.63H, major rotamer), 3.27 (s, 1.89H, major 
rotamer), 3.42 (s, 1.11H, minor rotamer), 3.65-3.67 (overlap, 2.52H), 3.78 (t, J = 5.2 Hz, 
0.74H, minor rotamer), 3.96 (t, J = 5.2 Hz, 0.74H, minor rotamer), 4.35 (d, J = 2.4 Hz, 
0.74H, minor rotamer), 4.60 (d, J = 2.4 Hz, 1.26H, major rotamer), 7.277 (overlap d, J = 
8.4 Hz, 0.74H, minor rotamer), 7.281 (overlap d, J = 8.4 Hz, 1.36H, major rotamer), 7.56 
(dd, J = 7.4, 7.4 Hz, 1H), 7.78 (ddd, J = 8.4, 7.4, 1.2 Hz 1H), 8.10 (d, J = 8.4 Hz, 1.26H, 
major rotamer), 8.12 (d, J = 8.4 Hz, 0.74H, minor rotamer), 8.43 (br d, J = 7.4 Hz, 0.63H, 
major rotamer), 8.44 (br d, J = 7.4 Hz, 0.37H, minor rotamer), 8.47 (d, J = 8.4 Hz, 0.63H, 
major rotamer), 8.49 (d, J = 8.4 Hz, minor rotamer); 13C NMR (75 MHz, CDCl3, assumed 
rotamer pairs in parentheses) δ 21.8, (35.9, 40.4), (45.7, 47.9), 59.2, (71.1, 71.3), (72.8, 
73.4), (78.3, 78.5), 115.0, 119.1, 123.0, 125.8, 128.3 (2C), 130.3 (2C), 133.2, 134.4, 139.9, 
144.2, 146.7, 146.9, (156.7, 157.0), (164.6, 165.1); HRMS (ESI) m/z 486.1205 ([M + Na]+, 
100%), calc’d for C23H21N5O4SNa 486.1212. 
 
 
N-Benzyl-N-(but-2-yn-1-yl)-5-[(4-
methylbenzene)sulfonyl]-5H-[1,2,4]triazino[5,6-b]indole-
3-carboxamide (II_49f). Prepared according to General 
Procedure C, beginning with II_44a (80 mg, 0.20 mmol, 1.0 
eq) and N-benzylbut-2-yn-1-amine [363] (49 mg, 0.30 mmol, 
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1.5 eq). Purification by flash chromatography (hexanes:EtOAc, 3:1, Rf = 0.19) gave II_49f 
(98 mg, 0.19 mmol, 95% yield) as brown orange oil: IR (neat) 3031, 2920, 1656, 1372, 
1191, 1179, 730 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.74 (br s, 1.23H, minor rotamer), 
1.88 (br s, 1.77H, major rotamer), 2.33 (s, 3H), 3.98 (s, 0.82H, minor rotamer), 4.32 (s, 
1.18H, major rotamer), 4.60 (s, 1.18H, major rotamer), 5.01 (s, 0.82H, minor rotamer), 
7.20 - 7.28 (overlap, 2H), 7.30 – 7.38 (overlap, 2H), 7.38 – 7.44 (overlap, major and minor 
rotamer, 1H), 7.45 - 7.50 (overlap, 2H), 7.56 – 7.62 (overlap, major and minor rotamer, 
1H), 7.79 (br dd, J = 7.2, 7.2 Hz, 0.59H, major rotamer), 7.81 (br dd, J = 7.2, 7.2 Hz, 0.41H, 
minor rotamer), 8.08 (d, J = 7.2 Hz, 1.18H, major rotamer), 8.12 (d, J = 7.2 Hz, 0.82H, 
minor rotamer), 8.40 – 8.52 (overlap, 2H); 13C NMR (100 MHz, CDCl3, assumed rotamer 
pairs in parentheses) δ (3.7, 3.8), 21.9, (33.9, 38.4), (48.0, 51.4), (72.9, 73.0), (80.9, 81.9), 
(115.06, 115.10), (119.19, 119.21), (123.0, 123.1), (125.79, 125.81), 127.9, (128.21, 
128.23, 2C), (128.4, 128.6, 2C), (128.88, 128.90, 2C), (130.2, 130.3, 2C), (133.19, 133.21), 
(134.48, 134.51), (135.4, 136.2), (139.9, 140.0), 144.2, (146.7, 146.8), 146.9, (157.0, 
157.4), (164.8, 164.9);  HRMS (ESI) m/z 510.1581 ([M + H]+, 100%), calc’d for 
C28H23N5O3S 510.1600. 
 
 
N-Benzyl-N-(but-3-yn-1-yl)-5-[(4-
methylbenzene)sulfonyl]-5H-[1,2,4]triazino[5,6-b]indole-
3-carboxamide (II_49g). Prepared according to General 
Procedure C, beginning with II_44a (80 mg, 0.2 mmol, 1.0 
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eq) and benzyl(but-3-yn-1-yl)amine [364] (48 mg, 0.3 mmol, 1.5 eq). Purification by flash 
chromatography (DCM:EtOAc, 20:1, Rf 0.38) gave II_49g (96 mg, 0.19 mmol, 93% yield) 
as a brown orange oil: IR (neat) 2947, 2833, 1655, 1450, 1373, 1191, 1179, 1036, 667 cm-
1; 1H NMR (400 MHz, CDCl3) δ 1.97 (t, J = 2.7 Hz, 0.48H, minor rotamer), 2.07 (t, J = 2.7 
Hz, 0.52H, major rotamer), 2.33 (s, 3H), 2.51 (td, J = 3.2, 2.7 Hz, 0.96H, minor rotamer), 
2.64 (td, J = 3.2, 2.7 Hz, 1.04H, major rotamer), 3.41 (t, J = 3.2 Hz, 0.96H, minor rotamer), 
3.70 (t, J = 3.2 Hz, 1.04H, major rotamer), 4.61 (s, 1.04H, major rotamer), 4.97 (s, 0.96H, 
minor rotamer), 7.21-7.30 (overlap, 2H), 7.34 (m, 2H), 7.38-7.48 (overlap, 3H), 7.55 (br 
dd, J = 8.2, 7.8 Hz, 0.52H, major rotamer), 7.57 (br dd, J = 8.2, 7.8 Hz, 0.48H, minor 
rotamer), 7.78 (ddd, J = 8.2, 7.8, 1.2 Hz, 0.48H, minor rotamer), 7.81 (ddd, J = 8.2, 7.8, 
1.8 Hz, 0.52H, major rotamer), 8.06 (d, J = 8.4 Hz, 1.04H, major rotamer), 8.10 (d, J = 8.4 
Hz, 0.96H, minor rotamer), 8.41 (br d, J = 8.2 Hz, 0.52H, major rotamer), 8.44 (br d, J = 
8.2 Hz, 0.48H, minor rotamer), 8.46 (d, J = 8.2 Hz, 0.48H, minor rotamer), 8.50 (d, J = 8.2 
Hz, 0.52H, major rotamer); 13C NMR (75 MHz, CDCl3, assumed rotamer pairs in 
parenthesis) δ (17.4, 18.8), 21.8, (44.2, 46.9), (48.6, 53.5), (70.2, 71.2), (80.6, 81.6), (115.0, 
115.1), 119.1, (122.96, 123.01), 125.8, 127.9, (128.18, 128.20, 2C), (128.26, 128.30, 2C), 
129.0 (2C), 130.3 (2C), (133.17, 133.23), (134.45, 134.47) (135.7, 136.4), (139.82, 
139.94), (144.12, 144.22), 146.6, (146.85, 146.92), (157.27, 157.41), (165.4, 165.7); 
HRMS (ESI) m/z 532.1429 ([M + Na]+, 100%), calc’d for C28H23N5O3SNa 532.1419. 
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N-(Cyanomethyl)-N-methyl-5-[(4-methylbenzene)sulfonyl]-
5H-[1,2,4]triazino[5,6-b]indole-3-carboxamide (II_49h). 
Prepared according to General Procedure C, starting with 
II_44a (80 mg, 0.20 mmol, 1.0 eq) and methylaminoacetonitrile 
hydrochloride (25.8 mg, 0.24 mmol, 1.2 eq). Purification by flash chromatography 
(DCM:EtOAc, 10:1, Rf = 0.41) gave II_49h (80 mg, 0.19 mmol, 95% yield) as brown 
orange oil: IR (neat) 2924, 2251, 1666, 1374, 1193, 1179, 737, 667 cm-1; 1H NMR (300 
MHz, CDCl3) δ 2.34 (s, 2.25H, minor rotamer), 2.35 (s, 2.25, major rotamer), 3.23 (s, 
2.25H, major rotamer), 3.37 (s, 0.75H, minor rotamer), 4.58 (s, 0.5H, minor rotamer), 4.65 
(s, 1.5H, major rotamer), 7.29 (d, J = 8.4 Hz, 2H), 7.575 (dd, J = 7.8, 7.5 Hz, 0.25H, minor 
rotamer), 7.583 (dd, J = 7.8, 7.5 Hz, 0.75H, major rotamer), 7.82 (dd, J = 8.1, 7.8 Hz, 1H), 
8.09 (d, J = 8.4 Hz, 1.5H, major rotamer), 8.11 (d, J = 8.4 Hz, 0.5H, minor rotamer), 8.41 
(br d, J = 7.5 Hz, 0.25H, minor rotamer), 8.44 (br d, J = 7.5 Hz, 0.75H, major rotamer), 
8.48 (d, J = 8.1 Hz, 1H); 13C NMR (75 MHz, CDCl3, assumed rotamer pairs in parentheses) 
δ 21.9, (34.4, 35.6), (37.1, 40.0), 114.7, 115.1, 118.8, 123.1, 126.0, 128.3 (2C), 130.4 (2C), 
133.6, 134.2, 140.1, 144.5, 146.6, 147.1, (155.2, 155.6), (164.0, 164.9); HRMS (ESI) m/z 
443.0902 ([M + Na]+, 100%), calc’d for C20H16N6O3SNa 443.0902. 
 
13-Methyl-8-[(4-methylbenzene)sulfonyl]8,10,13-
triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),3,5,9,11(15)-
hexaen-12-one (II_50a). Prepared according to General Procedure 
D, starting with II_49a (30 mg, 0.071 mmol). Purification by flash 
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chromatography (DCM:EtOAc, 2:1, Rf = 0.17) gave II_50a (27 mg, 0.069 mmol, 96% 
yield) as a white yellow solid: mp 271-272 °C; IR (neat) 3057, 2987, 1739, 1692, 1375, 
1175, 667 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.28 (s, 3H), 3.26 (s, 3H), 4.40 (s, 2H), 7.20 
(d, J = 8.4 Hz, 2H), 7.32 (dd, J = 8.0, 7.8 Hz, 1H), 7.51 (dd, J = 7.8, 7.8 Hz, 1H),  7.86 (d, 
J = 7.8 Hz, 1H), 8.13 (s, 1H), 8.20 (d, J = 8.4 Hz, 2H), 8.42 (d, J = 8.0 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 21.8, 30.4, 49.7, 115.0, 120.3, 121.1, 121.7, 122.8, 123.9, 128.6 (2C), 
129.3, 129.6 (2C), 130.6, 135.5, 138.8, 145.4, 147.7, 151.3, 166.3; HRMS (ESI) m/z 
414.0873 ([M + Na]+, 100%), calc’d for C21H17N3O3SNa 414.0888. 
8-[(4-Methylbenzene)sulfonyl]-8,10,13- 
triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2,4,6,9,11(15)-
hexaen-12-one (II_50b). Prepared according to General Procedure 
D, starting with II_49b (30 mg, 0.074 mmol), in DMF (0.1 M), at 160 °C for 30 min. 
Purification by flash chromatography (DCM:MeOH, 10:1, Rf = 0.34) gave II_50b (23 mg, 
0.061 mmol, 83% yield) as a light yellow solid: mp. 304 °C; IR (neat) 3206, 2926, 2857, 
1681, 1376, 1175, 1091 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 2.28 (s, 3H), 4.49 (s, 2H), 
7.34 (d, J = 8.4 Hz, 2H), 7.52 (dd, J = 7.6, 7.2 Hz, 1H), 7.70 (dd, J = 8.2 Hz, 7.6 Hz, 1H), 
8.00 (d, J = 8.4 Hz, 2H), 8.30 (d, J = 7.2 Hz, 1H), 8.39 (d, J = 8.2 Hz, 1H), 8.78 (s, 1H), 
9.10 (br s, NH); 13C NMR (100 MHz, DMSO) δ 21.1, 42.5, 114.5, 120.2, 122.0, 122.2, 
124.4, 125.2, 127.2 (2C), 129.5, 130.0 (2C), 134.2, 134.6, 137.9, 145.8, 148.0, 150.9, 
167.5; HRMS (ESI) m/z 378.0920 ([M + H]+, 100%), calc’d for C20H15N3O3S 378.0912. 
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14,14-Dimethyl-8-[(4methylbenzene)sulfonyl]-8,10,13-
triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),3,5,9,11(15)-
hexaen-12-one (II_50c). Prepared according to General Procedure 
D, starting with II_49c (30 mg, 0.069 mmol). Purification by flash 
chromatography (100% EtOAc, Rf = 0.26) gave II_50c (25 mg, 0.069 mmol, 91% yield) 
as an off-white paste: IR (neat) 3218, 3068, 2977, 1704, 1375, 1190, 1177, 910, 738 cm-1; 
1H NMR (400 MHz, CDCl3) δ 1.63 (s, 6H), 2.31 (s, 3H), 7.23 (d, J = 8.2 Hz, 2H), 7.41 
(dd, J = 8.4, 7.6 Hz, 1H), 7.45 (br s, NH), 7.62 (dd, J = 8.0, 8.0 Hz, 1H), 7.99 (br d, J = 7.6 
Hz, 1H), 8.21 (s, 1H), 8.23 (d, J = 8.2 Hz, 2H), 8.52 (d, J = 8.4 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 21.8, 28.2 (2C), 57.1, 115.3, 121.20, 121.24, 121.3, 121.9, 124.0, 128.6 
(2C), 129.67, 129.74 (2C), 135.7, 139.2, 142.7, 145.4, 146.2, 151.7, 167.2; HRMS (ESI) 
m/z 428.1035 ([M + Na]+, 100%), calc’d for C22H19N3O3SNa 428.1045. 
 
 
13-(Furan-2-ylmethyl)-8-[(4-methylbenzene)sulfonyl]-
8,10,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-
1(16),2(7),3,5,9,11(15)-hexaen-12-one (II_50d). Prepared 
according to General Procedure D, starting with II_49d (30 
mg, 0.062 mmol). Purification by flash chromatography (DCM:EtOAc, 10:1, Rf = 0.38) 
gave II_50d (27 mg, 0.060 mmol, 98% yield) as a white solid: mp 251-252 °C; IR (neat) 
2939, 2833, 1687, 1374, 1174, 1033, 751, 540 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.30 
(s, 3H), 4.40 (s, 2H), 4.85 (s, 2H), 6.33 (br s, 1H), 6.36 (d, J = 3.2 Hz, 1H), 7.22 (d, J = 8.4 
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Hz, 2H), 7.33 (overlap dd, J = 8.0, 7.6 Hz, 1H), 7.34 (overlap br s, 1H) 7.52 (dd, J = 7.9, 
7.6 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 8.13 (s, 1H), 8.21 (d, J = 8.4 Hz, 2H), 8.44 (d, J = 
8.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 21.8, 39.7, 47.4, 105.1, 109.1, 110.7, 115.1, 
120.6, 121.2, 121.7, 122.8, 123.9, 128.7 (2C), 129.4, 129.7 (2C), 130.9, 135.6, 139.0, 
142.9, 145.4, 147.6, 150.1, 151.4, 165.8; HRMS (ESI) m/z 480.0988 ([M + Na]+, 100%), 
calc’d for C25H19N3O4SNa 480.0994. 
 
 
13-(2-Methoxyethyl)-8-[(4-methylbenzene)sulfonyl]-
8,10,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-
1(16),2(7),3,5,9,11(15)-hexaen-12-one (II_50e). Prepared 
according to General Procedure D, starting with II_49e (30 
mg, 0.065 mmol). Purification by flash chromatography (DCM:EtOAc, 1:1, Rf = 0.14) 
gave II_50e (27 mg, 0.062 mmol, 97% yield) as a white yellow solid: mp 247-248 °C; IR 
(neat) 3052, 2922, 1703, 1376, 1192, 1176, 742, 664 cm-1; 1H NMR (400 MHz, CDCl3) δ 
2.27 (s, 3H), 3.43 (s, 3H), 3.67 (t, J = 4.7 Hz, 2H), 3.86 (t, J = 4.7 Hz, 2H), 4.57 (s, 2H), 
7.19 (d, J = 8.4 Hz, 2H), 7.29 (dd, J = 8.2, 8.0 Hz, 1H), 7.48 (dd, J = 8.0, 7.8 Hz, 1H),  7.81 
(d, J = 7.8 Hz, 1H), 8.09 (s, 1H), 8.17 (d, J = 8.4 Hz, 2H), 8.37 (d, J = 8.2 Hz, 1H); 13C 
NMR (75 MHz, CDCl3) δ 21.7, 43.1, 49.2, 58.9, 71.5, 114.9, 120.4, 121.2, 121.7, 122.7, 
123.8, 128.5 (2C), 129.2, 129.7 (2C), 131.4, 135.6, 138.7, 145.4, 147.6, 151.2, 166.2; 
HRMS (ESI) m/z 458.1158 ([M + Na]+, 100%), calc’d for C23H21N3O4SNa 458.1150. 
 
 
216 
 
 
13-Benzyl-16-methyl-8-[(4-methylbenzene)sulfonyl]-
8,10,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-
1(16),2(7),3,5,9,11(15)-hexaen-12-one (14f). Prepared 
according to General Procedure D, starting with 13f (35 mg, 0.069 mmol). Purification 
by flash chromatography (hexanes:EtOAc, 3:1, Rf = 0.19) gave 14f (31 mg, 0.064 mmol, 
93% yield) as a white solid: Decomposition at 238 °C; IR (neat) 2952, 2854, 1707, 1596, 
1177, 1090 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.30 (s, 3H), 2.64 (s, 3H), 4.23 (s, 2H), 
4.85 (s, 2H), 7.20-7.40 (overlap, 9H), 7.55 (br dd, J = 7.6, 7.6 Hz, 1H), 7.97 (br d, J = 7.2 
Hz, 1H), 8.21 (d, J = 6.4 Hz, 2H), 8.54 (d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
δ 16.3, 21.8, 46.4, 47.3, 115.0, 119.1, 122.7, 123.2, 123.9, 128.0, 128.6 (2C), 128.7, 128.8 
(2C), 129.0 (2C), 129.6 (2C), 130.9, 135.6, 136.9, 137.2, 138.8, 145.3, 147.1, 151.7, 166.5; 
HRMS (ESI) m/z 482.1532 ([M + H]+, 100%), calc’d for C28H23N3O3S 482.1538. 
 
 
2-Benzyl-10-[(4-methylbenzene)sulfonyl]-
1H,2H,3H,4H,10H-indole[2,3-b]1,7-naphthyridin-1-one 
(II_50g). Prepared according to General Procedure D, 
starting with II_49g (30 mg, 0.058 mmol, 1.0 eq), at 160 °C. 
Purification by flash chromatography (100% DCM, Rf = 0.20) gave II_50g (27 mg, 0.056 
mmol, 95% yield) as a brown solid: mp 232-233 °C; IR (neat) 2922, 2852, 1659, 1374, 
1176, 669, 580 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.22 (s, 3H), 2.94 (t, J = 6.5 Hz, 2H), 
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3.43 (t, J = 6.5 Hz, 2H), 4.77 (s, 2H), 7.15-7.28 (m, 8H), 7.48 (ddd, J = 8.4, 8.4, 1.5 Hz, 
1H), 7.78 (d, J = 7.5 Hz, 1H), 7.86 (s, 1H), 8.30 (d, J = 8.1 Hz, 2H), 8.40 (d, J = 8.4 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 21.8, 27.8, 45.0, 50.7, 115.1, 120.5, 121.4, 121.8, 
123.7, 127.1, 127.7, 128.4 (2C), 128.8 (2C), 129.2 (2C), 129.5, 129.6 (2C), 129.8, 135.7, 
137.3, 139.2, 143.5, 145.3, 150.0, 163.0; HRMS (ESI) m/z 504.1376 ([M + Na]+, 100%), 
calc’d for C28H23N3O3SNa 504.1358. 
 
Prop-2-yn-1-yl 5-[(4-Methylbenzene)sulfonyl]-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_54a). Prepared 
according to General Procedure E, starting with II_44a (40 mg, 
1.0 eq, 0.094 mmol), Otera Catalyst (11 mg, 0.1 eq, 0.01 mmol) and propargyl alcohol (0.1 
ml). Purification by flash chromatography (DCM:EtOAc, 10:1, Rf = 0.80) gave II_54a (34 
mg, 0.057 mmol, 84% yield) as an orange oil: IR (neat) 3200, 2924, 1753, 1381, 1179, 
1153, 737, 579 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.37 (s, 3H), 2.62 (t, J = 2.4 Hz, 1H), 
5.13 (d, J = 2.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.60 (dd, J = 7.8, 7.6 Hz, 1H), 7.85 (dd, 
J = 8.6, 7.8 Hz, 1H), 8.21 (d, J = 8.4 Hz, 2H), 8.51 (d, J = 7.6 Hz, 1H), 8.54 (d, J = 8.6 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 21.9, 54.3, 76.2, 77.0, 115.2, 118.8, 123.6, 125.9, 
128.9 (2C), 130.2 (2C), 133.9, 134.3, 140.7, 145.2, 146.6, 147.0, 151.9, 161.9; HRMS 
(ESI) m/z 407.0804 ([M + 1]+, 100%), calc’d for C20H14N4O4S 407.0814. 
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But-3-yn-1-yl 5-[(4-Methylbenzene)sulfonyl]-5H-
[1,2,4]triazino[5,6-b]indole-3-carboxylate (II_54b). 
Prepared according to General Procedure E, starting with 
II_44a (40 mg, 1.0 eq, 0.094 mmol), Otera Catalyst (11 mg, 
0.1 eq, 0.01 mmol) and propargyl alcohol (0.1 ml). Purification by flash chromatography 
(DCM:EtOAc, 20:1, Rf = 0.40) gave II_54b (37 mg, 0.057 mmol, 87% yield)  as yellow 
orange oil: IR (neat) 3294, 2961, 1745, 1378, 1178, 1154, 735, 579 cm-1; 1H NMR (400 
MHz, CDCl3) δ 2.08 (t, J = 2.8 Hz, 1H), 2.36 (s, 3H), 2.82 (dt, J = 6.8, 2.8 Hz, 2H), 4.65 
(t, J = 6.8 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 7.60 (dd, J = 8.0, 8.0 Hz, 1H), 7.85 (dd, J = 
8.0, 8.0 Hz, 1H), 8.21 (d, J = 8.6 Hz, 2H), 8.51 (d, J = 8.0 Hz, 1H), 8.54 (d, J = 8.0 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 19.2 21.9, 64.5, 70.6, 79.7, 115.2, 118.9, 123.5, 125.9, 
128.8 (2C), 130.2 (2C), 133.8, 134.4, 140.7, 145.1, 146.7, 147.0, 152.3, 162.4; HRMS 
(ESI) m/z 443.0800 ([M + Na]+, 100%), calc’d for C21H16N4O4SNa 443.0790. 
 
 
8-[(4-Methylbenzene)sulfonyl]-13-oxa-8,10-
diazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2(7),3,5,10,15-
hexaen-12-one (II_55a). Prepared according to General Procedure 
D, starting with II_54a (30 mg, 1.0 eq, 0.074 mmol), at 160 °C. 
Purification by flash chromatography (DCM:EtOAc, 5:1, Rf = 0.67, 22 mg) gave II_55a 
(0.061 mmol, 80% yield) as yellow oil: IR (neat) 2925, 2360, 2340, 1786, 1379, 1173, 910, 
732, 574 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.32 (s, 3H), 5.41 (s, 2H), 7.24 (d, J = 8.4 
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Hz, 2H), 7.44 (dd, J = 8.0, 7.8 Hz, 1H), 7.67 (dd, J = 8.4, 7.8 Hz, 1H), 8.00 (d, J = 8.4 Hz, 
2H), 8.20 (d, J = 8.4 Hz, 2H), 8.28 (s, 1H), 8.54 (d, J = 8.0 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 21.8, 67.6, 115.4, 121.1, 121.8, 122.0, 122.9, 124.3, 128.7 (2C), 129.7 (2C), 
130.7, 135.3, 135.9, 140.0, 140.9, 145.8, 152.5, 168.1; HRMS (ESI) m/z 401.0584 ([M + 
Na]+, 100%), calc’d for C20H14N2O4SNa 401.0572. 
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5.3 Experimental for Chapter III 
 
General Procedure A, IEDDA 
Reaction for the Preparation of the 
Unprotected Pyridazinoindoles.  
To a solution of tetrazine III_2 (2.0 eq) in anhydrous DCM (0.1 M), was injected indole 
solution (1.0 eq) in anhydrous DCM (0.05 M) slowly using syringe pump over 2 hours 
(depends on the scale) at 0 oC. The reaction was then allowed to warm up to room 
temperature, continued to stir for 16-24 hours till completion. The resulting reaction 
mixture was filtered and washed with DCM for three times. The organic filtrates were 
combined, the solvent was removed in vacuo, and the residue was purified by flash 
chromatography to yield the desired pyridazinoindole cycloadducts with dihydrotetrazine 
III_5 as a side product. 
 
 
General Procedure B, Regioselective 
Amidation (Method A). Magnesium 
chloride (1.5 eq), III_4 (1.0 eq), and 
DMAP (0.1 eq) were mixed in anhydrous DCM (0.1 M), and stirred for 10 minutes at room 
temperature. Primary amine (1.2 eq) was then added into the reaction mixture. The reaction 
was reflux overnight (TLC monitor till completion) and quenched by the addition of HCl 
(0.1 M). The reaction mixture was extracted with DCM three times. The organic extracts 
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were combined and the solvent was removed in vacuo, the residue was purified by flash 
chromatography to yield the desired regioselective amide products.  
 
 
General Procedure C, Regioselective 
Amidation (Method B). To a solution of 
secondary amine or amine salt (1.5 eq), 
trimethylaluminum (2.0 eq) was injected below the solvent surface at 0 oC. The reaction 
was allowed to warm up to room temperature and continued to stir for 30 minutes. The 
reaction mixture was then cannulated into a solution of III_4 (1.0 eq) in DCM (0.1 M) 
slowly at 0 oC. The resulting reaction mixture was allowed to warm up to room 
temperature, continued to stir for 18 hours at room temperature, and then quenched by the 
addition of HCl (0.1M). The reaction mixture was extracted with DCM for three times. The 
organic extracts were combined and the solvent was removed in vacuo, the residue was 
purified by flash chromatography to yield the desired regioselective amide products.  
 
 
General Procedure D, Regioselective 
Amidation (Method C). To a solution 
of primary amine or amine salt (1.1 eq), 
trimethylaluminum (1.0 eq) was 
injected below the solvent surface at 0 oC. The reaction was allowed to warm up to room 
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temperature and continued to stir for 30 minutes. The reaction mixture was then cannulated 
into a solution of III_4 (1.0 eq) in DCM slowly at -50 oC, continued to stir for 18 hours. 
The reaction was allowed to warm up to room temperature after completion and quenched 
by the addition of HCl (0.1M). The reaction mixture was extracted with DCM for three 
times. The organic extracts were combined and the solvent was removed in vacuo, the 
residue was purified by flash chromatography to yield the desired regioselective amide 
products.  
 
 
General Procedure E, Preparation of 
Protected Pyridazinoindoles. To a 
solution of unprotected pyridazinoindole 
(1.0 eq) in anhydrous THF (0.1 M), NaH (2.0 eq), TEA (2.0eq) and electrophiles (1.5 eq) 
were added at room temperature. The reaction mixture was refluxed for 2 days and 
quenched by the addition of water. The resulting mixture was extracted with EtOAc for 
three times and then with DCM once. The organic extracts were combined, washed with 
brine, and dried over anhydrous NaSO4. The solvent was removed in vacuo, the residue 
was purified by flash chromatography to yield the protected pyridazinoindole. 
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General Procedure F, Preparation of 
Amide from Protected 
Pyridazinoindoles. To a solution of 
protected pyridazinoindole (1.0 eq) in anhydrous DCM (0.1 M), the amine/aluminum 
complex mixture (1.5 eq), prepared by following General Procedure C, was cannulated 
into the reaction slowly at 0 oC. The reaction mixture was then allowed to warm up to room 
temperature, continued to stir for 18-24 hours till completion, and quenched by the addition 
of HCl solution (0.1 M). The resulting mixture was extracted with DCM for three times. 
The organic extracts were combined, washed with brine, and dried over anhydrous NaSO4. 
The solvent was removed in vacuo, the residue was purified by flash chromatography to 
yield the desired amide with excellent regioselectivity. 
 
 
General Procedure G, IEDDA for the 
Preparation of Carbazole Structures. 
Previously made protected 
pyridazinoindole amide (1.0 eq), BHT (0.1 eq) were mixed in anhydrous diglyme (0.005 
M). The reaction was refluxed for 7-9 hours with precise TLC monitoring (every 1 hour) 
till completion. The solvent was then removed in vacuo, the residue was purified by 
chromatography to yield the desired carbazole cycloadduct.  
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Methyl 4-(benzyl(methyl)carbamoyl)-5H-pyridazino[4,5-
b]indole-1-carboxylate (III_17). Prepared according to 
General Procedure C, starting with III_4 (50 mg, 1.0eq, 0.18 
mmol) and N-methyl-1-phenylmethanamine (26 mg, 1.5eq, 
0.21 mmol) with trimethylaluminum (2.0 eq). Purification by flash chromatography 
(DCM:EtOAc, 5:1, Rf 0.42) gave III_17 (62 mg, 0.17 mmol, 95% yield) as a white solid: 
mp, 218-220 oC; IR (neat) 3245, 3063, 2951, 1733, 1617, 1494, 1207, 1029, 735 cm-1; 1H 
NMR (400 MHz, CDCl3) δ (3.18, s, 3.61, s, rotamers, 3H), 4.18 (s, 3H), 4.20 (s, 3H), (4.92, 
s, 5.43, s, rotamers, 2H), 7.22-7.47 (overlap, 6H), 7.61 (d, J = 8.2 Hz, 1H), 7.71 (m, 1H), 
8.91 (d, J = 8.2 Hz, 1H), (10.57, s 10.60, s, rotamers, br, NH); 13C NMR (125 MHz, CDCl3, 
assumed rotamer pairs in parentheses) δ (35.1, 38.2), (53.1, 55.2), 53.5, 112.2, 118.8, 
(121.3, 121.4), 122.7, 127.0, 127.8, 128.1 (2C), 129.0 (2C), 130.9, (136.5, 136.8), (137.7, 
137.9), 141.0, 141.8, (145.4, 145.6) 165.8, 165.9; HRMS (ESI) m/z 397.1264 ([M + Na]+, 
100%), calc’d for C21H18N4O3Na 397.1277. 
 
 
Methyl 1-(phenylcarbamoyl)-5H-pyridazino[4,5-b]indole-4-
carboxylate (III_19). Prepared according to General Procedure 
D, starting with III_4 (50 mg, 1.0 eq, 0.18 mmol) and benzylamine 
(23 mg, 1.1 eq, 0.21 mmol). Purification by flash chromatography 
(DCM:EtOAc, 5:1, Rf 0.59, 28 mg) gave III_19 (0.08 mmol, 46% 
yield) as a yellow solid: mp, 215-217 oC; IR (neat) 3343, 2917, 2849, 1734, 1683, 1654, 
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1456, 1225 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.19 (s, 3H), 4.84 (d, J = 6.4 Hz, 2H), 7.29 
(d, J = 7.2 Hz, 1H), 7.35 (dd, J = 7.6, 7.6 Hz, 2H), 7.43 (d, J = 7.2, Hz, 2H), 7.50 (dd, J = 
7.6, 7.6 Hz, 1H),  7.66 (d, J = 8.4 Hz, 1H), 7.73 (dd, J = 7.6, 7.6 Hz, 1H), 8.43 (s, 1H), 
10.57 (br, NH); 13C NMR (100 MHz, CDCl3) δ 43.9, 53.6, 111.9, 119.3, 121.6, 123.3, 
127.8, 128.0, 129.0, 129.7, 131.4, 136.6, 138.0, 138.5, 141.3, 147.7, 164.1, 166.4; HRMS 
(ESI) m/z 361.1268 ([M + H]+, 100%), calc’d for C20H17N4O3 361.1301. 
 
 
Methyl 4-(benzylcarbamoyl)-5H-pyridazino[4,5-b]indole-1-
carboxylate (III_20). Prepared according to General Procedure B, 
starting with III_4 (50 mg, 1.0 eq, 0.18 mmol) and benzylamine (28 
mg, 1.5 eq, 0.26 mmol). Purification by flash chromatography 
(DCM:EtOAc, 9:1, Rf 0.58, 48 mg) gave III_20 (0.13 mmol, 76% 
yield) as a yellow oil: IR (neat) 3326, 3064, 3033, 2951, 1735, 1656, 1528, 1214, 915, 744 
cm-1; 1H NMR (400 MHz, CDCl3) δ 4.19 (s, 3H), 4.78 (d, J = 5.6 Hz, 2H), 7.24-7.39 
(overlap, 6H), 7.63-7.72 (overlap, 2H), 8.77 (t, br, J =5.6 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 
10.82 (br, NH); 13C NMR (100 MHz, CDCl3) δ 43.6, 53.6, 112.4, 118.5, 121.9, 122.9, 
127.2 (2C), 127.9, 128.0, 129.1 (2C), 131.3, 136.8, 137.6, 138.0, 141.5, 146.5, 164.7, 
165.9; HRMS (ESI) m/z 383.1106 ([M + H]+, 100%), calc’d for C20H16N4O3 383.1120. 
 
 
 
226 
 
Methyl 1-(benzylcarbamoyl)-5-methyl-5H-pyridazino[4,5-
b]indole-4-carboxylate (III_23). Prepared according to General 
Procedure C, starting with dimethyl 5-methyl-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate (40 mg, 1.0eq, 0.13 mmol) and 
benzylamine (22 mg, 1.5eq, 0.21 mmol) with trimethylaluminum 
(2.0 eq). Purification by flash chromatography (DCM:EtOAc, 10:1, Rf 0.40) gave III_23 
(45 mg, 0.12 mmol, 90% yield) as a yellow brown oil: IR (neat) 3307, 3031, 2953, 2926, 
1738, 1673, 1509, 1223, 1082, 911, 737, 699; 1H NMR (400 MHz, CDCl3) δ 4.00 (s, 3H), 
4.16 (s, 3H), 4.82 (d, J = 4.0 Hz, 2H), 7.28 (d, J = 7.2 Hz, 1H), 7.34 (dd, J = 7.6, 7.6 Hz, 
2H), 7.43 (d, J = 7.2 Hz, 2H), 7.50 (dd, J = 7.6, 7.6 Hz, 1H) 7.58 (d, J = 8.4 Hz, 1H), 7.75 
(d, J = 7.2, 7.2, 1.2 Hz, 1H) 8.87 (t, br, J =4.0 Hz, 1H), 9.50 (d, J = 8.4 Hz, 1H), 10.82 (br, 
NH); 13C NMR (100 MHz, CDCl3) δ 32.7, 43.8, 53.7, 109.7, 118.9, 121.1, 122.9, 127.7, 
127.9 (2C), 128.9 (2C), 129.4, 130.9, 136.2, 138.0, 140.2, 143.2, 147.2, 164.2, 166.0; 
HRMS (ESI) m/z 397.1282 ([M + Na]+, 100%), calc’d for C21H18N4O3Na 397.1277. 
 
 
Methyl 4-((cyclohexylmethyl)carbamoyl)-8-methoxy-
5H-pyridazino[4,5-b]indole-1-carboxylate (III_24). 
Prepared according to General Procedure B, starting with 
III_44 (40 mg, 1.0 eq, 0.13 mmol) and 
cyclohexylmethanamine (22 mg, 1.5 eq, 0.19 mmol). Purification by flash chromatography 
(DCM:EtOAc, 3:1, Rf 0.45, 41 mg) gave III_24 (0.10 mmol, 81% yield) as a yellow oil:  
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1H NMR (400 MHz, CDCl3) δ 1.03-1.27 (overlap, 6H), 1.63-1.84 (overlap, 7H), 3.43 (t, J 
= 6.4 Hz, 2H), 3.96 (s, 3H), 4.19 (s, 3H), 7.34 (dd, J = 9.2, 2.4 Hz, 1H), 7.53 (d, J = 9.2, 
Hz, 1H), 8.41 (d, J = 2.4 Hz, 1H), 8.49 (t, br, J = 5.6, 1H), 10.70 (br, NH); 13C NMR (100 
MHz, CDCl3) δ 26.0 (2C), 26.5, 31.1 (2C), 38.4, 45.8, 53.6, 56.1, 108.1, 113.1, 119.1, 
121.7, 121.8, 136.4, 136.9, 138.2, 146.3, 146.3, 155.9, 164.7, 166.0; HRMS (ESI) m/z 
397.1876 ([M + H]+, 100%), calc’d for C21H24N4O4 397.1876. 
 
 
Methyl 4-(isopropylcarbamoyl)-5H-pyridazino[4,5-b]indole-1-
carboxylate (III_25). Prepared according to General Procedure 
B, starting with III_4 (50 mg, 1.0 eq, 0.18 mmol) and propan-2-
amine (16 mg, 1.5 eq, 0.26 mmol). Purification by flash 
chromatography (DCM:EtOAc, 9:1, Rf = 0.58, 35 mg) gave III_25 (0.11 mmol, 64% yield) 
as a while yellow oil: IR (neat) 3433, 1732, 1698, 1652 1637, 1561, 1540, 1507, 745 cm-1; 
1H NMR (400 MHz, CDCl3) δ 1.37 (d, 6H), 4.20 (s, 3H), 4.37 (m, 1H), 7.46 (dd, J = 7.4, 
7.4 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.71 (dd, J = 7.4, 7.4 Hz, 1H), 8.24 (d, J = 8.0 Hz, 
1H), 8.90 (d, J =8.0 Hz, 1H), 10.79 (br, NH); 13C NMR (100 MHz, CDCl3) δ 22.9 (2C), 
41.8, 53.6, 112.4, 118.5, 121.9, 122.9, 127.2, 131.3, 136.8, 138.2, 141.5, 146.3, 163.7, 
165.8; HRMS (ESI) m/z 335.1098 ([M + Na]+, 100%), calc’d for C16H16N4O3Na 335.1120. 
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Methyl 4-(methyl(prop-2-yn-1-yl)carbamoyl)-5H-pyridazino[4,5-
b]indole-1-carboxylate (III_26). Prepared according to General 
Procedure C, starting with III_4 (50 mg, 1.0eq, 0.14 mmol) and N-
methyl propargylamine (18 mg, 1.5eq, 0.21 mmol) with 
trimethylaluminum (2.0 eq). Purification by flash chromatography (DCM:EtOAc, 5:1, Rf 
0.33) gave III_26 (54 mg, 0.17 mmol, 96% yield) as a yellow brown oil: IR (neat) 3297, 
1732, 1635, 1467, 1204, 1060, 911, 731 cm-1; 1H NMR (400 MHz, CDCl3) δ (2.24, t, 2.30, 
t, J = 2.8 Hz, rotamers, 1H), (3.34, s, 3.75, s, rotamers, 2H), 4.21 (s, 3H), (4.48, d, 5.22, d, 
J = 2.8 Hz, rotamers, 2H), 7.49 (dd, J = 8.8, 3.2 Hz, 1H), 7.77 (ddd, J = 8.8, 1.6, 1.6 Hz, 
1H), 9.11 (d, J = 1.6 Hz, 1H), 10.64 (br, NH); 13C NMR (75 MHz, CDCl3, assumed rotamer 
pairs in parentheses) δ (35.1, 37.7), (38.7, 41.2), 51.5, (72.4, 73.0), (70.4, 70.9), (78.0, 
78.4),  113.4, 115.7, 120.2, 129.6, 133.7, 137.9 139.4, (141.4, 141.5), 145.3, (164.8, 165.2), 
165.4; HRMS (ESI) m/z was not obtained.  
 
 
Methyl 4-(benzyl(methyl)carbamoyl)-8-methoxy-5H-
pyridazino[4,5-b]indole-1-carboxylate (III_27). 
Prepared according to General Procedure C, starting 
with III_44 (60 mg, 1.0eq, 0.19 mmol) and N-methyl-1-
phenylmethanamine (35 mg, 1.5eq, 0.285 mmol) with trimethylaluminum (2.0 eq). 
Purification by flash chromatography (DCM:EtOAc, 5:1, Rf 0.42) gave III_27 (75 mg, 
0.19 mmol, 97% yield) as a brown orange oil: 1H NMR (400 MHz, CDCl3) δ (3.16, s, 3.57, 
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s, rotamers, 3H), 3.95 (s, 3H), (4.17, s, 4.19, s, rotamers, 3H), (4.91, s, 5.36, s, rotamers, 
2H), 7.23-7.46 (overlap, 7H), 8.39 (s, 1H), (10.68, s 10.73, s, rotamers, br, NH); 13C NMR 
(75 MHz, CDCl3, assumed rotamer pairs in parentheses) δ (35.0, 38.3), (53.0, 55.3), 53.6, 
56.1, 108.0, 113.0, 119.3, 121.2, 119.3, 128.0, 128.1 (2C), 129.0 (2C), 136.0, 136.5, 136.8, 
137.8, 142.0, 145.4, 155.8, 166.0; HRMS (ESI) m/z 486.1205 ([M + H]+, 100%), calc’d 
for C22H20N4O4 405.1563. 
 
 
Methyl 4-(benzylcarbamoyl)-8-methoxy-5H-pyridazino[4,5-
b]indole-1-carboxylate (III_28). Prepared according to General 
Procedure B, starting with III_44 (50 mg, 1.0 eq, 0.18 mmol) and 
benzylamine (16 mg, 1.5 eq, 0.26 mmol). Purification by flash 
chromatography (DCM:EtOAc, 3:1, Rf 0.41, 44 mg) gave III_25 
(0.11 mmol, 71% yield) as a yellow solid: mp, 198-200 oC; IR (neat) 3446, 2256, 1731, 
1653, 1266, 1169, 908, 733 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.96 (s, 3H), 4.20 (s, 3H), 
4.78 (d, J = 6.0 Hz, 2H), 7.29-7.41 (overlap, 6H), 7.54 (d, J = 9.2 Hz, 1H), 8.42 (d, J = 2.4 
Hz, 1H), 8.74 (t, J = 6.0 Hz, 1H), 10.79 (br, NH); 13C NMR (100 MHz, CDCl3) δ 43.6, 
53.6, 56.1, 108.1, 113.1, 119.1, 121.8, 122.0, 127.9 (2C), 128.0, 129.1 (2C), 136.4, 137.0, 
137.6, 138.0 146.3, 156.0, 164.7, 166.0; HRMS (ESI) m/z 391.1432 ([M + H]+, 100%), 
calc’d for C21H19N4O4 391.1406. 
 
 
 
230 
 
Methyl 4-(morpholinocarbamoyl)-5H-pyridazino[4,5-
b]indole-1-carboxylate (III_29). Prepared according to General 
Procedure C, starting with III_4 (40 mg, 1.0 eq, 0.18 mmol) and 
morpholine (23 mg, 1.5 eq, 0.26 mmol). Purification by flash 
chromatography (DCM:EtOAc, 3:1, Rf 0.37, 56 mg) gave III_24 (0.16 mmol, 95% yield) 
as a white solid: mp, 225-227 oC; 1H NMR (400 MHz, CDCl3) δ 3.84 (dd, J = 4.8, 4.8 Hz, 
2H), 3.89 (dd, J = 4.8, 4.8 Hz, 2H), 3.94 (dd, J = 4.8, 4.8 Hz, 2H), 4.46 (d, J = 4.8 Hz, 2H), 
7.44 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.0, Hz, 1H), 7.65 (dd, J = 8.0, 8.0 Hz, 1H), 8.90 (d, 
J = 8.0 Hz, 1H), 10.49 (br, NH); 13C NMR (100 MHz, CDCl3) δ 43.8, 48.4, 53.3, 66.9, 
67.4, 112.1 118.5, 121.3, 122.6, 126.9, 130.8, 137.6, 140.8, 141.2, 145.3, 164.0, 165.7; 
HRMS (ESI) m/z 363.1072 ([M + Na]+, 100%), calc’d for C17H16N4O4Na 363.1069. 
 
 
Methyl 8-methoxy-4-(morpholine-4-carbonyl)-5H-
pyridazino[4,5-b]indole-1-carboxylate (III_30). Prepared 
according to General Procedure C, starting with III_44 (40 
mg, 1.0eq, 0.13 mmol) and morpholine (6 mg, 1.5eq, 0.19 
mmol) with trimethylaluminum (2.0 eq). Purification by flash chromatography 
(DCM:EtOAc, 8:1, Rf 0.32) gave III_30 (43 mg, 0.12 mmol, 92% yield) as a yellow solid: 
mp, 226-228 oC; IR (neat) 3245, 3063, 2951, 1733, 1493, 1436, 1258, 808, 727 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 3.84 (t, J = 4,8 Hz, 2H),  3.88 (t, J = 4,8 Hz, 2H), 3.94 (t, J = 
4,8 Hz, 2H), 3.96 (s, 3H), 4.19 (s, 3H), 4.47 (t, J = 4,8 Hz, 2H), 7.33 (dd, J = 9.0, 2.8 Hz, 
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1H), 7.49 (d, J = 9.0 Hz, 1H), 8.43 (d, J = 2.8 Hz, 1H), 10.34 (br, NH); 13C NMR (125 
MHz, CDCl3, assumed rotamer pairs in parentheses) δ 43.8, 48.4, 53.4, 55.9, 67.0, 67.4 
107.9, 112.7,119.1, 121.2, 121.5, 135.7, 137.9, 141.3, 145.1, 155.7, 164.0, 165.7; HRMS 
(ESI) m/z 393.1201 ([M + Na]+, 100%), calc’d for C18H18N4O5Na 393.1175. 
 
 
Methyl 4-(benzyl(but-3-yn-1-yl)carbamoyl)-8-bromo-
5H-pyridazino[4,5-b]indole-1-carboxylate (III_31). 
Prepared according to General Procedure C, starting with 
dimethyl 8-bromo-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (50 mg, 1.0eq, 0.14 mmol) and N-benzylbut-
3-yn-1-amine (33 mg, 1.5eq, 0.21 mmol) with trimethylaluminum (2.0 eq). Purification by 
flash chromatography (DCM:EtOAc, 8:1, Rf 0.44) gave III_31 (62 mg, 0.13 mmol, 92% 
yield) as a yellow brown oil: IR (neat) 3393, 3307, 3031, 2953, 1731, 1635, 1464,1202, 
1137, 812 cm-1; 1H NMR (400 MHz, CDCl3) δ (1.88, t, 2.00, t, J = 3.6 Hz, rotamers, 1H), 
(2.64, dt, 2.81, dt, J = 9.2, 3.6 Hz, rotamers, 2H), (3.74, t, 4.20, t, J = 9.2 Hz, rotamers, 
2H), (4.18, s, 4.21, s, rotamers, 3H), (5.03, s, 5.48, s, rotamers, 2H), 7.24-7.45 (overlap, 
7H), (7.70, d, 7.73, d, J = 2.6 Hz, rotamers, 1H), (9.04, d, 9.06, d, J = 2.6 Hz, 1H), (10.33, 
s 10.88, s, rotamers, br, NH); 13C NMR (100 MHz, CDCl3, assumed rotamer pairs in 
parentheses) δ (16.8, 19.1), (45.8, 47.4), 50.7, (53.2, 53.3), (69.9, 70.4), (80.9, 81.1), 113.1, 
115.3, (119.8, 120.0), (127.4, 127.5), 127.44 (2C), 128.3, 128.5 (2C), 129.2, 133.3, 136.0, 
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(137.3, 137.5), 139.1, (141.5, 141.6), 145.0, 165.1, 165.4; HRMS (ESI) m/z 513.0543 ([M 
+ Na]+, 100%), calc’d for C24H19BrN4O3Na 513.0538. 
 
 
Methyl 4-(benzyl(but-3-yn-1-yl)carbamoyl)-9-bromo-5H-
pyridazino[4,5-b]indole-1-carboxylate (III_32). Prepared 
according to General Procedure C, starting with dimethyl 9-
bromo-5H-pyridazino[4,5-b]indole-1,4-dicarboxylate (50 mg, 
1.0eq, 0.14 mmol) and N-benzylbut-3-yn-1-amine (33 mg, 
1.5eq, 0.21 mmol) with trimethylaluminum (2.0 eq). Purification by flash chromatography 
(DCM:EtOAc, 5:1, Rf 0.42) gave III_32 (63 mg, 0.13 mmol, 93% yield) as a brown oil: 
IR (neat) 3293, 3063, 2950, 2921, 1744, 1634, 1611, 1446, 1240, 1206, 1169, 921 cm-1; 1H 
NMR (400 MHz, CDCl3) δ (1.90, t, 2.01, t, J = 2.8 Hz, rotamers, 1H), (2.64, dt, 2.82, dt, J 
= 6.8, 2.8 Hz, rotamers, 2H), (3.74, t, 4.20, t, J = 6.8 Hz, rotamers, 2H), (4.08, s, 4.11, s, 
rotamers, 3H), (5.02, s, 5.48, s, rotamers, 2H), 7.24-7.62 (overlap, 8H), (10.93, s 10.98, s, 
rotamers, br, NH); 13C NMR (75 MHz, CDCl3, assumed rotamer pairs in parentheses) δ 
(17.4, 19.7), (46.4, 48.1), 51.3, (53.5, 53.9), (70.5, 70.9), (81.5, 81.7), 111.8, 117.4, 118.1, 
119.0, (127.6, 127.9), 128.0 (2C), 128.1, 129.1 (2C), 131.0. 136.6, (137.1, 137.2), (141.3, 
141.4), 141.7, 149.2, (165.8, 166.1), 167.0; HRMS (ESI) m/z 491.0727 ([M + H]+, 100%), 
calc’d for C24H20N4O3 491.0719. 
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1-Acetyl-N-benzyl-5-methyl-5H-pyridazino[4,5-b]indole-4-
carboxamide (III_33). Prepared according to General Procedure C, 
starting with dimethyl 5-methyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (40 mg, 1.0 eq, 0.13 mmol) and benzylamine (21 mg, 
1.5 eq, 0.20 mmol). Trimethylaluminum (2.0 eq) was injected to the 
solution of 1-methyl indole in DCM (0.1 M) at 0 oC, and continued to stir for 2 hours, then 
the amine was added into the reaction mixture. Purification by flash chromatography 
(DCM:EtOAc, 3:1, Rf 0.56, 38 mg) gave III_33 (0.10 mmol, 76% yield) as a yellow oil: 
IR (neat) 3289, 3029, 2927, 1703, 1668, 1516, 1141, 912, 737, 650 cm-1; 1H NMR (400 
MHz, CDCl3) δ 3.02 (s, 3H), 4.24 (s, 3H), 4.78 (d, J = 5.6 Hz, 2H), 7.23-7.48 (overlap, 
6H), 7.61 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 8.32 (t, J = 5.6 Hz, 1H), 9.97 (d, J 
= 8.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 28.7, 34.6, 44.2, 110.5, 118.6, 120.6, 122.7, 
127.2, 127.9 (2C), 129.0 (2C), 131.1, 136.7, 137.6, 141.4, 143.8, 151.3, 164.4, 201.0; 
HRMS (ESI) m/z 359.1502 ([M + H]+, 100%), calc’d for C21H18N4O2 359.1508. 
 
 
Methyl 4-(benzyl(but-3-yn-1-yl)carbamoyl)-7-bromo-
5H-pyridazino[4,5-b]indole-1-carboxylate (III_34). 
Prepared according to General Procedure C, starting with 
dimethyl dimethyl 7-bromo-5H-pyridazino[4,5-b]indole-
1,4-dicarboxylate (50 mg, 1.0eq, 0.14 mmol) and N-
benzylbut-3-yn-1-amine (30 mg, 1.5eq, 0.21 mmol) with trimethylaluminum (2.0 eq). 
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Purification by flash chromatography (DCM:EtOAc, 8:1, Rf 0.67) gave III_34 (57 mg, 
0.12 mmol, 85% yield) as a yellow brown oil: IR (neat) 3396, 3305, 3031, 2953, 1732, 
1608, 1440, 1259, 1204, 1137, 909, 806 cm-1 ; 1H NMR (400 MHz, CDCl3) δ (1.89, t, 2.01, 
t, J = 2.8 Hz, rotamers, 1H), (2.64, dt, 2.82, dt, J = 7.2, 2.8 Hz, rotamers, 2H), (3.74, t, 4.24, 
t, J = 6.8 Hz, rotamers, 2H), (4.17, s, 4.20, s, rotamers, 3H), (5.03, s, 5.54, s, rotamers, 2H), 
7.23-7.42 (overlap, 5H), 7.53 (d, J = 2.0 Hz, 1H), 7.76 (d, J = 2.0 Hz, 1H), (10.68, s 10.74, 
s, rotamers, br, NH); 13C NMR (75 MHz, CDCl3, assumed rotamer pairs in parentheses) δ 
(17.4, 19.7), (46.5, 48.0), 51.4, (53.7, 53.9), (70.4, 70.9), (81.5, 81.8), 115.4, 117.8, 121.3, 
125.2, 126.4, 127.0 127.8, 128.0 (2C), 128.5, 128.8, (128.9, 129.1, 2C), 131.0. 136.7, 
(138.1, 138.2), (141.7, 141.8), 142.0, 145.5, (165.6, 165.8), 166.0; HRMS (ESI) m/z 
491.0760 ([M + H]+, 100%), calc’d for C24H20BrN4O3 491.0719. 
 
 
Methyl 4-(diethylcarbamoyl)-8-methoxy-5-methyl-5H-
pyridazino[4,5-b]indole-1-carboxylate (III_35). Prepared 
according to General Procedure C, starting with III_44 (40 
mg, 1.0eq, 0.13 mmol) and diethylamine (14 mg, 1.5eq, 0.19 
mmol) with trimethylaluminum (2.0 eq). Purification by flash chromatography 
(DCM:EtOAc, 10:1, Rf 0.32) gave III_35 (39 mg, 0.11 mmol, 83% yield) as a yellow 
brown oil: IR (neat) 3235, 2935, 1730, 1631, 1489, 1265, 1148, 816, 659 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 1.34 (t, J = 7.2 Hz, 3H), 1.42 (t, J = 7.2 Hz, 3H), 3.68 (q, J = 7.2 Hz, 
2H), 3.94 (s, 3H), 3.99 (q, J = 7.2 Hz, 2H), 4.19 (s, 3H), 7.29 (dd, J = 8.8, 2.4 Hz, 2H), 
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7.45 (d, J = 8.8 Hz, 2H), 8.40 (d, J = 2.4 Hz, 1H), 10.67 (br, NH); 13C NMR (100 MHz, 
CDCl3) δ 12.7, 14.8, 42.3, 44.3, 53.3, 55.9, 107.8, 112.7, 119.1, 120.9, 121.2, 135.7, 137.6, 
142.0, 145.1, 155.5, 164.9, 165.9; HRMS (ESI) m/z 379.1380 ([M + Na]+, 100%), calc’d 
for C21H18N4O3Na 379.1382. 
 
 
Methyl (S)-4-(8-methyl-6-(phenoxymethyl)-1,3,4,7,8,10-
hexahydro-2H-pyrano[4,3-c][1,6]naphthyridine-2-
carbonyl)-5H-pyridazino[4,5-b]indole-1-carboxylate 
(III_37). Prepared according to General Procedure C, 
starting with III_4 (100 mg, 1.0eq, 0.35 mmol) and (S)-8-
methyl-6-(phenoxymethyl)-1,3,4,7,8,10-hexahydro-2H-pyrano[4,3-c][1,6]naphthyridine 
[365] (163 mg, 1.5eq, 0.53 mmol) with trimethylaluminum (2.0 eq). Purification by flash 
chromatography (DCM:EtOAc, 1:1, Rf 0.32) gave III_37 (144 mg, 0.26 mmol, 73% yield) 
as a yellow solid: mp 245-247 oC; IR (neat) 3310 2957, 2929, 1733, 1652, 1496, 1457, 
1262, 1129, 1031 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.86-0.97 (m, 1H), 1.15-1.23 
(overlap, 2H), (1.31, d, 1.38, d, J = 6.2 Hz, rotamers, 4H), 2.68-2.91 (overlap, 2H), 3.28 
(m, 2H), 3.77 (m, 1H), 4.14 (m, 1H), 4.22 (s, 3H), 4.34-4.92 (overlap, 4H), (5.13, s, 5.15, 
s, rotamers, 2H), (5.38, d, 5.56, d, J = 17.6, rotamers, 1H), 6.91-7.01 (overlap, 3H), 7.26 
(m, 2H), 7.53 (m, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.70 (m, 1H), (8.90, d, 8.94, d, J = 4.4 Hz, 
1H), (10.43, s 10.54, s, rotamers, br, NH); 13C NMR (100 MHz, CDCl3, assumed rotamer 
pairs in parentheses) δ (21.7, 21.8), 29.9, 31.5, (31.9, 32.0), 33.1, (41.7, 42.2), 53.7, 65.3, 
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(70.3, 70.5), 112.3, 115.0, 118.7, 118.8, 121.4, 121.7, 122.9, 123.4, 127.1, 127.3, 127.8, 
129.7, 131.2, 138.0, 141.1, (141.3, 141.5), 145.7, 150.9, 152.2, 158.8, (164.7, 165.1), 
165.9; HRMS (ESI) m/z 564.2212 ([M + H]+, 100%), calc’d for C32H30N5O5 564.2247. 
 
 
Dimethyl 8-methyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_43). Prepared according to General Procedure 
A, starting with 5-methyl-1H-indole (1.50 g, 1.0 eq, 11.43 mmol) 
and III_2 (4.53 g, 2.0 eq, 22.87 mmol). Purification by flash 
chromatography (DCM:EtOAc, 1:1, Rf 0.20, 3.18 g) gave III_4 (10.63 mmol, 93% yield) 
as a yellow solid: mp, 195-197 oC; IR (neat) 3343, 2953, 2227, 1737, 1729, 1215, 1161, 
912, 731, 587 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.47 (s, 3H), 4.05 (s, 3H), 4.15 (s, 3H), 
7.38 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 8.5, Hz, 1H), 8.43 (s, 1H), 10.57 (br, NH); 13C NMR 
(100 MHz, CDCl3) δ 21.7, 53.3, 53.4, 111.9, 118.3, 121.0, 126.1,132.5, 132.6, 136.7, 
137.5, 139.3, 146.1, 165.9, 166.0; HRMS (ESI) m/z 300.0992 ([M + H]+, 100%), calc’d 
for C15H13N3O4 300.0984. 
 
 
Dimethyl 8-methoxy-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_44). Prepared according to General 
Procedure A, starting with 5-methoxy-1H-indole (1.00 g, 1.0 eq, 
6.79 mmol) and III_2 (2.69 g, 2.0 eq, 13.59 mmol). Purification  
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by flash chromatography (DCM:EtOAc, 1:1, Rf 0.11, 1.88 g) gave III_4 (5.96 mmol, 88% 
yield) as a bright yellow solid: mp, 202-203 oC; IR (neat) 3345, 2952, 1733, 1490, 1440, 
1225, 1165, 816 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.96 (s, 3H), 4.17 (s, 3H), 4.20 (s, 
3H), 7.36 (dd, J = 9.2, 2.4 Hz, 1H), 7.57 (d, J = 9.2, Hz, 1H), 8.39 (d, J = 2.4 Hz, 1H), 
10.27 (br, NH); 13C NMR (100 MHz, CDCl3) δ 53.70, 53.73, 56.2, 108.2, 113.4, 119.2, 
121.6 122.1, 136.0, 137.0, 138.0, 146.3, 156.1, 166.1, 166.4; HRMS (ESI) m/z 316.0918 
([M + H]+, 100%), calc’d for C15H14N3O5 316.0933. 
 
 
Dimethyl 6-fluoro-9H-carbazole-1,4-dicarboxylate (III_45). 
Prepared according to General Procedure A, starting with 5-
fluoro-1H-indole (1.20 g, 1.0 eq, 8.88 mmol) and III_2 (3.52 g, 
2.0 eq, 17.76 mmol). Purification by flash chromatography 
(DCM:EtOAc, 1:1, Rf 0.14, 2.41 g) gave III_45 (8.00 mmol, 90% yield) as a bright yellow 
solid: mp, 217-219 oC; IR (neat) 3196, 1735, 1490, 1258, 1206, 1172, 1081, 540 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 4.17 (s, 3H), 4.19 (s, 3H), 7.48 (ddd, J = 8.8, 8.8, 2.4 Hz, 1H), 
7.64 (dd, J = 8.4, 4.4 Hz, 1H), 8.62 (dd, J = 9.6, 2.4 Hz, 1H), 10.41 (br, 1H); 13C NMR 
(100 MHz, CDCl3) δ 53.68, 53.71, 112.7, 113.1, 119.3, 119.9, 121.5, 137.3, 138.4, 146.4, 
157.7, 160.1, 165.7, 166.1; HRMS (ESI) m/z 326.0546 ([M + Na]+, 100%), calc’d for 
C14H10FN3O4Na 326.0553. 
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Dimethyl 8-cyano-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_46). Prepared according to General 
Procedure A, starting with 1H-indole-5-carbonitrile (800 mg, 1.0 
eq, 5.63 mmol) and III_2 (2.23 g, 2.0 eq, 11.25 mmol). 
Purification by flash chromatography (DCM:EtOAc, 1:1, Rf 0.21, 1.35 g) gave III_46 
(4.35 mmol, 77% yield) as a light yellow solid: mp, 225-227 oC; IR (neat) 3353, 2953, 
2834, 1734, 1657, 1445, 1214, 1036, 760 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.20 (s, 3H), 
4.23 (s, 3H), 7.81 (d, J = 8.6 Hz, 1H), 7.97 (d, J = 8.6 Hz, 1H), 9.41 (s, 1H), 10.60 (br, 
NH); 13C NMR (100 MHz, DMSO with TFA) δ 53.1, 53.4, 104.4, 115.0, 117.6, 119.5, 
119.8, 131.1, 132.9, 137.2, 138.3, 143.7, 146.1, 164.1, 165.4; HRMS (ESI) m/z 311.0781 
([M + H]+, 100%), calc’d for C15H10N4O4 311.0780. 
 
 
1,4-Dimethyl 5-methyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate. Prepared according to General Procedure A, 
starting with 1-methyl-1H-indole (150 mg, 1.0 eq, 1.14 mmol) and 
III_2 (453 mg, 2.0 eq, 2.29 mmol). Purification by flash 
chromatography (DCM:EtOAc, 2:1, Rf 0.30, 315 mg) gave the desired product (1.05 mmol, 
92% yield) as a yellow solid: mp, 247-248 oC, decomposition; IR (neat) 3005, 2954, 1728, 
1442, 1208, 1095, 739, 651 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.96 (s, 3H), 4.15 (s, 3H), 
4.18 (s, 3H), 7.43 (ddd, J = 10.6, 10.6, 1.6 Hz, 1H), 7.54 (ddd, J = 11.0, 1.2, 1.2 Hz, 1H), 
7.71 (ddd, J = 10.6 10.6, 1.6 Hz, 1H), 8.76 (ddd, J = 11.0, 1.2, 1.2 Hz, 1H); 13C NMR (100 
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MHz, CDCl3) δ 32.6, 53.5, 53.7, 110.1, 118.1, 120.8, 122.8, 126.4, 130.9, 135.4, 140.4, 
142.8, 146.1, 165.9, 166.1; HRMS (ESI) m/z 322.0808 ([M + Na]+, 100%), calc’d for 
C15H13N3O4Na 322.0804. 
 
 
Dimethyl 9-bromo-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate. Prepared according to General Procedure A, 
starting with 4-bromo-1H-indole (200 mg, 1.0 eq, 1.02 mmol) and 
III_2 (404 mg, 2.0 eq, 2.04 mmol). Purification by flash 
chromatography (DCM:EtOAc, 1:1, Rf 0.44, 323 mg) gave the desired product (0.89 mmol, 
87% yield) as a yellow oil paste: IR (neat) 3344, 2953,1743, 1614, 1448, 1209, 1163. 785, 
734 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.12 (s, 3H), 4.15 (s, 3H), 7.48 (dd, J = 8.0, 8.0 
Hz, 1H), 7.60 (dd, J = 12.0, 0.8 Hz, 1H), 7.62 (dd, J = 12.0, 0.8 Hz, 1H), 10.61 (br, NH); 
13C NMR (100 MHz, CDCl3) δ 53.6, 53.8, 112.0, 117.4, 118.2, 118.7, 128.1, 131.4, 136.6, 
137.0, 141.8, 149.8, 166.0, 166.9; HRMS (ESI) m/z 363.9907 ([M + H]+, 100%), calc’d 
for C14H11N3O4Br 363.9933. 
 
 
Dimethyl 6-bromo-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate. Prepared according to General Procedure A, 
starting with 7-bromo-1H-indole (200 mg, 1.0 eq, 1.02 mmol) and 
III_2 (404 mg, 2.0 eq, 2.04 mmol). Purification by flash 
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chromatography (DCM:EtOAc, 1:1, Rf 0.23, 298 mg) gave the desired product (0. 82mmol, 
73% yield) as a yellow solid: mp, 224-226 oC; 1H NMR (400 MHz, DMSO) δ 4.09 (s, 3H), 
4.11 (s, 3H), 7.77-7.85 (overlap, 2H), 8.74 (s, 1H), 12.59 (br, NH); 13C NMR (100 MHz, 
DMSO) δ 52.8, 53.0, 114.0, 115.3, 119.0, 119.1, 127.5, 132.9, 136.3, 137.7, 140.4, 145.6, 
164.0, 165.3; HRMS (ESI) m/z 363.9924 ([M + H]+, 100%), calc’d for C14H11N3O4Br 
363.9933. 
 
 
Dimethyl 7-bromo-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate. Prepared according to General Procedure A, 
starting with 6-bromo-1H-indole (220 mg, 1.0 eq, 1.12 mmol) 
and III_2 (445 mg, 2.0 eq, 2.24 mmol). Purification by flash 
chromatography (DCM:EtOAc, 1:1, Rf 0.31, 311 mg) gave the desired product (0. 85mmol, 
76% yield) as a yellow solid: mp, 223-224 oC; IR (neat) 3431, 2953, 2509, 2257, 1729, 
1610, 1444, 1137, 462 cm-1; 1H NMR (400 MHz, DMSO) δ 4.10 (s, 3H), 4.11 (s, 3H), 7.58 
(dd, J = 8.8, 1.6 Hz, 1H), 8.03 (d, J = 1.6 Hz, 1H), 8.50 (d, J = 8.8 Hz, 1H), 12.57 (br, NH); 
13C NMR (100 MHz, DMSO) δ 53.7, 53.9, 116.7, 117.2, 120.4, 124.3, 125.9, 127.9, 137.3, 
138.3, 143.3, 146.4, 165.0, 166.2; HRMS (ESI) was not obtained.  
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Dimethyl 1-benzyl-2-(dimethylamino)-1H-imidazo[4,5-
d]pyridazine-4,7-dicarboxylate. Prepared according to General 
Procedure A, starting with 1-benzyl-N,N-dimethyl-1H-imidazol-
2-amine (51 mg, 1.0 eq, 0.25 mmol) and III_2 (100 mg, 2.0 eq, 0.51 
mmol). Purification by flash chromatography (DCM:EtOAc, 1:1, Rf 0.37, 56 mg) gave the 
desired product (0. 0.15 mmol, 60% yield) as a yellow oil: IR (neat) 3441, 2954, 1733, 
1606, 1545, 1443, 1205, 1132, 1021, 700 cm-1; 1H NMR (400 MHz, DMSO) δ 3.21 (s, 
6H), 3.74 (s, 3H), 4.10 (s, 3H), 5.51 (s, 2H), 6.75 (ddd, J = 2.2, 2.2, 2.2 Hz, 2H), 7.20-7.21 
(overlap, 3H) ; 13C NMR (100 MHz, CDCl3) δ 42.3 (2C), 51.1, 53.3, 126.3, 128.5, 129.2, 
134.9, 135.3, 139.3, 142.1, 143.2, 164.4, 165.0; HRMS (ESI) was not obtained.  
 
 
Dimethyl 8-methyl-5-tosyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_48). Prepared according to General 
Procedure E, starting with III_43 (400 mg, 1.0 eq, 1.34 mmol). 
Purification by flash chromatography (DCM:EtOAc, 4:1, Rf 0.75, 
558 mg) gave III_48 (1.23 mmol, 92% yield) as a yellow solid: 
mp, 194-196 oC; IR (neat) 2954, 2940, 2360, 2342, 1738, 1731, 1378, 1166, 668, 541 -1cm; 
1H NMR (400 MHz, CDCl3) δ 2.26 (s, 3H), 2.47 (s, 3H), 4.12 (s, 3H), 4.15 (s, 3H), 7.08 
(d, J = 8.4 Hz, 2H), 7.49 (dd, J = 8.8, 1.2 Hz, 1H), 7.52 (d, J = 8.4 Hz, 2H), 8.08 (d, J = 
8.8 Hz, 1H), 8.32 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 21.6, 21.7, 53.6, 53.8, 115.9, 
121.7, 125.4, 125.9, 127.3 (2C), 130.1 (2C), 133.5, 134.6, 136.1, 138.4, 145.7, 146.4, 
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146.9, 165.2, 165.3; HRMS (ESI) m/z 454.1085 ([M + H]+, 100%), calc’d for C22H19N3O6S 
454.1073. 
 
 
Dimethyl 8-methoxy-5-tosyl-5H-pyridazino[4,5-b]indole-
1,4-dicarboxylate (III_49). Prepared according to General 
Procedure E, starting with III_44 (450 mg, 1.0 eq, 1.43 mmol). 
Purification by flash chromatography (DCM:EtOAc, 10:1, Rf 
0.32, 630 mg) gave III_49 (1.34 mmol, 94% yield) as a light 
yellow paste; IR (neat) 3006, 2955, 1737, 1439, 1203, 1168, 1040, 734, 586 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 2.26 (s, 3H), 3.88 (s, 3H), 4.136 (s, 3H), 4.142 (s, 3H), 7.07 (d, J = 
8.0 Hz, 2H), 7.28 (dd, J = 9.2, 2.8 Hz, 1H), 7.49 (d, J = 8.0 Hz, 2H), 8.10-8.14 (overlap, 
2H); 13C NMR (100 MHz, CDCl3) δ 21.3, 53.7, 53.8, 55.9, 108.2, 117.2, 121.3, 122.8, 
125.8, 127.2 (2C), 130.1 (2C), 133.2, 134.6, 135.0, 145.9, 146.4, 146.9, 157.9, 165.1, 
165.3; HRMS (ESI) m/z 470.1032 ([M + H]+, 100%), calc’d for C22H19N3O7S 470.1022. 
 
 
Dimethyl 8-fluoro-5-tosyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_50). Prepared according to General Procedure 
E, starting with III_45 (450 mg, 1.0 eq, 1.65 mmol). Purification 
by flash chromatography (DCM:EtOAc, 5:1, Rf 0.35, 425 mg) gave 
III_50 (1.57 mmol, 95% yield) as a light yellow paste: IR (neat) 
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2955, 2360, 1736, 1593, 1477, 1380, 1167, 735, 583 cm-1; 1H NMR (400 MHz, CDCl3) δ 
2.28 (s, 3H), 4.14 (s, 3H), 4.15 (s, 3H), 7.10 (d, J = 8.0 Hz, 2H),  7.43 (ddd, J = 8.0, 8.0, 
2.6 Hz, 1H), 7.52 (d, J = 8.0 Hz, 2H), 8.19 (dd, J = 8.8, 4.0 Hz, 1H), 8.37 (dd, J = 8.8, 2.6 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 21.8, 53.8, 53.9, (112.6, 112.9, 120.0, 120.3, 1C), 
(117.5, 117.6, 1C), 123.0, 125.2, 127.3 (2C), 130.2 (2C), 133.2, 135.3, 136.49, 136.51, 
146.0, 146.7, 146.8, 159.2, 161.6, 164.9, 165.0; HRMS (ESI) m/z 458.0842 ([M + H]+, 
100%), calc’d for C21H16FN3O6S 458.0822. 
 
 
Dimethyl 5-((4-methoxyphenyl)sulfonyl)-8-methyl-5H-
pyridazino[4,5-b]indole-1,4-dicarboxylate (III_53). Prepared 
according to General Procedure E, starting with III_43 (670 mg, 
1.0 eq, 2.24 mmol). Purification by flash chromatography 
(DCM:EtOAc, 4:1, Rf 0.68, 934 mg) gave III_53 (1.99 mmol, 
89% yield) as a yellow solid: mp, 163-165 oC; IR (neat) 2953, 
2360, 1738, 1593, 1166, 1088, 732, 587 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.48 (s, 3H), 
3.74 (s, 3H), 4.14 (s, 3H), 4.16 (s, 3H), 6.73 (ddd, J = 8.8, 2.0, 2.0 Hz, 2H), 7.50 (dd, J = 
8.4, 1.2 Hz, 1H), 7.60 (ddd, J = 8.8, 2.0, 2.0 Hz, 2H), 8.10 (d, J = 8.4 Hz, 1H), 8.33 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ 21.7, 53.6, 53.7, 55.8, 114.7 (2C), 115.9 121.7, 125.4, 
127.7, 129.7 (2C), 133.4, 136.1, 138.5, 145.7, 146.9, 164.6, 165.3, 165.4; HRMS (ESI) m/z 
470.1022 ([M + H]+, 100%), calc’d for C22H19N3O7S 470.1022. 
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Dimethyl 5-((4-fluorophenyl)sulfonyl)-8-methoxy-5H-
pyridazino[4,5-b]indole-1,4-dicarboxylate (III_56). Prepared 
according to General Procedure E, starting with III_44 (400 
mg, 1.0 eq, 1.27 mmol). Purification by flash chromatography 
(DCM:EtOAc, 5:1, Rf 0.39, 437 mg) gave III_58 (0.92 mmol, 
73% yield) as a light yellow oil: IR (neat) 3106, 2955, 2360, 1738, 1589, 1484, 1204, 1169, 
1040, 734, 586 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.88 (s, 3H), 4.13 (s, 3H), 4.14 (s, 3H), 
6.97 (dd, J = 8.4, 8.4 Hz, 2H), 7.29 (ddd, J = 9.0, 1.6, 1.6 Hz, 1H), 7.66 (m, 2H), 8.09-8.11 
(overlap, 2H); 13C NMR (100 MHz, CDCl3) δ 53.7, 53.9, 55.9, 108.4, 116.8, 117.1, 121.5, 
122.9, 125.9, 130.2 (2C), 132.1, 134.3, 134.8, 145.8, 146.8, 158.1, 164.6, 165.1 (2C), 
168.0; HRMS (ESI) m/z 474.0772 ([M + H]+, 100%), calc’d for C21H16FN3O7S 474.0771. 
 
 
Dimethyl 5-(phenylsulfonyl)-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_58) Prepared according to General Procedure 
E, starting with III_4 (600 mg, 1.0 eq, 2.10 mmol). Purification by 
flash chromatography (DCM:EtOAc, 4:1, Rf 0.75, 795 mg) gave 
III_58 (1.83 mmol, 90% yield) as a white solid: mp, 183-184 oC; IR 
(neat) 3091, 2953, 2852, 1735, 1440, 1176, 1042, 909, 729 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 4.12 (s, 3H), 4.15 (s, 3H), 7.33 (dd, J = 7.8, 7.8 Hz, 2H), 7.45-7.50 (overlap, 2H), 
7.66-7.70 (overlap, 2H), 8.18 (d, J = 8.8 Hz, 1H), 8.57 (d, J = 8.0 Hz, 1H); 13C NMR (100 
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MHz, CDCl3) δ 53.7, 53.8, 116.1, 121.5, 125.4, 126.1, 126.4, 127.2 (2C), 129.5 (2C), 
132.1, 134.4, 135.1, 136.5, 140.1, 145.6, 146.9, 165.1, 165.2; HRMS (ESI) m/z 426.0751 
([M + H]+, 100%), calc’d for C20H15N3O6S 426.0760. 
 
 
Dimethyl 8-methyl-5-(phenylsulfonyl)-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate (III_59) Prepared according to 
General Procedure E, starting with III_43 (600 mg, 1.0 eq, 2.00 
mmol). Purification by flash chromatography (DCM:EtOAc, 4:1, 
Rf 0.72, 558 mg) gave III_59 (1.76 mmol, 88% yield) as a light 
yellow solid: mp, 175-177 oC; IR (neat) 2953, 2306, 2342, 1735, 1377, 1218, 1165, 726, 
590 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.48 (s, 3H), 4.13 (s, 3H), 4.16 (s, 3H), 7.32 (dd, 
J = 8.0, 8.0 Hz, 2H), 7.47-7.52 (overlap, 2H), 7.67 (d, J = 8.0 Hz, 2H), 8.09 (d, J = 8.8 Hz, 
1H), 8.34 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 21.7, 53.7, 53.8, 115.9, 121.7, 125.4, 
126.1, 127.2, 129.5, 133.5, 134.6, 135.0, 136.3, 136.5, 138.4, 145.7, 146.9, 165.2, 165.3; 
HRMS (ESI) m/z 440.0920 ([M + H]+, 100%), calc’d for C21H17N3O6S 440.0916. 
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Dimethyl 8-methoxy-5-(phenylsulfonyl)-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate (III_60). Prepared according to 
General Procedure E, starting with III_44 (450 mg, 1.0 eq, 
1.43 mmol). Purification by flash chromatography 
(DCM:EtOAc, 5:1, Rf 0.41, 572 mg) gave III_60 (1.26 mmol, 
88% yield) as a light yellow paste: IR (neat) 2954, 2839, 1737, 1483, 1440, 1203, 729, 587 
cm-1; 1H NMR (400 MHz, CDCl3) δ 3.87 (s, 3H), 4.13 (s, 3H), 4.14 (s, 3H), 7.26-7.32 
(overlap, 3H), 7.47 (dd, J = 7.4, 7.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 2H), 8.09-8.13 (overlap, 
2H); 13C NMR (100 MHz, CDCl3) δ 53.7, 53.8, 55.9, 108.3, 117.2, 121.3, 122.8, 125.8, 
127.2 (2C), 129.5 (2C), 134.5, 135.0, 136.2, 145.9, 146.8, 158.0, 165.1, 165.2; HRMS 
(ESI) m/z 456.0853 ([M + H]+, 100%), calc’d for C21H17N3O7S 456.0865. 
 
 
Dimethyl 8-fluoro-5-(phenylsulfonyl)-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate (III_61). Prepared according to 
General Procedure E, starting with III_45 (450 mg, 1.0 eq, 1.48 
mmol). Purification by flash chromatography (DCM:EtOAc, 5:1, 
Rf 0.48, 553 mg) gave III_61 (1.24 mmol, 84% yield) as a white 
solid: mp 181-182 oC; IR (neat) 2955, 2245, 1733, 1379, 1164, 1040, 726, 564 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 4.13 (s, 3H), 4.15 (s, 3H), 7.31 (dd, J = 8.0, 8.0 Hz, 2H), 7.43 
(ddd, J = 8.8, 8.8, 2.8 Hz, 1H), 7.51 (dd, J = 7.6, 7.6 Hz, 1H), 8.18 (dd, J = 4.8, 4.8 Hz, 
1H), 8.37 (dd, J = 9.6, 2.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 53.7, 53.9, (112.7, 
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113.0, 120.1, 120.4, 1C), 117.5, 123.0, 124.4, 125.2, 127.2 (2C), 129.6 (2C), 135.2, 136.2, 
136.41, 136.42, 140.2, 145.9, 146.0, 146.7, 159.2, 161.7, 164.9, 165.0; HRMS (ESI) m/z 
444.0681 ([M + H]+, 100%), calc’d for C20H14FN3O6S 444.0666. 
 
 
Dimethyl 8-fluoro-5-(m-tolylsulfonyl)-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate (III_65). Prepared according to 
General Procedure E, starting with III_45 (500 mg, 1.0 eq, 1.65 
mmol). Purification by flash chromatography (DCM:EtOAc, 5:1, 
Rf 0.48, 641 mg) gave III_50 (1.40 mmol, 85% yield) as a light 
yellow paste: IR (neat) 2955, 2245, 1735, 1476, 1166, 1043, 733, 595 cm-1; 1H NMR (400 
MHz, CDCl3) δ 2.30 (s, 3H), 4.17 (s, 3H), 4.20 (s, 3H), 7.26-7.30 (m, 1H), 7.37 (d, J = 7.2 
Hz, 1H), 7.45-7.52 (overlap, 3H), 8.21 (m, 1H), 8.42 (ddd, J = 9.2, 2.8, 2.8 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 21.4, 53.7, 53.9, (112.6, 112.9, 120.0, 120.3, 1C), (117.4, 117.5, 
1C), 123.0, 124.4, 125.1, 127.4 (2C), 129.4 (2C), 135.2, 136.1, 136.40, 136.41, 140.2, 
145.9, 146.0, 146.7, 146.8, 159.1, 161.6, 164.9, 165.0; HRMS (ESI) m/z 458.0820 ([M + 
H]+, 100%), calc’d for C21H16FN3O6S 458.0822. 
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Dimethyl 5-benzoyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_66). Prepared according to General Procedure 
E, starting with III_44 (700 mg, 1.0 eq, 2.45 mmol). Purification 
by flash chromatography (DCM:EtOAc, 10:1, Rf 0.22, 849 mg) 
gave III_66 (2.18 mmol, 88% yield) as a yellow oil: IR (neat) 2955, 2236, 1714 1599, 
1401, 1208, 1084, 908, 726, 645 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.81 (s, 3H), 4.21 (s, 
3H), 7.26 (m, 1H), 7.46-7.55 (overlap, 4H), 7.72 (dd, J = 7.6, 7.6 Hz, 1H), 7.90 (d, J = 7.6, 
Hz, 2H), 8.33 (d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 53.3, 53.8, 108.1, 113.7, 
119.5, 123.3, 124.6, 126.6,  129.6 (2C), 130.5 (2C), 131.5, 133.1, 135.0, 135.9, 141.1, 
142.3, 147.1, 164.6, 165.6, 168.7; HRMS (ESI) m/z 390.1080 ([M + H]+, 100%), calc’d 
for C21H15N3O5 390.1090. 
 
 
Dimethyl 5-benzoyl-8-methyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_67). Prepared according to General 
Procedure E, starting with III_43 (450 mg, 1.0 eq, 1.50 mmol). 
Purification by flash chromatography (DCM:EtOAc, 4:1, Rf 0.60, 
516 mg) gave III_67 (1.28 mmol, 85% yield) as a light yellow solid: mp, 180-182 oC; IR 
(neat) 2952, 2360, 2342, 1733, 1716, 1440, 1218, 918, 752 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 2.51 (s, 3H), 3.81 (s, 3H), 4.22 (s, 3H), 7.11 (d, J = 8.8 Hz, 1H), 7.35 (ddd, J = 
8.4, 0.4, 0.4 Hz, 1H), 7.51-7.59 (overlap, 2H), 7.71 (dd, J = 7.2, 7.2 Hz, 1H), 7.91 (dd, J = 
8.0, 1.6, Hz, 2H), 8.55 (d, J = 0.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 21.6, 53.3, 53.7, 
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113.4, 119.6, 123.2, 126.1, 129.5 (2C), 130.5 (2C), 132.9, 133.3, 134.5, 134.9, 135.9, 
139.4, 142.4, 147.1, 164.7, 165.7, 168.8; HRMS (ESI) m/z 404.1259 ([M + H]+, 100%), 
calc’d for C22H17N3O5 404.1246. 
 
 
Dimethyl 5-benzoyl-8-methoxy-5H-pyridazino[4,5-b]indole-
1,4-dicarboxylate (III_68). Prepared according to General 
Procedure E, starting with III_44 (600 mg, 1.0 eq, 1.90 mmol). 
Purification by flash chromatography (DCM:EtOAc, 5:1, Rf 
0.26, 721 mg) gave III_68 (1.72 mmol, 90% yield) as a bright yellow oil: IR (neat) 3129, 
3001, 2951, 2236, 1728, 1706, 1203, 1094, 915, 725, 646 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 3.81 (s, 3H), 3.93 (s, 3H), 4.21 (s, 3H), 7.15 (overlap, 2H), 7.53 (dd, J = 7.6, 7.6 
Hz, 2H), 7.71 (dd, J = 7.6, 7.6 Hz, 1H), 7.79 (d, J = 7.6, Hz, 2H), 8.33 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ 53.4, 53.8, 56.0, 108.1, 114.5, 120.4, 121.2, 123.4, 129.6 (2C), 130.5 
(2C), 133.2, 134.9, 135.8, 136.0, 142.5, 146.9, 156.9, 164.6, 165.7, 168.7; HRMS (ESI) 
m/z 420.1185 ([M + H]+, 100%), calc’d for C22H17N3O6 420.1196. 
 
 
Dimethyl 5-benzoyl-8-fluoro-5H-pyridazino[4,5-b]indole-1,4-
dicarboxylate (III_69). Prepared according to General 
Procedure E, starting with III_45 (400 mg, 1.0 eq, 1.32 mmol). 
Purification by flash chromatography (DCM:EtOAc, 5:1, Rf 0.35,  
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425 mg) gave III_69 (1.04 mmol, 79% yield) as a light yellow paste: IR (neat) 2954, 2242, 
1728, 1450, 1260, 1168, 1089, 916, 724 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.80 (s, 3H), 
4.22 (s, 3H), 7.25-7.34 (overlap, 2H), 7.54 (dd, J = 8.0, 8.0 Hz, 2H), 7.71-7.78 (overlap, 
3H), 8.60 (ddd, J = 9.6, 0.8, 0.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 53.4, 53.9, (112.6, 
112.8, 119.7, 119.9, 1C), (114.7, 114.8, 1C), (120.6, 120.7, 1C), 123.0, 129.7 (2C), 130.5 
(2C), 133.0, 135.2, 136.5, 137.5, 142.6, 147.0, 158.4, 160.8, 164.5, 165.4, 168.4; HRMS 
(ESI) m/z 408.0998 ([M + H]+, 100%), calc’d for C21H14FN3O5 408.0996. 
 
 
Dimethyl 8-methyl-5-(m-tolylsulfonyl)-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate (III_63). Prepared according to 
General Procedure E, starting with III_43 (530 mg, 1.0 eq, 1.77 
mmol). Purification by flash chromatography (DCM:EtOAc, 4:1, 
Rf 0.77, 763 mg) gave III_63 (1.68 mmol, 95% yield) as a light 
yellow solid: mp, 195-197 oC; IR (neat) 2954, 2360, 2342, 1737, 
1438, 1378, 1219, 1166, 1047, 598 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.30 (s, 3H), 2.47 
(s, 3H), 4.11 (s, 3H), 4.15 (s, 3H), 7.19 (dd, J = 8.0, 8.0 Hz, 1H), 7.27 (d, J = 8.0, 1H), 
7.44-7.50 (overlap, 3H), 8.05 (d, J = 8.4 Hz, 1H), 8.32 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 21.4, 21.6, 53.6, 53.8, 115.8, 121.6, 124.4, 125.2, 125.9, 127.4, 129.3, 133.4, 
134.5, 135.8, 136.1, 136.4, 138.3, 140.0, 145.6, 146.9, 165.1, 165.3; HRMS (ESI) m/z 
454.1064 ([M + H]+, 100%), calc’d for C22H19N3O6S 454.1073. 
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Dimethyl 9-(methylsulfonyl)-9H-carbazole-1,4-dicarboxylate. 
Prepared according to General Procedure E, starting with III_4 
(600 mg, 1.0 eq, 2.10 mmol), electrophiles (1.2 eq), TEA (2.0 eq), 
NaH (2.0 eq). Purification by flash chromatography (DCM:EtOAc, 
5:1, Rf 0.57, 430 mg) gave the desired product (1.10 mmol, 53% yield) as a brown solid: 
mp, 183-185 oC; IR (neat) 3009, 2966, 1730, 1375, 1307,1172, 1045, 974, 736 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 3.69 (s, 3H), 4.12 (s, 3H), 4.18 (s, 3H), 7.48 (dd, J = 7.8, 7.8 
Hz, 1H), 7.70 (ddd, J = 8.1, 7.8, 1.2 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 8.64 (d, J = 7.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 38.1, 49.7, 49.8 110.8, 116.3, 119.8, 121.3, 122.3, 
127.8, 129.7, 135.7, 139.8, 143.1, 161.2, 162; HRMS (ESI) m/z 364.0603, ([M + H]+, 
100%), calc’d for C15H13N3O6S 364.0603. 
 
 
5.4 Experimental for Chapter IV 
 
General Procedure A, 
Preparation of Substituted 
Maleimides IV_86: To a solution of maleimide (1.2 eq), alcohol (1.0 eq) and 
triphenylphosphine (1.2 eq) in THF (0.1 M) was added DIAD (1.2 eq) at 0 oC. The reaction 
mixture was allowed to warm up to room temperature and continued to stir for 20 hours. 
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The solvent was removed in vacuo and the residue was purified by flash chromatography 
to yield desired maleimides IV_86.  
 
 
General Procedure B, 
Preparation of Enantioenriched 
Cycloadducts (IV_91) of 
Anthrone and Substituted Maleimides (IV_86): Mix anthrone (1.0 eq), maleimide (1.2 
eq) and catalyst IV_102 (0.1 eq) in anhydrous chloroform at room temperature. The 
reaction mixture was continued to stir for 12 hours (TLC monitored to completion). The 
solvent was removed in vacuo and the residue was purified by flash chromatography to 
yield desired cycloadducts (IV_91).  
 
 
General Procedure C, 
Regioselective Grignard 
Additions of Cycloadducts 
(IV_91): To a solution of cycloadducts IV_91 (1.0 eq) in chloroform (0.1M), Grignard 
reagent (3 or 4.0 eq) was added at -78 oC slowly. The reaction mixture was allowed to 
warm up to room temperature and continued to stir for 18 hours (TLC monitored to 
completion). Then the reaction was cooled to 0 oC, and quenched with saturated ammonium 
chloride solution. The mixture was extracted with ethyl acetate and DCM for three times 
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respectively. The organic layers were combined and the solvent was removed in vacuo, the 
residue was purified by flash chromatography to yield the desired intermediate product 
IV_104.  
 
 
General Procedure D, Intramolecular 
Cycloaddition of Grignard Addition 
Intermediate Products (IV_104): To a 
solution of Grignard addition intermediate products IV_104 (1.0 eq) in DCE (0.1M), 
trifluoroacetic acid (20.0 eq) was injected at 0 oC slowly. The reaction mixture was allowed 
to warm up to room temperature and continued to stir for 7 hours (TLC monitored to 
completion). Then the reaction was cooled to 0 oC, and diluted with DCM. The mixture 
was stirred for another 10 minutes. The solvent was removed in vacuo, the residue was 
purified by flash chromatography to yield the desired intramolecular cycloadducts IV_105 
 
 
General Procedure E, Retro-Diels-Alder 
Cycloreversion of IV_134 to Give Alkaloid 
Structures (IV_106): To a solution of 
intramolecular cycloadducts (IV_105) (1.0 eq) in THF (0.1M), KH (suspension in mineral 
oil, 60%, 4.0 eq) was added at 0 oC slowly. The reaction mixture was allowed to warm up 
to room temperature and continued to stir for 10 minutes (TLC monitored to completion). 
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Then the reaction was cooled to 0 oC, and quenched with water. The mixture was extracted 
with ethyl acetate and DCM for three times respectively. The organic layers were combined 
and the solvent was removed in vacuo, the residue was purified by flash chromatography 
to yield the desired cycloreversion products IV_106.  
 
 
1-(3,4-Dimethoxyphenethyl)-1H-pyrrole-2,5-dione (IV_86e). 
Prepared according to General Procedure A, beginning with 
maleimide (480 mg, 4.94 mmol, 1.2 eq) and 2-(3,4-
dimethoxyphenyl)ethanol (750 mg, 4.12mmol, 1.0 eq). Purification by flash 
chromatography (hexanes:EtOAc, 3:1, Rf 0.29) gave IV_86e (1.05 g, 4.02 mmol, 98% 
yield) as a light yellow solid: mp 198-199 °C; IR (neat) 3092, 2952, 2837, 1699, 1515, 
1030, 693 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.82 (t, J = 6.5 Hz, 2H), 3.72 (t, J = 6.5 Hz, 
2H), 3.82 (s, 3H), 3.84 (s, 3H), 6.63 (s, 2H), 6.68 (s, 2H), 6.71 (d, J = 7.5 Hz, 1H), 6.75 (d, 
J = 7.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 34.1, 39.2, 56.0 (overlap, 2C), 111.4, 
112.0, 120.953, 130.4, 134.2 (2C), 147.9, 149.0, 170.7; HRMS (ESI) m/z 262.1070 ([M + 
1]+, 100%), calculated for C14H15NO4 262.1079. 
 
 
1-(3,4,5-Trimethoxyphenethyl)-1H-pyrrole-2,5-dione 
(IV_86f). Prepared according to General Procedure A, 
beginning with maleimide (412 mg, 4.24 mmol, 1.2 eq) and 2-
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(3,4,5-trimethoxyphenyl)ethanol (750 mg, 3.53 mmol, 1.0 eq). Purification by flash 
chromatography (hexanes:EtOAc, 3:1, Rf 0.21) gave IV_86f (1.00 g, 3.43 mmol, 97% 
yield) as a white solid: mp 203-204 °C; IR (neat) 3081, 2944, 1708, 1410, 1233, 1141, 848, 
696 cm-1; 1H NMR (500 MHz, CDCl3) δ 2.83 (t, J = 7.8 Hz, 2H), 3.74 (t, J = 7.8 Hz, 2H), 
3.80 (s, 3H), 3.83 (s, 3H), 6.40 (s, 2H), 6.66 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 22.1, 
34.9, 39.1, 56.3, 61.0, 105.8 (2C), 133.5, 134.2 (2C), 136.9, 153 .4 (2C), 170.7 (2C); 
HRMS (ESI) m/z 292.1188 ([M + H]+, 100%), calculated for C15H17NO5 292.1185. 
 
 
1-(4-Methoxyphenethyl)-1H-pyrrole-2,5-dione (IV_86g). 
Prepared according to General Procedure A, beginning with 
maleimide (612 mg, 6.31 mmol, 1.2 eq) and 2-(4-
methoxyphenyl)ethanol (800 mg, 5.26 mmol, 1.0 eq). Purification by flash 
chromatography (hexanes:EtOAc, 3:1, Rf 0.53) gave IV_86g (1.18 g, 5.10 mmol, 97% 
yield) as a white solid: mp 128-129 °C; IR (neat) 3089, 2943, 2843, 1698, 1512, 1029, 817 
cm-1; 1H NMR (400 MHz, CDCl3) δ 2.81 (t, J = 7.6 Hz, 2H), 3.69 (t, J = 7.6 Hz, 2H), 3.75 
(s, 3H), 6.62 (s, 2H), 6.79 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H); 13C NMR (100 
MHz, CDCl3) δ 33.7, 39.4, 55.3, 114.0 (2C), 129.87 (2C), 129.92, 134.1 (2C), 158.5, 170.7 
(2C); HRMS was not obtained. 
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1-(2-(1H-Indol-3-yl)ethyl)-1H-pyrrole-2,5-dione (IV_86h). 
Prepared according to General Procedure A, beginning with 
maleimide (564 mg, 5.81 mmol, 1.2 eq) and 2-(1H-indol-3-yl)ethanol 
(780 mg, 4.84mmol, 1.0 eq). Purification by flash chromatography (hexanes:EtOAc, 3:1, 
Rf 0.51) gave IV_86h (1.10 g, 4.58 mmol, 95% yield) as a yellow solid: mp 175-176 °C; 
IR (neat) 3408, 3099, 2943, 1699, 1408, 1141, 744, 695 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 3.05 (t, J = 8.0 Hz, 2H), 3.82 (t, J = 8.0 Hz, 2H), 6.64 (s, 2H), 7.04 (s, 1H), 7.12 (dd, J = 
7.8, 7.2 Hz, 1H), 7.18 (dd, J = 7.8, 7.2 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.65 (d, J = 7.8 
Hz, 1H), 7.97 (br s, NH); 13C NMR (100 MHz, CDCl3) δ 24.2, 38.3, 111.0, 112.1, 118.6, 
119.4, 121.8, 122.0, 127.2, 133.9 (2C), 136.0, 170.6 (2C); HRMS (ESI) m/z 241.0988 ([M 
+ H]+, 100%), calculated for C14H12N2O2 241.0977. 
 
 
(11R,15R)-9-Hydroxy-13-(4-methoxyphenethyl)-
9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (IV_91g). Prepared according to General 
Procedure B, starting with anthrone (1.0 g, 1.0 eq, 
5.15 mmol) and IV_86g (1.43 mg, 1.2 eq, 6.18 mmol), purification by flash 
chromatography (hexanes:EtOAc, 3:1, Rf 0.50) gave IV_91 (2.15 g, 5.05 mmol, 98% yield) 
as a white solid: mp 161 °C; IR (neat) 3505, 2951, 2836, 1688, 1513, 1155, ,908, 725 cm-
1; 1H NMR (400 MHz, CDCl3) δ 1.81-1.91 (overlap, 2H), 3.08 (d, J = 8.6 Hz, 1H), 3.18-
3.25 (overlap, 2H), 3.29 (dd, J = 8.6, 3.4 Hz, 1H), 3.74 (s, 3H), 4.53 (br s, OH), 4.74 (d, J 
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= 3.4 Hz, 1H), 6.77 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8.6 Hz, 2H), 7.11-7.29 (overlap, 5H), 
7.36 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.69 (d, J = 7.6 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 32.0, 40.0, 44.7, 47.6, 50.6, 55.4, 114.0, 120.9, 121.2, 123.8, 124.8, 126.9, 
127.0, 127.2, 127.3, 129.7, 136.8, 139.1, 141.1, 142.6, 158.5, 176.3, 177.8; HRMS,  (ESI) 
m/z 448.1530 ([M + Na]+, 100%), calculated for C27H23NO4Na 448.1525. 
 
 
(11R,15R)-13-(3,4-Dimethoxyphenethyl)-9-
hydroxy-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (IV_91e). 
Prepared according to General Procedure B, starting 
with anthrone (1.0 g, 1.0 eq, 5.15 mmol) and IV_86e (1.61 g, 1.2 eq, 6.18 mmol), 
purification by flash chromatography (hexanes:EtOAc, 3:1, Rf  0.17) gave IV_91e (2.30 g, 
5.05 mmol, 98% yield) as a light yellow solid: mp 167-168 °C; IR (neat) 3502, 2941, 2836, 
2254, 1689, 1155, 726 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.82-1.88 (overlap, 2H), 3.08 
(d, J = 8.5 Hz, 1H), 3.21-3.25 (overlap, 2H), 3.28 (dd, J = 8.5, 3.3 Hz, 1H), 3.80 (s, 3H), 
3.81 (s, 3H), 4.55 (br s, OH), 4.74 (d, J = 3.3 Hz, 1H), 6.56 (d, J = 1.9 Hz, 1H), 6.59 (dd, 
J = 8.1, 1.9 Hz, 1H), 6.72 (d, J = 8.1 Hz, 1H), 7.11-7.29 (overlap, 5H), 7.35 (d, J = 7.2 Hz, 
1H), 7.52 (d, J = 7.6 Hz, 1H), 7.68 (d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
32.5, 39.9, 44.7, 47.5, 50.6, 55.92, 55.94, 77.4, 111.3, 111.8, 120.7, 120.8, 121.1, 123.8, 
124.7, 126.8, 126.9, 127.1, 127.3, 130.1, 136.7, 139.0, 141.0, 142.5, 147.8, 149.0, 176.3, 
177.7; HRMS (ESI) m/z 456.1829 ([M + H]+, 100%), calculated for C28H25NO5 456.1811. 
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(11R,15R)-9-Hydroxy-13-(3,4,5-
trimethoxyphenethyl)-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (IV_91f). 
Prepared according to General Procedure B, starting 
with anthrone (1.0 g, 1.0 eq, 5.15 mmol) and IV_86f (1.80 g, 1.2 eq, 6.18 mmol), 
purification by flash chromatography (hexanes:EtOAc, 3:1, Rf 0.14) gave IV_91f (2.37 g, 
4.90 mmol, 95% yield) as a colorless oil: IR (neat) 3497, 2941, 2840, 2359, 1690, 1590, 
1458, 1127, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.79-1.85 (overlap, 2H), 3.09 (d, J = 
8.4 Hz, 1H), 3.22-3.27 (overlap, 2H), 3.31 (dd, J = 8.4, 3.6 Hz, 1H), 3.77 (s, 3H), 3.81 (s, 
6H), 4.49 (br s, OH), 4.74 (d, J = 3.6 Hz, 1H), 6.26 (s, 2H), 7.11-7.29 (overlap, 5H), 7.36 
(d, J = 7.2 Hz, 1H), 7.51 (d, J = 7.2 Hz, 1H), 7.68 (d, J = 7.6 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 33.3, 39.9, 44.8, 47.6, 50.7, 56.3 (2C), 60.9, 77.3, 105.6, 120.9, 121.1, 123.9, 
124.8, 126.95, 127.04, 127.2, 127.4, 133.3, 136.76, 136.84, 139.1, 141.1, 142.5, 153.4, 
176.4, 177.9; HRMS (ESI) m/z 486.1933 ([M + H]+, 100%), calculated for C29H27NO6 
486.1917. 
 
 
(11R,15R)-13-(2-(1H-Indol-3-yl)ethyl)-9-hydroxy-9,10-
dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione 
(IV_91h). Prepared according to General Procedure B, 
starting with anthrone (1.0 g, 1.0 eq, 5.15 mmol) and IV_86h 
(1.48 g, 1.2 eq, 6.18 mmol), purification by flash chromatography (hexanes:EtOAc, 3:1, Rf 
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0.30) gave IV_91h (2.24 g, 4.95 mmol, 96% yield) as a light yellow solid: mp 221-222 °C; 
IR (neat) 3415, 2949, 1688, 1458, 1161, 737 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.03-
2.10 (overlap, 2H), 3.08 (d, J = 8.6 Hz, 1H), 3.30 (dd, J = 8.6, 3.4 Hz, 1H), 3.33-3.38 
(overlap, 2H), 4.53 (br s, OH), 4.75 (d, J = 3.4 Hz, 1H), 6.89 (s, 1H), 7.09-7.20 (overlap, 
5H), 7.26-7.37 (overlap, 4H), 7.51-7.55 (overlap, 2H), 7.69 (d, J = 7.2 Hz, 1H), 7.90 (br s, 
NH); 13C NMR (100 MHz, CDCl3) δ 22.7, 39.0, 44.8, 47.6, 50.7, 77.4, 111.2, 112.2, 118.9, 
119.7, 120.9, 121.2, 121.8, 122.4, 123.9, 124.8, 126.9, 127.0, 127.3, 127.4, 136.3, 136.8, 
139.2, 141.1, 142.6, 176.5, 178.0; HRMS (ESI) m/z 435.1694 ([M + H]+, 100%), calculated 
for C28H22N2O3 435.1709. 
 
 
(9R,10R,11R,12R,15R)-13-(3,4-Dimethoxyphenethyl)-
10,12-dihydroxy-12-methyl-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-14-one (IV_104a). Prepared 
according to General Procedure C, starting with IV_91e 
(1.0 g, 1.0 eq, 2.20 mmol) and methyl Grignard reagent (3.0 eq), purification by flash 
chromatography (hexanes:EtOAc, 3:1, Rf 0.31) gave IV_104a (100% conversion) as a 
yellow oil: IR (neat) 3472, 2938, 2835, 1662, 1515, 1262, 909, 725 cm-1; 1H NMR (500 
MHz, CDCl3) δ 1.39 (s, 3H), 1.89 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.23 (ddd, J = 12.5, 
12.5, 5.0 Hz, 1H), 2.79-2.82 (overlap, 2H), 2.87 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.98 (d, 
J = 10.0 Hz, 1H), 3.24 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 3.83 (s, 3H), 3.84 (s, 3H), 4.64 (d, 
J = 3.0 Hz, 1H), 5.35 (br s, OH), 6.58-6.62 (overlap, 2H), 6.74 (d, J = 8.0 Hz, 1H), 7.14-
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7.27 (overlap, 4H), 7.33 (d, J = 7.0 Hz, 1H), 7.38 (d, J = 7.0 Hz, 1H), 7.66-7.68 (overlap, 
2H); 13C NMR (125 MHz, CDCl3) δ 28.6, 34.7, 40.9, 43.9, 49.5, 52.2, 55.9 (2C), 90.6, 
111.2, 111.8, 120.6, 120.7, 122.7, 123.2, 123.5, 126.3, 126.6, 127.0, 127.4, 131.2, 138.3, 
140.1, 143.1, 143.8, 147.6, 148.9, 172.3; HRMS (ESI) m/z,  ([M + Na]+, 100%) 494.1941, 
calculated for C29H29NO5Na 494.1943. 
 
 
(9R,10R,11R,12S,15R)-13-(3,4-Dimethoxyphenethyl)-
10,12-dihydroxy-12-phenyl-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-14-one (IV_104b). Prepared 
according to General Procedure C, starting with IV_91e 
(1.0 g, 1.0 eq, 2.20 mmol) and methyl Grignard reagent (4.0 eq), purification by flash 
chromatography (hexanes:EtOAc, 3:1, Rf 0.31) gave IV_104b as a pink oil: IR (neat) 3538, 
3471, 3068, 2937, 2835, 1668, 1515, 1263, 1143, 727 cm-1; 1H NMR (500 MHz, CDCl3) δ 
1.84 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.08 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.58 (ddd, J 
= 12.5, 12.5, 5.0 Hz, 1H), 2.97 (dd, J = 10.0, 3.0 Hz, 1H), 3.12 (d, J = 10.0 Hz, 1H), 3.15 
(br s, OH), 3.23 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 3.77 (s, 3H), 3.78 (s, 3H), 4.71 (d, J = 
3.0 Hz, 1H), 5.35 (br s, OH), 6.46-6.47 (overlap, 2H), 6.66 (d, J = 8.0 Hz, 1H), 7.09 (ddd, 
J = 7.5, 7.5, 1.5 Hz, 1H), 7.19 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.21-7.34 (overlap, 8H), 7.47 
(dd, J = 7.0, 1.0 Hz, 1H), 7.64 (d, J = 7.0 Hz, 1H), 7.72 (dd, J = 7.0, 1.0 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 34.7, 42.3, 44.1, 51.8, 52.7, 55.9, 56.0, 77.6, 93.2, 111.3, 111.8, 120.6, 
120.8, 123.0, 123.4, 123.6, 124.3, 124.6, 126.4, 126.7, 127.2, 127.6, 128.5, 128.9 (2C), 
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131.2, 138.5, 139.9, 143.2, 143.8, 144.0, 147.6, 148.9, 173.4 ; HRMS (ESI) m/z,  ([M + 
H]+, 100%) 534.2260, calculated for C34H31NO5 534.2280. 
 
 
(9R,10R,11R,12R,15R)-10,12-Dihydroxy-12-methyl-13-
(3,4,5-trimethoxyphenethyl)-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-14-one (IV_104c). Prepared 
according to General Procedure C, starting with IV_91f 
(1.0, 1.0 eq, 2.06 mmol) and methyl Grignard reagent (3.0 
eq), purification by flash chromatography (hexanes:EtOAc, 3:1, Rf 0.09) gave IV_104c 
(100% conversion) as a light yellow oil: IR (neat) 3447, 2936, 2839, 1658, 1457, 1127, 
727 cm-1; 1H NMR (500 MHz, CDCl3) δ 1.37 (s, 3H), 1.83 (ddd, J = 12.5, 12.5, 5.0 Hz, 
1H), 2.18 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.77-2.79 (overlap, 2H), 2.85 (ddd, J = 12.5, 
12.5, 5.0 Hz, 1H), 2.95 (d, J = 10.0 Hz, 1H), 3.22 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 3.76 
(s, 3H), 3.78 (s, 6H), 4.61 (d, J = 3.0, 1H), 5.29 (br s, OH), 6.26 (s, 2H), 7.10-7.24 (overlap, 
4H), 7.29 (d, J = 7.5 Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 7.62-7.63 (overlap, 2H); 13C NMR 
(125 MHz, CDCl3) δ 28.6, 35.5, 40.8, 43.9, 49.5, 52.2, 56.2 (2C), 60.8, 77.4, 90.6, 105.6, 
120.7, 122.7, 123.2, 123.5, 126.3, 126.6, 127.0, 127.4, 134.3, 136.6, 138.3, 140.1, 143.1, 
143.8, 153.2 (2C), 172.3; HRMS (ESI) m/z 524.2048 ([M + Na]+, 100%), calculated for 
C30H31NO6 524.2049. 
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(9R,10R,11R,12S,15R)-10,12-Dihydroxy-12-phenyl-13-
(3,4,5-trimethoxyphenethyl)-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-14-one (IV_104d). Prepared 
according to General Procedure C, starting with IV_91f 
(1.0 g, 1.0 eq, 2.06 mmol) and phenyl Grignard reagent (4.0 
eq), purification by flash chromatography (hexanes:EtOAc, 3:1, Rf 0.12) gave IV_104d 
(100% conversion) as a light yellow oil: IR (neat) 3531, 3451, 2938, 2838, 1667, 1457, 
1126, 907, 729 cm-1; 1H NMR (500 MHz, CDCl3) δ 1.84 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 
2.10 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.62 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.99 (dd, J = 
10.0, 3.0 Hz, 1H), 3.14 (d, J = 10.0 Hz, 1H), 3.27 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 3.76 
(s, 3H), 3.77 (s, 6H), 4.74 (d, J = 3.0 Hz, 1H), 5.35 (br s, OH), 6.19 (s, 2H), 7.11 (ddd, J = 
7.5, 7.5, 1.5 Hz, 1H), 7.20-7.36 (overlap, 9H), 7.50 (dd, J = 7.0, 1.0 Hz, 1H), 7.66 (d, J = 
7.0 Hz, 1H), 7.73 (dd, J = 7.0, 1.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 35.5, 42.0, 
44.1, 51.8, 52.6 (2C), 60.8, 77.6, 93.3, 105.5 (2C), 120.8, 122.9, 123.4, 123.6, 124.6 (2C), 
126.4, 126.7, 127.2, 127.6, 128.6, 129.0 (2C), 134.2, 136.6, 138.5, 139.8, 143.1, 143.7, 
144.0, 153.2 (2C), 173.4; HRMS (ESI) m/z 546.2291, ([M – H2O]+, 100%), calculated for 
C35H31NO5 546.2280. 
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(8aR,9R,14R,14aR,14bR)-9-Hydroxy-2,3-dimethoxy-14b-methyl-
5,8a,9,14,14a,14b-hexahydro-9,14-
[1,2]benzenobenzo[5,6]isoindolo[1,2-a]isoquinolin-8(6H)-one 
(IV_105a). Prepared according to General Procedure D, starting 
with IV_104a  and CF3COOH (20.0 eq), purification by flash 
chromatography (hexanes : EtOAc, 3:1, Rf 0.06) gave IV_105a (97% yield over two steps) 
as a brown oil: IR (neat) 3455, 2955, 2251, 1663, 1510, 1458, 1252, 910, 728 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 1.61 (s, 3H), 2.40 (dd, J = 12.0, 2.8 Hz, 1H), 2.84-2.93 (overlap, 
3H), 3.11 (d, J = 8.4, Hz, 1H), 3.78 (s, 3H), 3.85 (s, 3H), 3.90 (dd, J = 9.6, 4.4 Hz, 1H), 
4.64 (d, J = 1.6 Hz, 1H), 5.01 (br s, OH), 6.42 (s, 1H), 6.59 (s, 1H), 7.10-7.20 (overlap, 
4H), 7.31 (d, J = 5.6 Hz, 1H), 7.35 (d, J = 5.6 Hz, 1H), 7.57-7.59 (overlap, 2H); 13C NMR 
(125 MHz, CDCl3) 24.8, 26.9, 35.2, 45.8, 50.0, 52.4, 56.0, 56.5, 63.4, 77.4, 108.5, 112.0, 
120.7, 121.4, 122.8, 125.1, 125.6, 126.1, 126.2, 126.3, 126.4, 136.1, 138.7, 141.8, 143.9, 
144.0, 147.8, 148.2, 174.5; HRMS (ESI) m/z,  ([M + H]+, 100%) 454.2010, calculated for 
C29H28NO4 454.2018. 
 
 
(8aR,9R,14R,14aR,14bS)-9-Hydroxy-2,3-dimethoxy-14b-phenyl-
5,8a,9,14,14a,14b-hexahydro-9,14-
[1,2]benzenobenzo[5,6]isoindolo[1,2-a]isoquinolin-8(6H)-one 
(IV_105b). Prepared according to General Procedure D, starting 
with IV_104b and CF3COOH (20.0 eq), purification by flash 
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chromatography (hexanes : EtOAc, 3:1, Rf 0.31) gave IV_105b as a pink oil: IR (neat) 
3538, 3471, 3068, 2937, 2835, 1668, 1515, 1263, 1143, 727 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 1.84 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.08 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 
2.58 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 2.97 (dd, J = 10.0, 3.0 Hz, 1H), 3.12 (d, J = 10.0 
Hz, 1H), 3.15 (br s, OH), 3.23 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H), 3.77 (s, 3H), 3.78 (s, 3H), 
4.71 (d, J = 3.0 Hz, 1H), 5.35 (br s, OH), 6.46-6.47 (overlap, 2H), 6.66 (d, J = 8.0 Hz, 1H), 
7.09 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.19 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.21-7.34 (overlap, 
8H), 7.47 (dd, J = 7.0, 1.0 Hz, 1H), 7.64 (d, J = 7.0 Hz, 1H), 7.72 (dd, J = 7.0, 1.0 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ 34.7, 42.3, 44.1, 51.8, 52.7, 55.9, 56.0, 77.6, 93.2, 111.3, 
111.8, 120.6, 120.8, 123.0, 123.4, 123.6, 124.3, 124.6, 126.4, 126.7, 127.2, 127.6, 128.5, 
128.9 (2C), 131.2, 138.5, 139.9, 143.2, 143.8, 144.0, 147.6, 148.9, 173.4 ; HRMS (ESI) 
m/z,  ([M + H]+, 100%) 534.2260, calculated for C34H31NO5 534.2280. 
 
 
 (8aR,9R,14R,14aR,14bR)-9-Hydroxy-2,3,4-trimethoxy-14b-
methyl-5,8a,9,14,14a,14b-hexahydro-9,14-
[1,2]benzenobenzo[5,6]isoindolo[1,2-a]isoquinolin-8(6H)-one 
(IV_105c). Prepared according to General Procedure D, starting with 
IV_104c and CF3COOH (20.0 eq), purification by flash chromatography (hexanes:EtOAc, 
3:1, Rf 0.11) gave IV_105c (94% yield over two steps) as a light yellow oil: IR (neat) 3444, 
2940, 1663, 1457, 1131, 1104, 909, 728 cm-1; 1H NMR (500 MHz, CDCl3) δ 1.56 (s, 3H), 
2.38 (d, J = 15.0 Hz, 1H), 2.74-2.88 (overlap, 2H), 2.92 (d, J = 11.0 Hz, 1H), 3.12 (d, J 
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=11.0 Hz, 1H), 3.76 (s, 3H), 3.79 (s, 3H), 3.92 (dd, J = 12.5, 6.0 Hz, 1H), 4.10 (s, 1H), 4.69 
(s, 1H), 5.12 (br s, OH), 6.24 (s, 1H), 7.06-7.19 (overlap, 4H), 7.31-7.34 (overlap, 2H), 
7.56 (d, J = 7.3 Hz, 1H), 7.59 (d, J = 7.3 Hz, 1H) ; 13C NMR (125 MHz, CDCl3) δ 23.0, 
28.1, 35.2, 45.7, 49.0, 52.6, 56.0, 60.8, 60.9, 63.0, 77.2, 107.4, 120.5, 121.4, 122.9, 126.0, 
126.1, 126.2, 126.3, 128.2, 129.6, 139.6, 140.6, 142.2, 143.8, 144.6, 150.1, 152.7, 174.0;  
HRMS (ESI) m/z,  ([M + H]+, 100%) 484.2137, calculated for C30H30NO5 484.2124. 
 
 
(8aR,9R,14R,14aR,14bS)-9-Hydroxy-2,3,4-trimethoxy-14b-phenyl-
5,8a,9,14,14a,14b-hexahydro-9,14-
[1,2]benzenobenzo[5,6]isoindolo[1,2-a]isoquinolin-8(6H)-one 
(IV_105d). Prepared according to General Procedure D, starting with 
IV_104d and CF3COOH (20.0 eq), purification by flash chromatography (hexanes:EtOAc, 
3:1, Rf 0.11) gave IV_105d (87% yield over two steps) purification by flash 
chromatography (hexanes:EtOAc, 3:1, Rf 0.14) gave IV_105d (87% yield over two steps) 
as a light yellow oil: 1H NMR (500 MHz, CDCl3) δ 2.34 (m, 1H), 2.79-2.92 (overlap, 2H), 
3.11 (d, J = 11.5 Hz, 1H), 3.69 (dd, J = 11.5, 1.5 Hz, 1H), 3.77 (s, 3H), 3.89 (s, 3H), 3.98 
(m, 1H), 4.11 (s, 3H),  4.18 (d, J = 1.5 Hz, 1H), 5.91 (d, J = 7.0 Hz, 1H), 6.26 (s, 1H), 6.70 
(dd, J = 7.5, 7.5 Hz, 1H), 7.03 (dd, J = 7.5, 7.5 Hz, 1H),  7.07-7.11 (overlap, 2H), 7.15 (dd, 
J = 7.5, 7.5 Hz, 1H), 7.22 (d, J = 7.0 Hz, 1H), 7.53-7.56 (overlap, 2H); 13C NMR (125 
MHz, CDCl3) 28.0, 36.1, 45.7, 48.6, 52.6, 56.0, 60.8, 61.3, 70.0, 107.8, 120.2, 120.8, 122.8, 
125.7, 125.8, 126.0, 126.4, 127.0, 128.2, 128.8, 129.6, 138.8, 139.4, 141.0, 142.4, 142.9, 
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145.8, 150.5, 152.9, 174.0; HRMS (ESI) m/z,  ([M + H]+, 100%) 546.2269, calculated for 
C35H31NO5 546.2280. 
 
 
(R)-8,9-Dimethoxy-10b-methyl-6,10b-dihydropyrrolo[2,1-
a]isoquinolin-3(5H)-one. Prepared according to General 
Procedure E, starting with IV_105a and NaH (3.0 eq), purification 
by flash chromatography (DCM:MeOH (10%), Rf 0.52) gave 
IV_106a Rf 0.52) as a light yellow oil: IR (neat) 3479, 2933, 1674, 1517, 1258, 1144, 811 
cm-1; 1H NMR (400 MHz, CDCl3) δ 1.57 (s, 3H), 2.63 (dd, J = 15.5, 4.0 Hz, 1H), 2.90 (m, 
1H), 3.20 (ddd, J = 13.0, 13.0, 4.5 Hz, 1H), 3.81 (s, 3H), 3.86 (s, 3H), 4.40 (dd, J = 13.0, 
6.5 Hz, 1H), 6.07 (d, J = 6.0 Hz, 1H), 6.57 (s, 1H), 6.67 (s, 1H), 7.32 (d, J = 6.0 Hz, 1H); 
13C NMR (125 MHz, CDCl3) 26.9, 29.4, 34.8, 56.0, 56.3, 65.7, 109.2, 112.2, 125.2, 125.4, 
129.4, 147.8, 148.3, 153.3, 170.3; HRMS (ESI) m/z,  ([M + H]+, 100%) 260.1283, 
calculated for C15H18NO3 260.1287; []D +190.0 (c, 1.0, CHCl3). 
 
 
(S)-8,9-Dimethoxy-10b-phenyl-6,10b-dihydropyrrolo[2,1-
a]isoquinolin-3(5H)-one (IV_106b). Prepared according to 
General Procedure E, starting with IV_105b and NaH (3.0 eq), 
purification by flash chromatography (hexanes : EtOAc, 3:1, Rf 0.10) 
gave IV_106b as a light yellow oil: IR (neat) 2936, 1684, 1516, 1448, 1257, 1228, 1019, 
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914, 730 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.64 (d, J = 12.8 Hz, 1H), 2.93-3.02 (overlap, 
2H), 3.82 (s, 3H), 3.87 (s, 3H), 4.16 (dd, J = 5.2, 5.2 Hz, 1H), 6.27 (d, J = 4.4 Hz, 1H), 
6.68 (s, 1H), 6.69 (s, 1H), 7.03-7.06 (overlap, 2H), 7.24-7.28 (overlap, 3H), 7.47 (d, J = 
4.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) 28.7, 34.9, 56.1, 56.3, 71.1, 111.0, 112.2, 126.0, 
126.8, 127.2, 127.3, 128.3, 128.8, 139.7, 147.5, 148.8, 152.4, 171.6; HRMS (ESI) m/z,  
([M + H]+, 100%) 322.1449, calculated for C20H20NO3 322.1443; []D -212.0 (c, 1.0, 
CHCl3).  
 
 
(R)-7,8,9-Trimethoxy-10b-methyl-6,10b-dihydropyrrolo[2,1-
a]isoquinolin-3(5H)-one (IV_106c). Prepared according to General 
Procedure E, starting with IV_105c and NaH (3.0 eq), purification 
by flash chromatography (DCM:MeOH, 20:1, Rf 0.45) gave IV_106c 
as a colorless oil: IR (neat) 2938, 1691, 1492, 1410, 1116, 1022, 812 cm-1; 1H NMR (500 
MHz, CDCl3) δ 1.58 (s, 3H), 2.63 (dd, J = 16.0, 4.0 Hz, 1H), 2.89 (m, 1H), 3.15 (ddd, J = 
13.0, 13.0, 4.5, 1H), 3.80 (overlap, 6H), 4.00 (s, 3H), 4.38 (dd, J = 13.5, 6.5 Hz, 1H), 6.04 
(d, J = 6.0, 1H), 6.38 (s, 1H), 7.66 (d, J = 6.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 24.7, 
30.1, 34.2, 56.0, 60.7, 60.8, 65.2, 107.7, 123.0, 124.9, 129.3, 140.5, 151.2, 152.8, 153.4, 
170.1; HRMS (ESI) m/z,  ([M + H]+, 100%) 290.1394, calculated for C16H20NO4 290.1392; 
.[]D +178.0 (c, 1.0, CHCl3). 
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(S)-7,8,9-Trimethoxy-10b-phenyl-6,10b-dihydropyrrolo[2,1-
a]isoquinolin-3(5H)-one (IV_106d). Prepared according to 
General Procedure E, starting with IV_105d and NaH (3.0 eq), 
purification by flash chromatography (DCM:MeOH, 20:1, Rf 0.29) 
gave IV_106d as a light yellow oil: IR (neat) 2938, 2841, 1693, 1599, 1492, 1132, 813, 
732 cm-1; 1H NMR (500 MHz, CDCl3) δ 2.65 (d, J = 12.5 Hz, 1H), 2.94 (overlap, 2H), 3.48 
(s, 3H), 3.80 (s, 3H), 3.85 (s, 3H), 4.16 (dd, J = 13.0, 6.0 Hz, 1H), 6.24 (d, J = 5.5 Hz, 1H), 
6.49 (s, 1H), 7.03-7.05 (overlap, 2H), 7.24-7.28 (overlap, 3H), 7.89 (d, J = 5.5 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ 29.5, 34.3, 56.0, 60.2, 60.8, 70.4, 107.5, 121.3, 125.8, 
126.7, 128.1, 128.5, 130.6, 140.4, 140.6, 151.5, 152.9, 153.4, 170.8; HRMS (ESI) m/z, ([M 
+ H]+, 100%) 352.1541, calculated for C21H22NO4 352.1549; .[]D -201.0 (c, 1.0, CHCl3). 
 
 
(R)-11b-Methyl-5,6,11,11b-tetrahydro-3H-indolizino[8,7-b]indol-3-
one (IV_106g). Prepared according to General Procedure E, starting 
with IV_105g and NaH (3.0 eq), purification by flash chromatography 
(DCM:MeOH, 20:1, Rf 0.23) gave IV_106g as a light yellow oil: IR 
(neat) 3404, 2938, 2841, 1693, 1421, 1152, 815, 737 cm-1; 1H NMR (500 MHz, CDCl3) δ 
1.68 (s, 3H), 2.79 (dd, J = 15.0, 5.0 Hz, 1H), 2.89 (ddd, J = 15.0, 11.2, 6.0 Hz, 1H), 3.25 
(ddd, J = 13.2, 11.2, 5.0 Hz, 1H), 4.60 (dd, J = 13.2, 6.0 Hz, 1H), 6.17 (d, J = 6.0 Hz, 1H), 
7.12 (m, 1H), 7.20 (m, 1H), 7.32 (d, J = 6.0 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.48 (d, J = 
7.8 Hz, 1H), 7.99 (br, NH); 13C NMR (100 MHz, CDCl3) δ 21.9, 24.5, 35.6, 64.4, 107.6, 
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111.0, 118.8, 119.8, 122.4, 125.9, 126.6, 133.8, 136.3, 151.5, 171.1; []D +272.0 (c, 1.0, 
CHCl3). 
 
 
(9R,10R,11R,12R,15R)-13-(3,4-Dimethoxyphenethyl)-
10,12-dihydroxy-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-14-one (IV_107). To a solution 
of IV_91e in anhydrous THF (0.1 M) was injected DIBAL 
at -78 oC slowly. The reaction mixture was allowed to warm up to room temperature and 
continued to stir for 3 hours till completion. The reaction was quenched by the addition of 
NH4Cl (0.1 M), and was extracted using EtOAc and DCM for three times. The organic 
extracts were combined, washed with water, brine and dried over anhydrous sodium 
sulfate. The filtrate was collected and the solvent was removed in vacuo. The residue was 
purified by flash chromatography (hexanes:EtOAc, 3:1, Rf 0.10) to give IV_107 (100% 
conversion) as a light yellow oil: 1H NMR (500 MHz, CDCl3) δ 2.22 (m, 1H), 2.35-2.41 
(overlap, 2H), 2.81-2.92 (overlap, 2H), 3.05-3.14 (overlap, 2H), 3.75 (s, 3H), 3.76 (s, 3H), 
4.53 (s, 1H), 4.97 (m, 1H), 5.13 (br s, OH), 5.22, (d, J = 3.0 Hz, 1H), 6.51-6.53 (overlap, 
2H), 6.65 (d, J = 8.0 Hz, 1H), 7.06-7.29 (overlap, 6H), 7.55-7.56 (overlap, 2H); 13C NMR 
(125 MHz, CDCl3) δ 33.7, 41.7, 42.6, 43.4, 52.9, 56.0 (2C), 77.3, 84.5, 111.3, 111.8, 120.6, 
120.7, 122.7, 123.3, 126.4, 126.7, 127.1, 127.5, 130.9, 139.1, 140.2, 143.6, 143.8, 147.8, 
149.1, 172.8; HRMS (ESI) m/z, ([M + Na]+, 100%) 480.1765, calculated for C28H27NO5Na 
480.1787. 
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(8aR,9R,14R,14aR,14bR)-9-Hydroxy-2,3-dimethoxy-
5,8a,9,14,14a,14b-hexahydro-9,14-
[1,2]benzenobenzo[5,6]isoindolo[1,2-a]isoquinolin-8(6H)-one 
(IV_108). Prepared according to General Procedure D, starting with 
IV_107  and CF3COOH (20.0 eq), purification by flash 
chromatography (hexanes : EtOAc, 3:1, Rf 0.13) gave IV_108 (94% yield over two steps) 
as a pink brown oil: 1H NMR (500 MHz, CDCl3) δ 2.47 (dd, J = 14.0, 4.5 Hz, 1H), 2.57 
(ddd, J = 14.0, 14.0, 4.5 Hz, 1H), 2.80 (m, 1H), 2.93 (d, J = 10.0, Hz, 1H), 3.02 (ddd, J = 
10.0, 3.0, 3.0 Hz, 1H), 3.15 (br s, OH), 3.82 (s, 3H), 3.92-3.96 (overlap, 4H), 4.13 (d, J = 
3.0 Hz, 1H), 4.47 (d, J = 3.0 Hz, 1H), 5.16 (br s, OH), 6.52 (s, 1H), 6.74 (s, 1H),  7.14-7.17 
(overlap, 2H), 7.21-7.26 (overlap, 2H), 7.35 (d, J = 7.0 Hz, 1H), 7.39 (d, J = 7.0 Hz, 1H), 
7.62 (d, J = 7.0 Hz, 1H), 7.65 (d, J = 7.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) 27.6, 
37.3, 45.9, 48.5, 53.4, 56.0, 56.5, 59.9, 77.0, 107.7, 112.0,  120.4, 121.4, 123.4, 124.7, 
125.9, 126.2, 126.5, 126.6, 126.9, 129.0, 137.7, 140.2, 142.8, 143.9, 148.3, 148.4, 171.6; 
HRMS (ESI) m/z, ([M + H]+, 100%) 440.1881, calculated for C28H25NO4 440.1862. []D 
+253.0 (c, 1.0, CHCl3). 
 
 
(R)-8,9-Dimethoxy-6,10b-dihydropyrrolo[2,1-a]isoquinolin-
3(5H)-one (IV_109). Prepared according to General Procedure E, 
starting with IV_108 but with NaOH (3.0 eq) instead of NaH, 
purification by flash chromatography (DCM:MeOH, 20:1, Rf 0.12)  
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gave IV_109 (15% yield over two steps, unstable, decomposed rapidly on silica gel) as a 
pink brown oil: 1H NMR (500 MHz, CDCl3) δ 2.87 (m, 2H), 3.35 (dt, J = 13.0, 4.0 Hz, 
2H), 3.87 (s, 3H), 3.90 (s, 3H), 4.29 (dd, J = 13.0, 6.0 Hz, 1H), 6.08 (d, J = 6.0 Hz, 1H), 
6.61 (s, 1H), 6.97 (s, 1H), 7.30 (d, J = 6.0 Hz, 1H). The compound is not stable enough for 
further characterization. 
 
 
(R)-8,9-Dimethoxy-10b-methyl-1,2,3,5,6,10b-
hexahydropyrrolo[2,1-a]isoquinoline (IV_114). Pd/C (10% wt.) 
was added into the solution of IV_106a in THF (0.1 M) at room 
temperature, the reaction mixture was stirred with a hydrogen balloon for 24 hours. The 
reaction mixture as filtered with Celite and the solvent of the filtrate was removed in vacuo. 
The crude residue was redissolve in anhydrous THF (0.1 M), and LiAlH4 (2.0 eq) was 
added into the mixture slowly at 0 oC. The reaction was refluxed in THF for 3 hours and 
continued to stir for 15 hours at room temperature. The reaction was quenched by the 
addition of NH4Cl (1.0 M), and extracted with EtOAc for 3 times. The organic extracts 
were combined and the solvent was removed in vacuo. The residue was purified by 
chromatography to give IV_114 as a white solid: mp, 87-89 oC; 1H NMR (400 MHz, 
CDCl3) δ 1.76 (m, 1H), 1.94 (m, 2H), 2.37 (m, 1H), 2.71 (m, 3H), 3.06 (m, 2H), 3.20 (m, 
1H), 3.53 (t, J = 8.0 Hz, 1H), 3.87 (s, 6H), 6.59 (s, 1H), 6.63 (s, 1H); 13C NMR (100 MHz, 
CDCl3) 22.3, 27.8, 30.6, 48.2, 53.1, 55.9, 56.0, 62.8, 108.9, 111.3, 126.1, 130.5, 147.3, 
147.4; HRMS was not obtained. []D +53.0 (c, 1.0, CHCl3). 
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5.5 Addendum 
 
 
Scheme 2.24  Intramolecular IEDDA Reaction of Amide III_85ba 
 
 
 
 
Entry Temperature Solvent Time II_86 (%) 
1 W, 160 °C diglyme 20 min 0, no reaction 
2 W, 160 °C DMF 20 min 0, no reaction 
3 W, 200 °C diglyme 20 min 0, decomposition 
4 W, 200 °C DMF 20 min 0, decomposition 
5 W, 180 °C diglyme 20 min 0, decomposition 
6 W, 180 °C DMF 20 min 0, decomposition 
7 thermal, 160 °C diphenyl ether 12 h, 24 h 0, no reaction 
8 thermal, 200 °C diphenyl ether 12 h 0, unknownb 
 a UPLC conversions. 
 b Detected two distinct mass signals with unknown structure.  
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Scheme 2.27  Intramolecular IEDDA Reaction of Triazine II_93 
 
 
 
Entry Temperature Solvent Time II_94 (%) 
1 thermal, 160 °C diglyme 72 h 0, no reaction 
2 thermal, 180 °C diphenyl ether 12, 24 h 0, no reaction 
3 thermal, 200 °C diphenyl ether 12, 24 h 0, no reaction 
4 thermal, 250 °C diphenyl ether 4, 7, 24 h 0, decomposition 
5 W, 160 °C diglyme 30, 90 min 0, no reaction 
6 W, 200 °C diglyme 30, 90 min 0, no reaction 
7 W, 220 °C, SiC diglyme 30 min 0, decomposition 
a UPLC conversions. 
  
274 
 
(N1,N4-Dibenzyl-5H-pyridazino[4,5-b]indole-1,4-
dicarboxamide (III_21). Prepared according to General 
Procedure C, starting with III_4 (50 mg, 1.0eq, 0.18 mmol) 
and benzylamine (excess, more than 4 eq)) with 
trimethylaluminum (excess, more than 4 eq). Purification by 
flash chromatography (DCM:EtOAc, 8:1, Rf = 0.74) gave 
III_21 (73 mg, 0.17 mmol, 96% yield) as a white solid: H NMR (400 MHz, CDCl3) δ 4.76 
(d, J = 6.0 Hz, 2H), 4.82 (d, J = 6.0 Hz, 2H), 7.26-7.43 (overlap, 10H), 8.60 (t, J = 6.0 Hz, 
1H), 8.75 (t, J = 6.0 Hz, 1H), 9.44 (d, J = 8.0 Hz, 1H), 10.81(br, NH). 
 
 
Methyl 4-(cyclohexylcarbamoyl)-8-methoxy-5H-
pyridazino[4,5-b]indole-1-carboxylate. Prepared according 
to General Procedure C, starting with III_44. Purification by 
flash chromatography gave it as a light yellow oil: H NMR (400 
MHz, CDCl3) δ 0.77-2.02 (overlap, 10H), 3.92 (s, 3H), 4.82 (m, 1H), 4.15 (s, 3H), 7.31 
(dd, J = 8.8, 2.4 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 8.27 (d, J = 8.8 Hz, 1H), 8.37 (d, J = 
2.4 Hz, 1H), 10.67 (br, NH). 13C NMR (100 MHz, CDCl3) 24.9 (2C), 25.7, 33.1 (2H), 48.6, 
53.6, 56.1, 108.0, 113.1, 119.1, 121.7, 121.9, 136.4, 137.0, 138.3, 146.3, 155.9, 163.7, 
166.1. 
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Methyl 8-bromo-4-(methyl(prop-2-yn-1-yl)carbamoyl)-5H-
pyridazino[4,5-b]indole-1-carboxylate. Prepared according to 
General Procedure C, starting with dimethyl 8-bromo-5H-
pyridazino[4,5-b]indole-1,4-dicarboxylate. Purification by flash chromatography gave the 
desired as a yellow brown oil: 1H NMR (400 MHz, CDCl3) δ (2.24, t, 2.30, t, J = 2.4 Hz, 
rotamers, 1H), (3.34, s, 3.75, s, rotamers, 2H), 4.21 (s, 3H), (4.49, d, 5.22, d, J = 2.4 Hz, 
rotamers, 2H), (7.48, d, 7.50, d, J = 4.0 Hz, rotamers, 1H), (7.58, d, 7.78, d, J = 2.0 Hz, 
1H), 9.11 (d, J = 2.0 Hz, 1H), (10.63, br, 10.65, br, rotamers, NH); 13C NMR (100 MHz, 
CDCl3, assumed rotamer pairs in parentheses) δ (35.0, 37.6), (38.5, 41.2), 53.5, (72.5, 
73.2), (77.9, 78.3),  113.6, 115.6, 120.2, 129.4, 133.6, 137.5 139.5, (141.4, 141.5), (145.2, 
145.3), 164.8, 165.3. 
 
 
Methyl 4-(benzylcarbamoyl)-5-tosyl-5H-pyridazino[4,5-
b]indole-1-carboxylate. Starting with III_20 (1.0 eq), TsCl 
(2.0 eq) and TEA (excess), the reaction mixture was refluxed 
for 24 hours in DCM (0.1 M). The solvent was removed in vacuo, the residue was purified 
by flash chromatography to give the desired product. H NMR (400 MHz, CDCl3) δ 2.38 
(s, 3H), 4.18 (s, 3H), 4.79 (d, J = 5.6 Hz, 2H), 7.25-7.50 (overlap, 7H), 7.55 (t, J = 5.6 Hz, 
1H), 7.65 (ddd, J = 8.0, 0.8 Hz, 1H), 7.88 (d, J = 8.0 Hz, 2H), 7.95 (d, J = 8.0 Hz, 1H) 8.68 
(d, J = 8.0 Hz, 1H). 
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Dimethyl 5-((4-Methoxyphenyl)sulfonyl)-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate. Prepared according to General 
Procedure E, starting with III_4. Purification gave shown product 
as a yellow solid: 1H NMR (400 MHz, CDCl3) δ 3.71 (s, 3H), 4.12 
(s, 3H), 4.14 (s, 3H), 6.73 (d, J = 9.2 Hz, 2H), 7.45 (dd, J = 8.4, 8.4 
Hz, 1H), 7.61-7.66 (overlap, 3H), 8.17 (d, J = 8.4 Hz, 1H), 8.54 (d, J = 8.4 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 53.6, 53.8, 55.8, 114.7 (2C), 116.1, 121.4, 125.3, 125.9, 126.3, 
127.6, 129.7 (2C), 132.0, 134.3, 140.1, 145.6, 146.9, 164.7, 165.2. 
 
 
Dimethyl 5-((4-Nitrophenyl)sulfonyl)-5H-pyridazino[4,5-
b]indole-1,4-dicarboxylate. Prepared according to General 
Procedure E, starting with III_4 and 4-nitrobenzenesulfonyl 
chloride. Purification by flash chromatography gave the desired 
product as a light yellow solid: 1H NMR (300 MHz, CDCl3) δ 4.13 
(s, 3H), 4.16 (s, 3H), 7.54 (dd, J = 7.2, 7.2, 1H), 7.74 (dd, J = 7.7, 7.2, 1H), 7.95 (d, J = 
9.3, 2H), 8.15-8.21 (overlap, 3H), 8.64 (d, J = 7.7, 1H); 13C NMR (75 MHz, CDCl3) δ 53.9, 
54.0, 115.9, 121.6, 124.8 (2C), 125.7, 126.7, 126.9, 128.7 (2C), 132.6, 134.3, 139.8, 141.9, 
145.3, 147.1, 151.2, 164.9, 165.0. 
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(8aR,9R,14R,14aR,14bR)-14b-Butyl-9-hydroxy-2,3-dimethoxy-
5,8a,9,14,14a,14b-hexahydro-9,14-
[1,2]benzenobenzo[5,6]isoindolo[1,2-a]isoquinolin-8(6H)-one. 
Prepared according to General Procedure D, starting with 
cycloaddition precursor and CF3COOH (20.0 eq), purification by flash chromatography 
(hexanes:EtOAc, 3:1, Rf 0.21) gave the shown product as a light yellow oil: IR (neat) 3458, 
2957, 2360, 2342, 1699, 1661, 1516, 1459, 1263, 1029, 912, 760 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 1.06 (s, 3H), 1.55 (m, 3h), 1.93 (t, J = 10.0 Hz, 1H), 2.37 (m, 2H), 2.91 (m, 2H), 
3.44 (m, 2H), 3.81 (s, 3H) 3.84 (s, 3H), 4.46 (d, J = 3.2 Hz, 1H), 4.46 (dd, J = 7.2, 7.2 Hz, 
1H), 5.12 (br, s, OH), 6.54-6.57 (overlap, 2H), 6.74 (d, J = 8.0 Hz, 1H), 7.06 (dd, J = 7.4, 
7.4 Hz, 1H), 7.14-7.26 (overlap, 4H), 7.34 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 7.2 Hz, 1H), 
7.67 (d, J = 7.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 14.1, 24.0, 29.4, 31.4, 40.8, 42.0, 
46.9, 56.1, 77.3, 103.8, 111.5, 111.9, 120.5, 120.7, 121.1, 123.6, 124.6, 126.4, 126.5, 126.6, 
126.7, 131.1, 137.4, 138.7, 140.3, 142.2, 143.0, 147.8, 149.1, 176.4; HRMS (ESI) m/z,  
([M + H]+, 100%) 496.2475, calculated for C32H33NO4 496.2488. 
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